Patent Publication Number: US-2019185518-A9

Title: Warhead-containing peptidomimetic macrocycles as modulators of bfl-1

Description:
CROSS REFERENCE 
     This Application claims the benefit of U.S. Provisional Application No. 62/469,460, filed Mar. 9, 2017; U.S. Provisional Application No. 62/473,721, filed Mar. 20, 2017; and U.S. Provisional Application No. 62/477,741, filed Mar. 28, 2017, which are incorporated herein by reference in their entirety. 
    
    
     SEQUENCE LISTING 
     The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 27, 2018, is named 35224-820_201_SL.txt and is 1,594,927 bytes in size. 
     BACKGROUND OF THE INVENTION 
     Myeloid cell leukemia 1 (MCL-1) is a protein that inhibits cell death by binding and inhibiting pro-death factors, such as BCL-2 interacting mediator (BIM). BFL-1, an anti-apoptotic BCL-2 family member, blocks p53-mediated apoptosis and has oncogenic transforming activity. 
     INCORPORATION BY REFERENCE 
     All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety for all purposes, to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. 
     SUMMARY OF THE INVENTION 
     In some embodiments, the invention provides a peptidomimetic macrocycle of Formula (Ic): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, E, and F is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     WH is an amino acid with an electron accepting group susceptible to attack by a nucleophile; 
     each L is independently a macrocycle-forming linker; 
     each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 1  and the atom to which both R 1  and L″ are bound forms a ring; 
     each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 2  and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 1  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L′ and the atom to which both R 1  and L′ are bound forms a ring; 
     each R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L″ and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each n is independently 1, 2, 3, 4, or 5; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000; 
     t is 0; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or 
     a pharmaceutically-acceptable salt thereof. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  illustrates cell viability over time after treatment with a peptidomimetic macrocycle. 
         FIG. 2  illustrates cell viability over time after treatment with a peptidomimetic macrocycle. 
         FIG. 3  illustrates cell viability over time after treatment with a peptidomimetic macrocycle. 
         FIG. 4  illustrates cell viability over time after treatment with a peptidomimetic macrocycle. 
         FIG. 5  illustrates normalized fluorescence resonance energy transfer (FRET) signal after treatment with vehicle, a peptidomimetic macrocycle, or a BH3 mimetic. 
         FIG. 6  illustrates concentration of a peptidomimetic macrocycle in tissue over time after treatment. 
         FIG. 7  illustrates percentage remaining of a peptidomimetic macrocycle in plasma over time after treatment. 
         FIG. 8  illustrates results after A375-P cells were treated with BIM SAHB A1  or Aileron peptide 1 (40 μM). 
         FIG. 9  illustrates results after SK-MEL-2 cells were treated with BIM SAHB A1  or Aileron peptide 1 (40 μM). 
         FIG. 10  illustrates results after SK-MEL-28 cells were treated with BIM SAHB A1  or Aileron peptide 1 (40 μM). 
         FIG. 11  illustrates results after A375-P cells were treated with Aileron peptide 2 or Aileron peptide 3 (40 μM). 
         FIG. 12  illustrates results after SK-MEL-2 cells were treated with Aileron peptide 2 or Aileron peptide 3 (40 μM). 
         FIG. 13  illustrates results after SK-MEL-28 cells were treated with Aileron peptide 2 or Aileron peptide 3 (40 μM). 
         FIG. 14  illustrates how a stapled peptide derived from BIM broadly targets BCL-2 family proteins, neutralizes BIM&#39;s prosurvival relatives, and directly activates BAX. 
         FIG. 15  illustrates how a BH3-only protein (BIM) can directly activate mitochondrial BAK and cytosolic BAX, and inhibit the capacity of anti-apoptotic proteins to sequester activate forms of BAK and BAX, leading the inactive monomers of BAK and BAX to transform to toxic pore-forming proteins. 
         FIG. 16  compares high resolution X-ray structures of: a stapled BIM peptide bound to MCL-1; Noxa BH3 bound to MCL-1; and BIM BH3 bound to MCL-1. 
         FIG. 17  shows a 2 angstrom X-ray structure of a stapled BIM-BH3 peptide bound to MCL-1. 
         FIG. 18  illustrates how stapled BIM peptides of the disclosure can disrupt the formation of MCL-1/BAK complexes in living cells. 
         FIG. 19  compares normalized FRET signals of samples to determine the samples&#39; effects in disrupting MCL-1/BAK protein-protein interactions. 
         FIG. 20  shows that cross-linked peptide #16 exhibited on-mechanism cytotoxic activity against BAX-BAK wt/wt  MEF cells but did not exhibit on-mechanism cytotoxic activity in BAX-BAK −/−  double knock outs (DKO). 
         FIG. 21  shows that treatment of A375-P (1), SK-MEL-2 (2), and SK-MEL-28 (3) with peptide #16 induced higher levels of caspase-3/7 activation than the BIM SAHB A1  control. 
         FIG. 22  shows that treatment of A375-P (1), SK-MEL-2 (2), and SK-MEL-28 (3) with peptide #16 decreased the % viability of the cells, while treatment with BIM SAHB A1  had no effect on % viability. 
         FIG. 23  shows that peptide #16 was ten times more potent than BIM SAHB A1  in the MCL-1-1 driven Raji cell line. 
         FIG. 24  shows that Raji cell proliferation (fraction of control) decreased with increasing doses of peptide #16 in a dose-dependent manner. 
         FIG. 25  shows that Raji cell proliferation (fraction of control) decreased with increasing doses of ABT-199 in a dose-dependent manner. 
         FIG. 26  shows that the combination index (CI) of the combination study had additive to synergistic complementary effects. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The terminology used herein is for the purpose of describing particular cases only and is not intended to be limiting. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms “including”, “includes”, “having”, “has”, “with”, or variants thereof are used in either the detailed description or the claims, such terms are intended to be inclusive in a manner similar to the term “comprising”. 
     The term “about” or “approximately” can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed. The term “about” has the meaning as commonly understood by one of ordinary skill in the art. In some embodiments, the term “about” refers to ±10%. In some embodiments, the term “about” refers to ±5%. 
     As used herein, the term “macrocycle” refers to a molecule having a chemical structure including a ring or cycle formed by at least 9 covalently bonded atoms. 
     As used herein, the term “peptidomimetic macrocycle” or “crosslinked polypeptide” refers to a compound comprising a plurality of amino acid residues joined by a plurality of peptide bonds and at least one macrocycle-forming linker which forms a macrocycle between a first naturally-occurring or non-naturally-occurring amino acid residue (or analogue) and a second naturally-occurring or non-naturally-occurring amino acid residue (or analogue) within the same molecule. Peptidomimetic macrocycles include embodiments where the macrocycle-forming linker connects the α carbon of the first amino acid residue (or analogue) to the α carbon of the second amino acid residue (or analogue). The peptidomimetic macrocycles optionally include one or more non-peptide bonds between one or more amino acid residues or amino acid analogue residues, and optionally include one or more non-naturally-occurring amino acid residues or amino acid analogue residues in addition to any which form the macrocycle. A “corresponding uncrosslinked polypeptide” when referred to in the context of a peptidomimetic macrocycle is understood to relate to a polypeptide of the same length as the macrocycle and comprising the equivalent natural amino acids of the wild-type sequence corresponding to the macrocycle. 
     As used herein, the term “stability” refers to the maintenance of a defined secondary structure in solution by a peptidomimetic macrocycle of the invention as measured by circular dichroism, NMR or another biophysical measure, or resistance to proteolytic degradation in vitro or in vivo. Non-limiting examples of secondary structures contemplated in this invention are α-helices, 3 10  helices, β-turns, and β-pleated sheets. 
     As used herein, the term “helical stability” refers to the maintenance of a helical structure by a peptidomimetic macrocycle of the invention as measured by circular dichroism or NMR. For example, in some embodiments, the peptidomimetic macrocycles of the invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in α-helicity as determined by circular dichroism compared to a corresponding uncrosslinked macrocycle. 
     The term “amino acid” refers to a molecule containing both an amino group and a carboxyl group. Suitable amino acids include, without limitation, both the D- and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by organic synthesis or other metabolic routes. The term amino acid, as used herein, includes without limitation, α-amino acids, natural amino acids, non-natural amino acids, and amino acid analogues. 
     The term “α-amino acid” refers to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the α-carbon. 
     The term “β-amino acid” refers to a molecule containing both an amino group and a carboxyl group in a β configuration. The abbreviation “b-” prior to an amino acid represent a beta configuration for the amino acid. 
     The term “naturally occurring amino acid” refers to any one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V. 
     The following Table shows a summary of the properties of natural amino acids: 
     
       
         
           
               
               
               
               
               
               
             
               
                   
               
               
                   
                   
                   
                   
                 Side- 
                   
               
               
                   
                 3- 
                 1- 
                 Side- 
                 chain 
               
               
                   
                 Letter 
                 Letter 
                 chain 
                 charge 
                 Hydropathy 
               
               
                 Amino Acid 
                 Code 
                 Code 
                 Polarity 
                 (pH 7.4) 
                 Index 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 Alanine 
                 Ala 
                 A 
                 nonpolar 
                 neutral 
                 1.8 
               
               
                 Arginine 
                 Arg 
                 R 
                 polar 
                 positive 
                 −4.5 
               
               
                 Asparagine 
                 Asn 
                 N 
                 polar 
                 neutral 
                 −3.5 
               
               
                 Aspartie acid 
                 Asp 
                 D 
                 polar 
                 negative 
                 −3.5 
               
               
                 Cysteine 
                 Cys 
                 C 
                 polar 
                 neutral 
                 2.5 
               
               
                 Glutamic acid 
                 Glu 
                 E 
                 polar 
                 negative 
                 −3.5 
               
               
                 Glutamine 
                 Gln 
                 Q 
                 polar 
                 neutral 
                 −3.5 
               
               
                 Glycine 
                 Gly 
                 G 
                 nonpolar 
                 neutral 
                 −0.4 
               
               
                 Histidine 
                 His 
                 H 
                 polar 
                 positive(10%) 
                 −3.2 
               
               
                   
                   
                   
                   
                 neutral(90%) 
               
               
                 Isoleucine 
                 Ile 
                 I 
                 nonpolar 
                 neutral 
                 4.5 
               
               
                 Leucine 
                 Leu 
                 L 
                 nonpolar 
                 neutral 
                 3.8 
               
               
                 Lysine 
                 Lys 
                 K 
                 polar 
                 positive 
                 −3.9 
               
               
                 Methionine 
                 Met 
                 M 
                 nonpolar 
                 neutral 
                 1.9 
               
               
                 Phenylalanine 
                 Phe 
                 F 
                 nonpolar 
                 neutral 
                 2.8 
               
               
                 Proline 
                 Pro 
                 P 
                 nonpolar 
                 neutral 
                 −1.6 
               
               
                 Serine 
                 Ser 
                 S 
                 polar 
                 neutral 
                 −0.8 
               
               
                 Threonine 
                 Thr 
                 T 
                 polar 
                 neutral 
                 −0.7 
               
               
                 Tryptophan 
                 Trp 
                 W 
                 nonpolar 
                 neutral 
                 −0.9 
               
               
                 Tyrosine 
                 Tyr 
                 Y 
                 polar 
                 neutral 
                 −1.3 
               
               
                 Valine 
                 Val 
                 V 
                 nonpolar 
                 neutral 
                 4.2 
               
               
                   
               
            
           
         
       
     
     “Hydrophobic amino acids” include small hydrophobic amino acids and large hydrophobic amino acids. “Small hydrophobic amino acids” are glycine, alanine, proline, and analogues thereof. “Large hydrophobic amino acids” are valine, leucine, isoleucine, phenylalanine, methionine, tryptophan, tyrosine, and analogues thereof. “Polar amino acids” are serine, threonine, asparagine, glutamine, cysteine, and analogues thereof. “Charged amino acids” include positively charged amino acids and negatively charged amino acids. “Positively charged amino acids” include lysine, arginine, histidine, and analogues thereof. “Negatively charged amino acids” include aspartate, glutamate, and analogues thereof. 
     The term “amino acid analogue” refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptidomimetic macrocycle. Amino acid analogues include, without limitation, β-amino acids and amino acids where the amino or carboxy group is substituted by a similarly reactive group (e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution of the carboxy group with an ester). 
     The term “non-natural amino acid” refers to an amino acid which is not one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V. Non-natural amino acids or amino acid analogues include, without limitation, structures according to the following: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     Amino acid analogues include β-amino acid analogues. Examples of β-amino acid analogues include, but are not limited to, the following: cyclic β-amino acid analogues; β-alanine; (R)-β-phenylalanine; (R)-1,2,3,4-tetrahydro-isoquinoline-3-acetic acid; (R)-3-amino-4-(1-naphthyl)-butyric acid; (R)-3-amino-4-(2,4-dichlorophenyl)butyric acid; (R)-3-amino-4-(2-chlorophenyl)-butyric acid; (R)-3-amino-4-(2-cyanophenyl)-butyric acid; (R)-3-amino-4-(2-fluorophenyl)-butyric acid; (R)-3-amino-4-(2-furyl)-butyric acid; (R)-3-amino-4-(2-methylphenyl)-butyric acid; (R)-3-amino-4-(2-naphthyl)-butyric acid; (R)-3-amino-4-(2-thienyl)-butyric acid; (R)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-(3,4-dichlorophenyl)butyric acid; (R)-3-amino-4-(3,4-difluorophenyl)butyric acid; (R)-3-amino-4-(3-benzothienyl)-butyric acid; (R)-3-amino-4-(3-chlorophenyl)-butyric acid; (R)-3-amino-4-(3-cyanophenyl)-butyric acid; (R)-3-amino-4-(3-fluorophenyl)-butyric acid; (R)-3-amino-4-(3-methylphenyl)-butyric acid; (R)-3-amino-4-(3-pyridyl)-butyric acid; (R)-3-amino-4-(3-thienyl)-butyric acid; (R)-3-amino-4-(3-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-(4-bromophenyl)-butyric acid; (R)-3-amino-4-(4-chlorophenyl)-butyric acid; (R)-3-amino-4-(4-cyanophenyl)-butyric acid; (R)-3-amino-4-(4-fluorophenyl)-butyric acid; (R)-3-amino-4-(4-iodophenyl)-butyric acid; (R)-3-amino-4-(4-methylphenyl)-butyric acid; (R)-3-amino-4-(4-nitrophenyl)-butyric acid; (R)-3-amino-4-(4-pyridyl)-butyric acid; (R)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid; (R)-3-amino-4-pentafluoro-phenylbutyric acid; (R)-3-amino-5-hexenoic acid; (R)-3-amino-5-hexynoic acid; (R)-3-amino-5-phenylpentanoic acid; (R)-3-amino-6-phenyl-5-hexenoic acid; (S)-1,2,3,4-tetrahydro-isoquinoline-3-acetic acid; (S)-3-amino-4-(1-naphthyl)-butyric acid; (S)-3-amino-4-(2,4-dichlorophenyl)butyric acid; (S)-3-amino-4-(2-chlorophenyl)-butyric acid; (S)-3-amino-4-(2-cyanophenyl)-butyric acid; (S)-3-amino-4-(2-fluorophenyl)-butyric acid; (S)-3-amino-4-(2-furyl)-butyric acid; (S)-3-amino-4-(2-methylphenyl)-butyric acid; (S)-3-amino-4-(2-naphthyl)-butyric acid; (S)-3-amino-4-(2-thienyl)-butyric acid; (S)-3-amino-4-(2-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-(3,4-dichlorophenyl)butyric acid; (S)-3-amino-4-(3,4-difluorophenyl)butyric acid; (S)-3-amino-4-(3-benzothienyl)-butyric acid; (S)-3-amino-4-(3-chlorophenyl)-butyric acid; (S)-3-amino-4-(3-cyanophenyl)-butyric acid; (S)-3-amino-4-(3-fluorophenyl)-butyric acid; (S)-3-amino-4-(3-methylphenyl)-butyric acid; (S)-3-amino-4-(3-pyridyl)-butyric acid; (S)-3-amino-4-(3-thienyl)-butyric acid; (S)-3-amino-4-(3-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-(4-bromophenyl)-butyric acid; (S)-3-amino-4-(4-chlorophenyl)-butyric acid; (S)-3-amino-4-(4-cyanophenyl)-butyric acid; (S)-3-amino-4-(4-fluorophenyl)-butyric acid; (S)-3-amino-4-(4-iodophenyl)-butyric acid; (S)-3-amino-4-(4-methylphenyl)-butyric acid; (S)-3-amino-4-(4-nitrophenyl)-butyric acid; (S)-3-amino-4-(4-pyridyl)-butyric acid; (S)-3-amino-4-(4-trifluoromethylphenyl)-butyric acid; (S)-3-amino-4-pentafluoro-phenylbutyric acid; (S)-3-amino-5-hexenoic acid; (S)-3-amino-5-hexynoic acid; (S)-3-amino-5-phenylpentanoic acid; (S)-3-amino-6-phenyl-5-hexenoic acid; 1,2,5,6-tetrahydropyridine-3-carboxylic acid; 1,2,5,6-tetrahydropyridine-4-carboxylic acid; 3-amino-3-(2-chlorophenyl)-propionic acid; 3-amino-3-(2-thienyl)-propionic acid; 3-amino-3-(3-bromophenyl)-propionic acid; 3-amino-3-(4-chlorophenyl)-propionic acid; 3-amino-3-(4-methoxyphenyl)-propionic acid; 3-amino-4,4,4-trifluoro-butyric acid; 3-aminoadipic acid; D-β-phenylalanine; β-leucine; L-β-homoalanine; L-β-homoaspartic acid γ-benzyl ester; L-β-homoglutamic acid δ-benzyl ester; L-β-homoisoleucine; L-β-homoleucine; L-β-homomethionine; L-β-homophenylalanine; L-β-homoproline; L-β-homotryptophan; L-β-homovaline; L-Nω-benzyloxycarbonyl-β-homolysine; Nω-L-β-homoarginine; O-benzyl-L-β-homohydroxyproline; O-benzyl-L-β-homoserine; O-benzyl-L-β-homothreonine; O-benzyl-L-β-homotyrosine; γ-trityl-L-β-homoasparagine; (R)-β-phenylalanine; L-β-homoaspartic acid γ-t-butyl ester; L-β-homoglutamic acid δ-t-butyl ester; L-No)-β-homolysine; Nδ-trityl-L-β-homoglutamine; No)-2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl-L-β-homoarginine; O-t-butyl-L-β-homohydroxy-proline; O-t-butyl-L-β-homoserine; O-t-butyl-L-β-homothreonine; O-t-butyl-L-β-homotyrosine; 2-aminocyclopentane carboxylic acid; and 2-aminocyclohexane carboxylic acid. 
     Amino acid analogues include analogues of alanine, valine, glycine or leucine. Examples of amino acid analogues of alanine, valine, glycine, and leucine include, but are not limited to, the following: α-methoxyglycine; α-allyl-L-alanine; α-aminoisobutyric acid; α-methyl-leucine; β-(1-naphthyl)-D-alanine; β-(1-naphthyl)-L-alanine; β-(2-naphthyl)-D-alanine; β-(2-naphthyl)-L-alanine; β-(2-pyridyl)-D-alanine; β-(2-pyridyl)-L-alanine; β-(2-thienyl)-D-alanine; β-(2-thienyl)-L-alanine; β-β-benzothienyl)-D-alanine; β-β-benzothienyl)-L-alanine; β-(3-pyridyl)-D-alanine; β-(3-pyridyl)-L-alanine; β-(4-pyridyl)-D-alanine; β-(4-pyridyl)-L-alanine; β-chloro-L-alanine; β-cyano-L-alanin; β-cyclohexyl-D-alanine; β-cyclohexyl-L-alanine; β-cyclopenten-1-yl-alanine; β-cyclopentyl-alanine; β-cyclopropyl-L-Ala-OH.dicyclohexylammonium salt; β-t-butyl-D-alanine; β-t-butyl-L-alanine; γ-aminobutyric acid; L-α,β-diaminopropionic acid; 2,4-dinitro-phenylglycine; 2,5-dihydro-D-phenylglycine; 2-amino-4,4,4-trifluorobutyric acid; 2-fluoro-phenylglycine; 3-amino-4,4,4-trifluoro-butyric acid; 3-fluoro-valine; 4,4,4-trifluoro-valine; 4,5-dehydro-L-leu-OH.dicyclohexylammonium salt; 4-fluoro-D-phenylglycine; 4-fluoro-L-phenylglycine; 4-hydroxy-D-phenylglycine; 5,5,5-trifluoro-leucine; 6-aminohexanoic acid; cyclopentyl-D-Gly-OH.dicyclohexylammonium salt; cyclopentyl-Gly-OH.dicyclohexylammonium salt; D-α,β-diaminopropionic acid; D-α-aminobutyric acid; D-α-t-butylglycine; D-(2-thienyl)glycine; D-(3-thienyl)glycine; D-2-aminocaproic acid; D-2-indanylglycine; D-allylglycine-dicyclohexylammonium salt; D-cyclohexylglycine; D-norvaline; D-phenylglycine; β-aminobutyric acid; β-aminoisobutyric acid; (2-bromophenyl)glycine; (2-methoxyphenyl)glycine; (2-methylphenyl)glycine; (2-thiazoyl)glycine; (2-thienyl)glycine; 2-amino-3-(dimethylamino)-propionic acid; L-α,β-diaminopropionic acid; L-α-aminobutyric acid; L-α-t-butylglycine; L-(3-thienyl)glycine; L-2-amino-3-(dimethylamino)-propionic acid; L-2-aminocaproic acid dicyclohexyl-ammonium salt; L-2-indanylglycine; L-allylglycine-dicyclohexyl ammonium salt; L-cyclohexylglycine; L-phenylglycine; L-propargylglycine; L-norvaline; N-α-aminomethyl-L-alanine; D-α,γ-diaminobutyric acid; L-α,γ-diaminobutyric acid; β-cyclopropyl-L-alanine; (N-β-(2,4-dinitrophenyl))-L-α,β-diaminopropionic acid; (N-β-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-D-α,β-diaminopropionic acid; (N-β-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-L-α,β-diaminopropionic acid; (N-β-4-methyltrityl)-L-α,β-diaminopropionic acid; (N-β-allyloxycarbonyl)-L-α,β-diaminopropionic acid; (N-γ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-D-α,γ-diaminobutyric acid; (N-γ-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)-L-α,γ-diaminobutyric acid; (N-γ-4-methyltrityl)-D-α,γ-diaminobutyric acid; (N-γ-4-methyltrityl)-L-α,γ-diaminobutyric acid; (N-γ-allyloxycarbonyl)-L-α,γ-diaminobutyric acid; D-α,γ-diaminobutyric acid; 4,5-dehydro-L-leucine; cyclopentyl-D-Gly-OH; cyclopentyl-Gly-OH; D-allylglycine; D-homocyclohexylalanine; L-1-pyrenylalanine; L-2-aminocaproic acid; L-allylglycine; L-homocyclohexylalanine; and N-(2-hydroxy-4-methoxy-Bzl)-Gly-OH. 
     Amino acid analogues include analogues of arginine or lysine. Examples of amino acid analogues of arginine and lysine include, but are not limited to, the following: citrulline; L-2-amino-3-guanidinopropionic acid; L-2-amino-3-ureidopropionic acid; L-citrulline; Lys(Me) 2 -OH; Lys(N 3 )—OH; Nδ-benzyloxycarbonyl-L-ornithine; Nω-nitro-D-arginine; Nω-nitro-L-arginine; α-methyl-ornithine; 2,6-diaminoheptanedioic acid; L-ornithine; (Nδ-1-(4,4-dimethyl-2,6-dioxo-cyclohex-1-ylidene)ethyl)-D-ornithine; (Nδ-1-(4,4-dimethyl-2,6-dioxo-cyclohex-1-ylidene)ethyl)-L-ornithine; (Nδ-4-methyltrityl)-D-ornithine; (Nδ-4-methyltrityl)-L-ornithine; D-ornithine; L-ornithine; Arg(Me)(Pbf)-OH; Arg(Me) 2 -OH (asymmetrical); Arg(Me)2-OH (symmetrical); Lys(ivDde)-OH; Lys(Me)2-OH.HCl; Lys(Me3)-OH chloride; Nω-nitro-D-arginine; and Nω-nitro-L-arginine. 
     Amino acid analogues include analogues of aspartic or glutamic acids. Examples of amino acid analogues of aspartic and glutamic acids include, but are not limited to, the following: α-methyl-D-aspartic acid; α-methyl-glutamic acid; α-methyl-L-aspartic acid; γ-methylene-glutamic acid; (N-γ-ethyl)-L-glutamine; [N-α-(4-aminobenzoyl)]-L-glutamic acid; 2,6-diaminopimelic acid; L-α-aminosuberic acid; D-2-aminoadipic acid; D-α-aminosuberic acid; α-aminopimelic acid; iminodiacetic acid; L-2-amino adipic acid; threo-β-methyl-aspartic acid; γ-carboxy-D-glutamic acid γ,γ-di-t-butyl ester; γ-carboxy-L-glutamic acid γ,γ-di-t-butyl ester; Glu(OAll)-OH; L-Asu(OtBu)-OH; and pyroglutamic acid. 
     Amino acid analogues include analogues of cysteine and methionine. Examples of amino acid analogues of cysteine and methionine include, but are not limited to, Cys(farnesyl)-OH, Cys(farnesyl)-OMe, α-methyl-methionine, Cys(2-hydroxyethyl)-OH, Cys(3-aminopropyl)-OH, 2-amino-4-(ethylthio)butyric acid, buthionine, buthioninesulfoximine, ethionine, methionine methylsulfonium chloride, selenomethionine, cysteic acid, [2-(4-pyridyl)ethyl]-DL-penicillamine, [2-(4-pyridyl)ethyl]-L-cysteine, 4-methoxybenzyl-D-penicillamine, 4-methoxybenzyl-L-penicillamine, 4-methylbenzyl-D-penicillamine, 4-methylbenzyl-L-penicillamine, benzyl-D-cysteine, benzyl-L-cysteine, benzyl-DL-homocysteine, carbamoyl-L-cysteine, carboxyethyl-L-cysteine, carboxymethyl-L-cysteine, diphenylmethyl-L-cysteine, ethyl-L-cysteine, methyl-L-cysteine, t-butyl-D-cysteine, trityl-L-homocysteine, trityl-D-penicillamine, cystathionine, homocystine, L-homocystine, (2-aminoethyl)-L-cysteine, seleno-L-cystine, cystathionine, Cys(StBu)-OH, and acetamidomethyl-D-penicillamine. 
     Amino acid analogues include analogues of phenylalanine and tyrosine. Examples of amino acid analogues of phenylalanine and tyrosine include β-methyl-phenylalanine, β-hydroxyphenylalanine, α-methyl-3-methoxy-DL-phenylalanine, α-methyl-D-phenylalanine, α-methyl-L-phenylalanine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 2,4-dichloro-phenylalanine, 2-(trifluoromethyl)-D-phenylalanine, 2-(trifluoromethyl)-L-phenylalanine, 2-bromo-D-phenylalanine, 2-bromo-L-phenylalanine, 2-chloro-D-phenylalanine, 2-chloro-L-phenylalanine, 2-cyano-D-phenylalanine, 2-cyano-L-phenylalanine, 2-fluoro-D-phenylalanine, 2-fluoro-L-phenylalanine, 2-methyl-D-phenylalanine, 2-methyl-L-phenylalanine, 2-nitro-D-phenylalanine, 2-nitro-L-phenylalanine, 2;4;5-trihydroxy-phenylalanine, 3,4,5-trifluoro-D-phenylalanine, 3,4,5-trifluoro-L-phenylalanine, 3,4-dichloro-D-phenylalanine, 3,4-dichloro-L-phenylalanine, 3,4-difluoro-D-phenylalanine, 3,4-difluoro-L-phenylalanine, 3,4-dihydroxy-L-phenylalanine, 3,4-dimethoxy-L-phenylalanine, 3,5,3′-triiodo-L-thyronine, 3,5-diiodo-D-tyrosine, 3,5-diiodo-L-tyrosine, 3,5-diiodo-L-thyronine, 3-(trifluoromethyl)-D-phenylalanine, 3-(trifluoromethyl)-L-phenylalanine, 3-amino-L-tyrosine, 3-bromo-D-phenylalanine, 3-bromo-L-phenylalanine, 3-chloro-D-phenylalanine, 3-chloro-L-phenylalanine, 3-chloro-L-tyrosine, 3-cyano-D-phenylalanine, 3-cyano-L-phenylalanine, 3-fluoro-D-phenylalanine, 3-fluoro-L-phenylalanine, 3-fluoro-tyrosine, 3-iodo-D-phenylalanine, 3-iodo-L-phenylalanine, 3-iodo-L-tyrosine, 3-methoxy-L-tyrosine, 3-methyl-D-phenylalanine, 3-methyl-L-phenylalanine, 3-nitro-D-phenylalanine, 3-nitro-L-phenylalanine, 3-nitro-L-tyrosine, 4-(trifluoromethyl)-D-phenylalanine, 4-(trifluoromethyl)-L-phenylalanine, 4-amino-D-phenylalanine, 4-amino-L-phenylalanine, 4-benzoyl-D-phenylalanine, 4-benzoyl-L-phenylalanine, 4-bis(2-chloroethyl)amino-L-phenylalanine, 4-bromo-D-phenylalanine, 4-bromo-L-phenylalanine, 4-chloro-D-phenylalanine, 4-chloro-L-phenylalanine, 4-cyano-D-phenylalanine, 4-cyano-L-phenylalanine, 4-fluoro-D-phenylalanine, 4-fluoro-L-phenylalanine, 4-iodo-D-phenylalanine, 4-iodo-L-phenylalanine, homophenylalanine, thyroxine, 3,3-diphenylalanine, thyronine, ethyl-tyrosine, and methyl-tyrosine. 
     Amino acid analogues include analogues of proline. Examples of amino acid analogues of proline include, but are not limited to, 3,4-dehydro-proline, 4-fluoro-proline, cis-4-hydroxy-proline, thiazolidine-2-carboxylic acid, and trans-4-fluoro-proline. 
     Amino acid analogues include analogues of serine and threonine. Examples of amino acid analogues of serine and threonine include, but are not limited to, 3-amino-2-hydroxy-5-methylhexanoic acid, 2-amino-3-hydroxy-4-methylpentanoic acid, 2-amino-3-ethoxybutanoic acid, 2-amino-3-methoxybutanoic acid, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-amino-3-benzyloxypropionic acid, 2-amino-3-benzyloxypropionic acid, 2-amino-3-ethoxypropionic acid, 4-amino-3-hydroxybutanoic acid, and α-methylserine. 
     Amino acid analogues include analogues of tryptophan. Examples of amino acid analogues of tryptophan include, but are not limited to, the following: α-methyl-tryptophan; β-(3-benzothienyl)-D-alanine; β-(3-benzothienyl)-L-alanine; 1-methyl-tryptophan; 4-methyl-tryptophan; 5-benzyloxy-tryptophan; 5-bromo-tryptophan; 5-chloro-tryptophan; 5-fluoro-tryptophan; 5-hydroxy-tryptophan; 5-hydroxy-L-tryptophan; 5-methoxy-tryptophan; 5-methoxy-L-tryptophan; 5-methyl-tryptophan; 6-bromo-tryptophan; 6-chloro-D-tryptophan; 6-chloro-tryptophan; 6-fluoro-tryptophan; 6-methyl-tryptophan; 7-benzyloxy-tryptophan; 7-bromo-tryptophan; 7-methyl-tryptophan; D-1,2,3,4-tetrahydro-norharman-3-carboxylic acid; 6-methoxy-1,2,3,4-tetrahydronorharman-1-carboxylic acid; 7-azatryptophan; L-1,2,3,4-tetrahydro-norharman-3-carboxylic acid; 5-methoxy-2-methyl-tryptophan; and 6-chloro-L-tryptophan. 
     In some embodiments, amino acid analogues are racemic. In some embodiments, the D isomer of the amino acid analogue is used. In some embodiments, the L isomer of the amino acid analogue is used. In other embodiments, the amino acid analogue comprises chiral centers that are in the R or S configuration. In still other embodiments, the amino group(s) of a β-amino acid analogue is substituted with a protecting group, e.g., tert-butyloxycarbonyl (BOC group), 9-fluorenylmethyloxycarbonyl (FMOC), tosyl, and the like. In yet other embodiments, the carboxylic acid functional group of a β-amino acid analogue is protected, e.g., as its ester derivative. In some embodiments the salt of the amino acid analogue is used. 
     A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide without abolishing or substantially abolishing its essential biological or biochemical activity (e.g., receptor binding or activation). An “essential” amino acid residue is a residue that, when altered from the wild-type sequence of the polypeptide, results in abolishing or substantially abolishing the polypeptide&#39;s essential biological or biochemical activity. 
     A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., K, R, H), acidic side chains (e.g., D, E), uncharged polar side chains (e.g., G, N, Q, S, T, Y, C), nonpolar side chains (e.g., A, V, L, I, P, F, M, W), beta-branched side chains (e.g., T, V, I) and aromatic side chains (e.g., Y, F, W, H). Thus, a predicted nonessential amino acid residue in a polypeptide, for example, is replaced with another amino acid residue from the same side chain family. Other examples of acceptable substitutions are substitutions based on isosteric considerations (e.g. norleucine for methionine) or other properties (e.g. 2-thienylalanine for phenylalanine). 
     The term “capping group” refers to the chemical moiety occurring at either the carboxy or amino terminus of the polypeptide chain of the subject peptidomimetic macrocycle. The capping group of a carboxy terminus includes an unmodified carboxylic acid (i.e. —COOH) or a carboxylic acid with a substituent. For example, the carboxy terminus can be substituted with an amino group to yield a carboxamide at the C-terminus. Various substituents include but are not limited to primary and secondary amines, including pegylated secondary amines. Non-limiting representative secondary amine capping groups for the C-terminus include: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     The capping group of an amino terminus includes an unmodified amine (i.e. —NH 2 ) or an amine with a substituent. For example, the amino terminus can be substituted with an acyl group to yield a carboxamide at the N-terminus. Various substituents include but are not limited to substituted acyl groups, including C 1 -C 6  carbonyls, C 7 -C 30  carbonyls, and pegylated carbamates. Non-limiting representative capping groups for the N-terminus include: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     The term “member” as used herein in conjunction with macrocycles or macrocycle-forming linkers refers to the atoms that form or can form the macrocycle, and excludes substituent or side chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane and 1,3-dimethyl cyclodecane are all considered ten-membered macrocycles as the hydrogen or fluoro substituents or methyl side chains do not participate in forming the macrocycle. 
     The symbol “ ” when used as part of a molecular structure refers to a single bond or a trans or cis double bond. 
     The term “amino acid side chain” refers to a moiety attached to the α-carbon (or another backbone atom) in an amino acid. For example, the amino acid side chain for alanine is methyl, the amino acid side chain for phenylalanine is phenylmethyl, the amino acid side chain for cysteine is thiomethyl, the amino acid side chain for aspartate is carboxymethyl, the amino acid side chain for tyrosine is 4-hydroxyphenylmethyl, etc. Other non-naturally occurring amino acid side chains are also included, for example, those that occur in nature (e.g., an amino acid metabolite) or those that are made synthetically (e.g., an α,α di-substituted amino acid). 
     The term “α,α di-substituted amino” acid refers to a molecule or moiety containing both an amino group and a carboxyl group bound to a carbon (the α-carbon) that is attached to two natural or non-natural amino acid side chains. 
     The term “polypeptide” encompasses two or more naturally or non-naturally-occurring amino acids joined by a covalent bond (e.g., an amide bond). Polypeptides as described herein include full length proteins (e.g., fully processed proteins) as well as shorter amino acid sequences (e.g., fragments of naturally-occurring proteins or synthetic polypeptide fragments). 
     The term “macrocyclization reagent” or “macrocycle-forming reagent” as used herein refers to any reagent which may be used to prepare a peptidomimetic macrocycle of the invention by mediating the reaction between two reactive groups. Reactive groups may be, for example, an azide and alkyne, in which case macrocyclization reagents include, without limitation, Cu reagents such as reagents which provide a reactive Cu(I) species, such as CuBr, CuI or CuOTf, as well as Cu(II) salts such as Cu(CO 2 CH 3 ) 2 , CuSO 4 , and CuCl 2  that can be converted in situ to an active Cu(I) reagent by the addition of a reducing agent such as ascorbic acid or sodium ascorbate. Macrocyclization reagents may additionally include, for example, Ru reagents known in the art such as Cp*RuCl(PPh 3 ) 2 , [Cp*RuCl] 4  or other Ru reagents which may provide a reactive Ru(II) species. In other cases, the reactive groups are terminal olefins. In such embodiments, the macrocyclization reagents or macrocycle-forming reagents are metathesis catalysts including, but not limited to, stabilized, late transition metal carbene complex catalysts such as Group VIII transition metal carbene catalysts. For example, such catalysts are Ru and Os metal centers having a +2 oxidation state, an electron count of 16 and pentacoordinated. In other examples, catalysts have W or Mo centers. Various catalysts are disclosed in Grubbs et al., “Ring Closing Metathesis and Related Processes in Organic Synthesis” Acc. Chem. Res. 1995, 28, 446-452, and U.S. Pat. No. 5,811,515; U.S. Pat. No. 7,932,397; U.S. Application No. 2011/0065915; U.S. Application No. 2011/0245477; Yu et al., “Synthesis of Macrocyclic Natural Products by Catalyst-Controlled Stereoselective Ring-Closing Metathesis,” Nature 2011, 479, 88; and Peryshkov et al., “Z-Selective Olefin Metathesis Reactions Promoted by Tungsten Oxo Alkylidene Complexes,” J. Am. Chem. Soc. 2011, 133, 20754. In yet other cases, the reactive groups are thiol groups. In such embodiments, the macrocyclization reagent is, for example, a linker functionalized with two thiol-reactive groups such as halogen groups. 
     The term “halo” or “halogen” refers to fluorine, chlorine, bromine or iodine or a radical thereof. 
     The term “alkyl” refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C 1 -C 10  indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, “alkyl” is a chain (straight or branched) having 1 to 20 (inclusive) carbon atoms in it. 
     The term “alkylene” refers to a divalent alkyl (i.e., —R—). 
     The term “alkenyl” refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C 2 -C 10  indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term “lower alkenyl” refers to a C 2 -C 6  alkenyl chain. In the absence of any numerical designation, “alkenyl” is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it. 
     The term “alkynyl” refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2 -C 10  indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term “lower alkynyl” refers to a C 2 -C 6  alkynyl chain. In the absence of any numerical designation, “alkynyl” is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it. 
     The term “aryl” refers to a monocyclic or bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of aryl groups include phenyl, biphenyl, naphthyl and the like. The term “arylalkoxy” refers to an alkoxy substituted with aryl. 
     “Arylalkyl” refers to an aryl group, as defined above, wherein one of the aryl group&#39;s hydrogen atoms has been replaced with a C 1 -C 5  alkyl group, as defined above. Representative examples of an arylalkyl group include, but are not limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2-propylphenyl, 3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3-butylphenyl, 4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl, 2-isobutylphenyl, 3-isobutylphenyl, 4-isobutylphenyl, 2-sec-butylphenyl, 3-sec-butylphenyl, 4-sec-butylphenyl, 2-t-butylphenyl, 3-t-butylphenyl and 4-t-butylphenyl. 
     “Arylamido” refers to an aryl group, as defined above, wherein one of the aryl group&#39;s hydrogen atoms has been replaced with one or more —C(O)NH 2  groups. Representative examples of an arylamido group include 2-C(O)NH2-phenyl, 3-C(O)NH 2 -phenyl, 4-C(O)NH 2 -phenyl, 2-C(O)NH 2 -pyridyl, 3-C(O)NH 2 -pyridyl, and 4-C(O)NH 2 -pyridyl, 
     “Alkylheterocycle” refers to a C 1 -C 5  alkyl group, as defined above, wherein one of the C 1 -C 5  alkyl group&#39;s hydrogen atoms has been replaced with a heterocycle. Representative examples of an alkylheterocycle group include, but are not limited to, —CH 2 CH 2 -morpholine, —CH 2 CH 2 -piperidine, —CH 2 CH 2 CH 2 -morpholine, and —CH 2 CH 2 CH 2 -imidazole. 
     “Alkylamido” refers to a C 1 -C 5  alkyl group, as defined above, wherein one of the C 1 -C 5  alkyl group&#39;s hydrogen atoms has been replaced with a —C(O)NH 2  group. Representative examples of an alkylamido group include, but are not limited to, —CH 2 —C(O)NH 2 , —CH 2 CH 2 —C(O)NH 2 , —CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH 2 CH 2 CH 2 CH 2 C(O)NH 2 , —CH 2 CH(C(O)NH 2 )CH 3 , —CH 2 CH(C(O)NH 2 )CH 2 CH 3 , —CH(C(O)NH 2 )CH 2 CH 3 , —C(CH 3 ) 2 CH 2 C(O)NH 2 , —CH 2 —CH 2 —NH—C(O)—CH 3 , —CH 2 —CH 2 —NH—C(O)—CH 3 —CH3, and —CH 2 —CH 2 —NH—C(O)—CH═CH 2 . 
     “Alkanol” refers to a C 1 -C 5  alkyl group, as defined above, wherein one of the C 1 -C 5  alkyl group&#39;s hydrogen atoms has been replaced with a hydroxyl group. Representative examples of an alkanol group include, but are not limited to, —CH 2 OH, —CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH, —CH 2 CH 2 CH 2 CH 2 OH, —CH 2 CH 2 CH 2 CH 2 CH 2 OH, —CH 2 CH(OH)CH 3 , —CH 2 CH(OH)CH 2 CH 3 , —CH(OH)CH 3  and —C(CH 3 ) 2 CH 2 OH. 
     “Alkylcarboxy” refers to a C 1 -C 5  alkyl group, as defined above, wherein one of the C 1 -C 5  alkyl group&#39;s hydrogen atoms has been replaced with a —COOH group. Representative examples of an alkylcarboxy group include, but are not limited to, —CH 2 COOH, —CH 2 CH 2 COOH, —CH 2 CH 2 CH 2 COOH, —CH 2 CH 2 CH 2 CH 2 COOH, —CH 2 CH(COOH)CH 3 , —CH 2 CH 2 CH 2 CH 2 CH 2 COOH, —CH 2 CH(COOH)CH 2 CH 3 , —CH(COOH)CH 2 CH 3  and —C(CH 3 ) 2 CH 2 COOH. 
     The term “cycloalkyl” as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted. Some cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. 
     The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like. 
     The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl. 
     The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl. 
     The term “heterocyclyl” refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring are substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like. 
     The term “substituent” refers to a group replacing a second atom or group such as a hydrogen atom on any molecule, compound or moiety. Suitable substituents include, without limitation, halo, hydroxy, mercapto, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, amino, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, and cyano groups. 
     In some embodiments, the compounds of this invention contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are included in the present invention unless expressly provided otherwise. In some embodiments, the compounds of this invention are also represented in multiple tautomeric forms, in such instances, the invention includes all tautomeric forms of the compounds described herein (e.g., if alkylation of a ring system results in alkylation at multiple sites, the invention includes all such reaction products). All such isomeric forms of such compounds are included in the present invention unless expressly provided otherwise. All crystal forms of the compounds described herein are included in the present invention unless expressly provided otherwise. 
     As used herein, the terms “increase” and “decrease” mean, respectively, to cause a statistically significantly (i.e., p&lt;0.1) increase or decrease of at least 5%. 
     As used herein, the recitation of a numerical range for a variable is intended to convey that the variable is equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable is equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable is equal to any real value within the numerical range, including the end-points of the range. As an example, and without limitation, a variable which is described as having values between 0 and 2 takes the values 0, 1 or 2 if the variable is inherently discrete, and takes the values 0.0, 0.1, 0.01, 0.001, or any other real values ≥0 and ≤2 if the variable is inherently continuous. 
     As used herein, unless specifically indicated otherwise, the word “or” is used in the inclusive sense of “or” and not the exclusive sense of “either/or.” 
     The term “on average” represents the mean value derived from performing at least three independent replicates for each data point. 
     The term “biological activity” encompasses structural and functional properties of a macrocycle of the invention. Biological activity is, for example, structural stability, alpha-helicity, affinity for a target, resistance to proteolytic degradation, cell penetrability, intracellular stability, in vivo stability, or any combination thereof. 
     The details of one or more particular embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. 
     Peptidomimetic Macrocycles of the Invention 
     The present invention provides pharmaceutical formulations comprising an effective amount of peptidomimetic macrocycles or pharmaceutically acceptable salts thereof. The peptidomimetic macrocycles of the invention are cross-linked (e.g., stapled or stitched) and possess improved pharmaceutical properties relative to their corresponding uncross-linked peptidomimetic macrocycles. These improved properties include improved bioavailability, enhanced chemical and in vivo stability, increased potency, and reduced immunogenicity (i.e., fewer or less severe injection site reactions). 
     In some embodiments, the peptidomimetic macrocycles of the invention are crosslinked and comprise a warhead, and are used for ligand-directed covalent modification of cysteine- and lysine-containing proteins. 
     In some embodiments, the peptide sequences are derived from BIM. 
     In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids from a BIM peptide sequence. 
     In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids that are different from the selected sequences from which the peptide is derived. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising a mutation at amino acid position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22. In some embodiments, mutations are mutations of non-essential amino acids. In some embodiments, mutations are mutations of essential amino acids. In some embodiments, mutations are mutations of hydrophobic amino acids. In some embodiments, mutations are mutations of naturally occurring amino acids. In some embodiments, mutations are mutations to a conservative amino acid. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid analogues. In some embodiments, a peptidomimetic macrocycle peptide derived from a human BIM peptide sequence can be a peptide comprising 1 or 2 capping groups. 
     In some embodiments, the peptidomimetic macrocycle comprises a C-terminal truncation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids from an amino acid sequence in Table 1. In some embodiments, the peptidomimetic macrocycle comprises a N-terminal truncation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acids from the sequence of BIM. 
     A non-limiting list of suitable BIM macrocycles for use in the present disclosure are given in Table 1. In Table 1, at the C-terminus, some peptides possess a carboxamide terminus (shown as —NH 2 ); some peptides possess a hydroxyl terminus (shown as —OH); some peptides possess a 5-carboxyfluorescein terminus (shown as −5-FAM); some peptides possess a isobutylamide terminus (shown as —NHiBu); some peptides possess a cyclohexylamide terminus (shown as —NHChx); some peptides possess a cyclohexylmethylamide terminus (shown as —NHMeChx); some peptides possess a phenethylamide terminus (shown as —NHPe); some peptides possess a n-butylamide terminus (shown as —NHBu); some peptides possess a sec-butylamide terminus (shown as —NHsBu); and some peptides possess an uncapped terminus (shown as no terminal modification). 
     In Table 1, at the N-terminus, some peptides possess an acetyl terminus (shown as Ac—); some peptides possess a fluorescein isothiocyanate terminus (shown as FITC-); some peptides possess a single-unit polyethylene glycol terminus (shown as dPEG1-); some peptides possess a five-unit polyethylene glycol terminus (shown as dPEG5-); some peptides possess an eleven-unit polyethylene glycol terminus (shown as dPEG11-); some peptides possess a propyl terminus (shown as Pr—); some peptides possess a biotin terminus (shown as Biotin-); some peptides possess a KLH terminus (shown as KLH-); some peptides possess an ovalbumin terminus (shown as OVA-); some peptides possess an uncapped terminus (shown as H—); some peptides possess a isobutyl terminus (shown as iBu-); some peptides possess a decanoyl terminus (shown as Decac-); some peptides possess a benzyl terminus (shown as Bz-); some peptides possess a cyclohexyl terminus (shown as Chx-); some peptides possess a benzyl terminus (shown as Bz-); some peptides possess a Vrl terminus (shown as Vrl-); some peptides possess a HBS terminus (shown as HBS—); some peptides possess a MeIm terminus (shown as MeImC-); some peptides possess a tert-butyl terminus (shown as t-Bu-U—); some peptides possess a nonanoyl terminus (shown as non-U—); some peptides possess a ethyl terminus (shown as Et-U—); some peptides possess a cyclohexyl terminus (shown as Chx-U—); some peptides possess a isopropyl terminus (shown as iPr-U—); some peptides possess a phenyl terminus (shown as Ph-U—); some peptides possess a uric terminus (shown as NH2CO—); some peptides possess a palmitoyl terminus (shown as Pam-); some peptides possess a heptenoic terminus (shown as Hep-); and some peptides possess a 5-carboxytetramethylrhodamine terminus (shown as 5-TAMRA-). 
     
       
         
           
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 SEQ ID NO 
                 Peptide sequence 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 1 
                 Ac-IWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 2 
                 Ac-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 3 
                 Ac-IWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 4 
                 FITC-IWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 5 
                 FITC-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 6 
                 FITC-IWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 7 
                 Ac-IWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 8 
                 Ac-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 9 
                 Ac-IRIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 10 
                 Ac-RRIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 11 
                 Ac-EIWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 12 
                 Ac-ERRIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 13 
                 Ac-IRIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 14 
                 Ac-RWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 15 
                 Ac-RRIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 16 
                 Ac-EIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 17 
                 Ac-ERWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 18 
                 Ac-EIRIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 19 
                 Ac-ERRIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 20 
                 PEG1-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 21 
                 PEG5-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 22 
                 PEG11-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 23 
                 Ac-IWIAQELR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 24 
                 Ac-RRIAQELR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 25 
                 Ac-ERRIAQELR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 26 
                 Ac-RRIAQELR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 27 
                 Ac-RRIAQELR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 28 
                 Ac-RRIAQELR$IGD$FNAYYAib-NH2 
               
               
                   
               
               
                 29 
                 Ac-RRIAQELR$IGD$FNASYAib-NH2 
               
               
                   
               
               
                 30 
                 Ac-IWIAQELR$IAibD$FNAYYAR-NH2 
               
               
                   
               
               
                 31 
                 Ac-IWIAQELR%IAibD%FNAYYAR-NH2 
               
               
                   
               
               
                 32 
                 Ac-IRIAQELRRIGDEFNETYTRR-NH2 
               
               
                   
               
               
                 33 
                 Ac-IRIAQELR$IGD$FNETYTRR-NH2 
               
               
                   
               
               
                 34 
                 Ac-IRIAQELR$IED$FNETYTRR-NH2 
               
               
                   
               
               
                 35 
                 Ac-IWIAQELR$/IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 36 
                 Pr-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 37 
                 Ac-IWIAQELR$IAibD$FNAYYARR-NH2 
               
               
                   
               
               
                 38 
                 Ac-IWIAQELR%IAibD%FNAYYARR-NH2 
               
               
                   
               
               
                 39 
                 Ac-IWIAQELR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 40 
                 Ac-IWIAQELR$IGD$FAAYYARR-NH2 
               
               
                   
               
               
                 41 
                 Ac-IWIAQELR$IGD$AAAYYARR-NH2 
               
               
                   
               
               
                 42 
                 Ac-IWIAQELR%IGD%FNAYYARR-NH2 
               
               
                   
               
               
                 43 
                 Ac-AWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 44 
                 Ac-IWAAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 45 
                 Ac-AWAAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 46 
                 Ac-IWIAibQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 47 
                 Ac-IWIAQELR$IGD$FNAAYARR-NH2 
               
               
                   
               
               
                 48 
                 Ac-IWIAQELR$IGD$FNAYAARR-NH2 
               
               
                   
               
               
                 49 
                 Ac-IWIAQELR$IGD$FNAAAARR-NH2 
               
               
                   
               
               
                 50 
                 Ac-IWIAQELR$IGD$FNAYYAibRR-NH2 
               
               
                   
               
               
                 51 
                 Ac-IAIAQELR%IAibD%FNAYYARR-NH2 
               
               
                   
               
               
                 52 
                 Ac-IAIAQELR$IAibD$FNAYYARR-NH2 
               
               
                   
               
               
                 53 
                 Ac-DIIRNIAibRHLA$VGD$NleDRSI-NH2 
               
               
                   
               
               
                 54 
                 Ac-DIIRNIARHLA$VGD$NleDKSI-NH2 
               
               
                   
               
               
                 55 
                 Ac-DIIKNIARHLA$VGD$NleDRSI-NH2 
               
               
                   
               
               
                 56 
                 Ac-DIIRNIARHLACVGDCNleDRSI-NH2 
               
               
                   
               
               
                 57 
                 Ac-DIIRNIARHLACVAibDCNleDRSI-NH2 
               
               
                   
               
               
                 58 
                 Ac-IWIAQELR$IGD$FNA-NH2 
               
               
                   
               
               
                 59 
                 Ac-IWIAQELR$IGD$FNRSI-NH2 
               
               
                   
               
               
                 60 
                 Ac-IWIAQELR$IGD$FNRSIARR-NH2 
               
               
                   
               
               
                 61 
                 Ac-IWIAQELR$IGD$NleDRSI-NH2 
               
               
                   
               
               
                 62 
                 Ac-IWIAQELR$VGD$NleDRSI-NH2 
               
               
                   
               
               
                 63 
                 Ac-IWIAQEAR$IGA$FNAYYARR-NH2 
               
               
                   
               
               
                 64 
                 Ac-WIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 65 
                 Ac-IAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 66 
                 Ac-AQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 67 
                 Ac-QELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 68 
                 Ac-ELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 69 
                 Ac-IWIAQELR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 70 
                 Ac-IWIAQELR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 71 
                 Ac-IWIAQELR$IGD$FNAYY-NH2 
               
               
                   
               
               
                 72 
                 Ac-IWIAQELR$IGD$FNAY-NH2 
               
               
                   
               
               
                 73 
                 Ac-IAIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 74 
                 Ac-IWIAAELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 75 
                 Ac-IWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 76 
                 Ac-IWIAQEAR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 77 
                 Ac-IWIAQELA$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 78 
                 Ac-IWIAQELR$AGD$FNAYYARR-NH2 
               
               
                   
               
               
                 79 
                 Ac-IWIAQELR$IAD$FNAYYARR-NH2 
               
               
                   
               
               
                 80 
                 Ac-IWIAQELR$IGA$FNAYYARR-NH2 
               
               
                   
               
               
                 81 
                 Ac-IWIAQELR$IGD$FNAYYAAR-NH2 
               
               
                   
               
               
                 82 
                 Ac-IWIAQELR$IGD$FNAYYARA-NH2 
               
               
                   
               
               
                 83 
                 Pr-RNIARHLA$VGD$FNAYYARR-NH2 
               
               
                   
               
               
                 84 
                 Pr-RNIARHLAib$VGD$FNAYYARR-NH2 
               
               
                   
               
               
                 85 
                 Pr-RNIAibRHLAib$VGD$FNAYYARR-NH2 
               
               
                   
               
               
                 86 
                 Pr-RNChgARHLA$VAibD$FNAYYARR-NH2 
               
               
                   
               
               
                 87 
                 Pr-RNChaARHLA$VAibD$FNAYYARR-NH2 
               
               
                   
               
               
                 88 
                 FITC-BaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 89 
                 Biotin-AhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 90 
                 KLH-CBaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 91 
                 OVA-CBaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 92 
                 FITC-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 93 
                 Biotin-AhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 94 
                 KLH-CBaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 95 
                 OVA-CBaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 96 
                 FITC-BaIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 97 
                 Biotin-AhxIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 98 
                 FITC-BaIWIAQELR$/IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 99 
                 Ac-BaIWIAQELR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 100 
                 Ac-IWIAQELR%IGD%FNAYYARR-NH2 
               
               
                   
               
               
                 101 
                 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 102 
                 Ac-IWIAQALR$IGD$FAAYYARR-NH2 
               
               
                   
               
               
                 103 
                 Ac-IWIAQALR$IAibD$FNAYYARR-NH2 
               
               
                   
               
               
                 104 
                 Ac-IWIAQ$LRR$GDEFNAYYARR-NH2 
               
               
                   
               
               
                 105 
                 Ac-IWIAQ$LRR$GDAFNAYYARR-NH2 
               
               
                   
               
               
                 106 
                 Ac-IWIAQ$LRA$GDAFNAYYARR-NH2 
               
               
                   
               
               
                 107 
                 Ac-IWI$QEL$RIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 108 
                 Ac-IWI$QAL$RIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 109 
                 Ac-IWI$QEL$RIGDAFNAYYARR-NH2 
               
               
                   
               
               
                 110 
                 Ac-IWI$QAL$RIGDAFNAYYARR-NH2 
               
               
                   
               
               
                 111 
                 Ac-IWIAQALR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 112 
                 Ac-RWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 113 
                 Ac-RNIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 114 
                 Ac-RNIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 115 
                 Ac-RRIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 116 
                 Ac-RNIAQALR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 117 
                 Ac-RRIAQALR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 118 
                 H-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 119 
                 Ac-IWIAQEChaR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 120 
                 Ac-IWChgAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 121 
                 Ac-IRIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 122 
                 Ac-IWIAQAibLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 123 
                 Ac-IWIAibQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 124 
                 Ac-IWIAQALR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 125 
                 Ac-IWIAQALR$IGD$FNAYYAibRR-NH2 
               
               
                   
               
               
                 126 
                 Ac-IWIAQALR$IGD$FNASIARR-NH2 
               
               
                   
               
               
                 127 
                 Ac-IWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 128 
                 Ac-IWIAQALR$IGD$FNAFFARR-NH2 
               
               
                   
               
               
                 129 
                 Ac-IWIAQALR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 130 
                 Ac-IWIAQALR$IGD$FNAYKA-NH2 
               
               
                   
               
               
                 131 
                 Ac-IWIAQALR$IGD$FNAYK-NH2 
               
               
                   
               
               
                 132 
                 Ac-IWIAQALR$IGD$FNASKARR-NH2 
               
               
                   
               
               
                 133 
                 Ac-RRIAQQLR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 134 
                 Ac-WIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 135 
                 Pr-WIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 136 
                 Ac-RWIAQQLR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 137 
                 H-NMeRWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 138 
                 Ac-NMeRWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 139 
                 Ac-IWIAQHLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 140 
                 Ac-RWIAQHLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 141 
                 Ac-RWIAQELR$ChgGD$FNAYYARR-NH2 
               
               
                   
               
               
                 142 
                 Ac-RWIAQELR$ChaGD$FNAYYARR-NH2 
               
               
                   
               
               
                 143 
                 Ac-IWIAQQLR$IGD$FNAFFARR-NH2 
               
               
                   
               
               
                 144 
                 Ac-RWIAQQLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 145 
                 Ac-RWIAQQLR$IGD$FNAYFARR-NH2 
               
               
                   
               
               
                 146 
                 Ac-RWIAQQLR$IGD$FNATIARR-NH2 
               
               
                   
               
               
                 147 
                 Ac-RWIAQQLR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 148 
                 Ac-RWIAQQLR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 149 
                 Ac-RWIAQQLR$IGD$FNAYY-NH2 
               
               
                   
               
               
                 150 
                 Ac-IWIAQ$LRR$GDQFNAYYARR-NH2 
               
               
                   
               
               
                 151 
                 Ac-IWIAQ$LRQ$GDQFNAYYARR-NH2 
               
               
                   
               
               
                 152 
                 Ac-RWIAQ$LRA$GDQFNAYYARR-NH2 
               
               
                   
               
               
                 153 
                 H-CBaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 154 
                 H-CBaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 155 
                 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 156 
                 H-CBaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 157 
                 Ac-RRIAQQLR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 158 
                 Ac-RRIAQALR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 159 
                 Ac-RRIAQQLR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 160 
                 Ac-IWIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 161 
                 Ac-RWIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 162 
                 Ac-RRIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 163 
                 Ac-RRIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 164 
                 Ac-RWIAQQLR$IGD$FNARYA-NH2 
               
               
                   
               
               
                 165 
                 Ac-RWIAQQLR$IGD$FNAYRA-NH2 
               
               
                   
               
               
                 166 
                 Ac-RWIAQQLR$IGD$FNARYA-NH2 
               
               
                   
               
               
                 167 
                 Ac-RWIAQQLR$IGD$FNAYRA-NH2 
               
               
                   
               
               
                 168 
                 Ac-RRIAQQLR$IGD$FNASIA-NH2 
               
               
                   
               
               
                 169 
                 Ac-RRIAQALR$IGD$FNASIA-NH2 
               
               
                   
               
               
                 170 
                 Ac-RRIAQALR$IGD$FNASI-NH2 
               
               
                   
               
               
                 171 
                 Ac-RWIAQQLR$IGD$FNARR-NH2 
               
               
                   
               
               
                 172 
                 Ac-RWIAQQLR$IGD$FNAR-NH2 
               
               
                   
               
               
                 173 
                 Ac-RRIAQQLR$IGD$FNAR-NH2 
               
               
                   
               
               
                 174 
                 Ac-RRIAQQLR$IGD$FNAib-NH2 
               
               
                   
               
               
                 175 
                 Ac-RRIAQQLR$IGD$FNA-NH2 
               
               
                   
               
               
                 176 
                 Ac-RRIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 177 
                 Ac-RRIAQQLR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 178 
                 Ac-RRIAQQLR$IGD$FNAYYAib-NH2 
               
               
                   
               
               
                 179 
                 Ac-RWIAQQLR$IGD$FNAibRRA-NH2 
               
               
                   
               
               
                 180 
                 Ac-RWIAibQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 181 
                 Ac-RWAibAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 182 
                 Ac-RAibIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 183 
                 Ac-RFIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 184 
                 Ac-RFIAQQLR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 185 
                 Ac-RAibIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 186 
                 Ac-RWIAQQhFR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 187 
                 Ac-RWIAQQ3cfR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 188 
                 Ac-RWIAQQ1NalR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 189 
                 Ac-RWIAQQ2NalR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 190 
                 Ac-IWIAQEAR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 191 
                 Ac-RRI$QAL$RIGDAibFNARRA-NH2 
               
               
                   
               
               
                 192 
                 Ac-RRIAQ$LRR$GDAibFNARRA-NH2 
               
               
                   
               
               
                 193 
                 iBu-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 194 
                 Dec-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 195 
                 Bz-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 196 
                 H-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 197 
                 Chx-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 198 
                 Vrl-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 199 
                 PhAc-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 200 
                 MeImC-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 201 
                 Pr-RWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 202 
                 Ac-RWIAQALR$IGD$FNASIARR-NH2 
               
               
                   
               
               
                 203 
                 Ac-RWIAQQLR$IGD$FNASIARR-NH2 
               
               
                   
               
               
                 204 
                 Ac-RWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 205 
                 Ac-RRIAQALR$IGD$FNAFYA-NH2 
               
               
                   
               
               
                 206 
                 Ac-RRIAQQLR$IGD$FNAFYA-NH2 
               
               
                   
               
               
                 207 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHPr 
               
               
                   
               
               
                 208 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHiBu 
               
               
                   
               
               
                 209 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHChx 
               
               
                   
               
               
                 210 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHBn 
               
               
                   
               
               
                 211 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHMeChx 
               
               
                   
               
               
                 212 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHEtPh 
               
               
                   
               
               
                 213 
                 Ac-RWIAQALR$IGD$FNAYYARR-NHsBu 
               
               
                   
               
               
                 214 
                 Ac-RWIAQALR$IGD$FNARR-NHPr 
               
               
                   
               
               
                 215 
                 Ac-RWIAQALR$IGD$FNARR-NHiBu 
               
               
                   
               
               
                 216 
                 Ac-RWIAQALR$IGD$FNARR-NHChx 
               
               
                   
               
               
                 217 
                 Ac-RWIAQALR$IGD$FNARR-NHBn 
               
               
                   
               
               
                 218 
                 Ac-RWIAQALR$IGD$FNARR-NHMeChx 
               
               
                   
               
               
                 219 
                 Ac-RWIAQALR$IGD$FNARR-NHEtPh 
               
               
                   
               
               
                 220 
                 Ac-RWIAQALR$IGD$FNARR-NHsBu 
               
               
                   
               
               
                 221 
                 Ac-RWIAQALR$IGA$FNAYYARR-NH2 
               
               
                   
               
               
                 222 
                 Ac-RWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 223 
                 Ac-IWIAQALR$IGA$FNARRA-NH2 
               
               
                   
               
               
                 224 
                 Ac-IWIAQALR$IGN$FNARRA-NH2 
               
               
                   
               
               
                 225 
                 Ac-RWIAQAFR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 226 
                 H-CAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 227 
                 H-CAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 228 
                 Pr-IPIAQALR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 229 
                 Pr-PWIAQALR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 230 
                 KLH-CAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 231 
                 OVA-CAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 232 
                 KLH-CAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 233 
                 OVA-CAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 234 
                 Ac-IWIAEELA$IGD$FDAYYA-NH2 
               
               
                   
               
               
                 235 
                 FITC-BaIWIAEELA$IGD$FDAYYA-NH2 
               
               
                   
               
               
                 236 
                 Ac-IWIAEELA$IGD$FDAYYAAA-NH2 
               
               
                   
               
               
                 237 
                 FITC-BaIWIAEELA$IGD$FDAYYAAA-NH2 
               
               
                   
               
               
                 238 
                 Ac-RWIAQALR$IGD$FNAYKARR-NH2 
               
               
                   
               
               
                 239 
                 Ac-RWIAQQLR$IGD$FNAYKARR-NH2 
               
               
                   
               
               
                 240 
                 Ac-RWIAQALR$IGD$FNAYK-NH2 
               
               
                   
               
               
                 241 
                 Ac-RWIAQALR$IGD$FNAFK-NH2 
               
               
                   
               
               
                 242 
                 Ac-RWIAQALR$IGD$hFNAYYARR-NH2 
               
               
                   
               
               
                 243 
                 Ac-RWIAQALR$IGD$1NalNAYYARR-NH2 
               
               
                   
               
               
                 244 
                 Ac-RWIAQALR$IGD$2NalNAYYARR-NH2 
               
               
                   
               
               
                 245 
                 Ac-R2NalIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 246 
                 Ac-RhFIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 247 
                 Ac-RWIAQALR$IGNle$FNAYYARR-NH2 
               
               
                   
               
               
                 248 
                 Ac-RWNleAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 249 
                 Ac-RWIAQNleLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 250 
                 Ac-RWIAQQLR$IGD$FNAYK-NH2 
               
               
                   
               
               
                 251 
                 H-CAhxIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 252 
                 Ac-IWIAQALR$IGD$FNAYOrnARR-NH2 
               
               
                   
               
               
                 253 
                 Ac-IWIAQALR$IGD$FNAYOrn-NH2 
               
               
                   
               
               
                 254 
                 Ac-IWIAQALR$IGD$FNAYR-NH2 
               
               
                   
               
               
                 255 
                 Ac-IWIAQALR$IGD$FNAYRA-NH2 
               
               
                   
               
               
                 256 
                 Ac-IWIAQALR$IFD$FNARRA-NH2 
               
               
                   
               
               
                 257 
                 Ac-RWIAQALR$IGD$FNARRA-NH2 
               
               
                   
               
               
                 258 
                 Ac-IWIAQELR$ChgGD$FNAYYARR-NH2 
               
               
                   
               
               
                 259 
                 Ac-IWIAQQLR$IGD$FNAYY-NH2 
               
               
                   
               
               
                 260 
                 Ac-IWIAQ$LRA$GDQFNAYYARR-NH2 
               
               
                   
               
               
                 261 
                 Ac-IWIAQALR$IGD$FAibAYK-NH2 
               
               
                   
               
               
                 262 
                 Ac-IWIAQALR$IGD$FAibAYYARR-NH2 
               
               
                   
               
               
                 263 
                 Ac-IWIAQALR$IGN$FNAFYARR-NH2 
               
               
                   
               
               
                 264 
                 Ac-RWIAQALR$IGN$FNAFYARR-NH2 
               
               
                   
               
               
                 265 
                 Ac-IWIAQAibLR$IGN$FNAFYARR-NH2 
               
               
                   
               
               
                 266 
                 Ac-IWIAQALR$IGN$FNAibFYARR-NH2 
               
               
                   
               
               
                 267 
                 Ac-IWIAQAibLR$IGN$FNAibFYARR-NH2 
               
               
                   
               
               
                 268 
                 Pr-RNChgARHLA$VAibD$FNAFYARR-NH2 
               
               
                   
               
               
                 269 
                 Ac-IWIAQAAR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 270 
                 Ac-IWIAQAAR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 271 
                 Ac-IWIAQAAR$IGA$ANAYYARR-NH2 
               
               
                   
               
               
                 272 
                 Ac-IWIAQAAR$IEA$ANAYYARR-NH2 
               
               
                   
               
               
                 273 
                 Ac-IWIAQALR$DIG$FNAYYARR-NH2 
               
               
                   
               
               
                 274 
                 Ac-IWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 275 
                 Ac-IWIAQALR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 276 
                 Ac-IWIAQALD$IGR$FNAYYARR-NH2 
               
               
                   
               
               
                 277 
                 Ac-IWIAQAAD$IGR$ANAYYARR-NH2 
               
               
                   
               
               
                 278 
                 Ac-IWIAQAAD$IER$ANAYYARR-NH2 
               
               
                   
               
               
                 279 
                 Ac-IWIAQAibLR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 280 
                 Ac-IWIAQQLR$IGD$FNAYRA-NH2 
               
               
                   
               
               
                 281 
                 Ac-IWI$QAL$RIGDAibFNAYYARR-NH2 
               
               
                   
               
               
                 282 
                 t-Bu-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 283 
                 non-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 284 
                 Et-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 285 
                 Chx-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 286 
                 iPr-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 287 
                 Ph-U-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 288 
                 NH2CO-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 289 
                 Ac-IWIAQAAR$IGR$ANAYYARR-NH2 
               
               
                   
               
               
                 290 
                 Ac-IWIAQAAD$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 291 
                 Ac-IWIAQALD$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 292 
                 Ac-IWIAQALR$IGR$FNAYYARR-NH2 
               
               
                   
               
               
                 293 
                 Ac-IWIAQAAR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 294 
                 Ac-IWIAQAAD$IGR$ANAYYARR-NH2 
               
               
                   
               
               
                 295 
                 Ac-IWIAQALD$IGR$FNAYYARR-NH2 
               
               
                   
               
               
                 296 
                 Ac-IWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 297 
                 Ac-IWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 298 
                 Ac-IWIAQALR$IGNle$FNAYYARR-NH2 
               
               
                   
               
               
                 299 
                 Ac-IWIAQALR$IGA$FNAFYARR-NH2 
               
               
                   
               
               
                 300 
                 Ac-IWIAQALR$IGN$FNAFYARR-NH2 
               
               
                   
               
               
                 301 
                 Ac-IWIAQALR$IGNle$FNAFYARR-NH2 
               
               
                   
               
               
                 302 
                 Ac-RWIAQAFR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 303 
                 Ac-IWIAQAFR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 304 
                 Ac-IWIAQAFR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 305 
                 Ac-IWIAQAFR$IGN$FNAFYARR-NH2 
               
               
                   
               
               
                 306 
                 Ac-IWIAQALR$IG$EFNAYYARR-NH2 
               
               
                   
               
               
                 307 
                 Ac-IWIAQALRR$GD$FNAYYARR-NH2 
               
               
                   
               
               
                 308 
                 Ac-IWIAQALRAibIGAmDEFNAYYARR-NH2 
               
               
                   
               
               
                 309 
                 Ac-IWIAQELR#IGD#FNAYYARR-NH2 
               
               
                   
               
               
                 310 
                 Ac-IWIAQELR$IGD#FNAYYARR-NH2 
               
               
                   
               
               
                 311 
                 Ac-IWIAQELR#IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 312 
                 Ac-IWIAQALR$IGD$FNAYYARR-NHiBu 
               
               
                   
               
               
                 313 
                 Chx-IWIAQALR$IGD$FNAYYARR-NHiBu 
               
               
                   
               
               
                 314 
                 Chx-U-IWIAQALR$IGD$FNAYYARR-NHiBu 
               
               
                   
               
               
                 315 
                 FITC-AhxIWIAQALR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 316 
                 FITC-AhxIWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 317 
                 FITC-AhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 318 
                 FITC-AhxRWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 319 
                 FITC-AhxRWIAQALR$IGNle$FNAYYARR-NH2 
               
               
                   
               
               
                 320 
                 FITC-AhxIWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 321 
                 FITC-AhxIWIAQALR$IGNle$FNAYYARR-NH2 
               
               
                   
               
               
                 322 
                 Ac-IWIAQELRbKIGDbEFNAYYARR-NH2 
               
               
                   
               
               
                 323 
                 Ac-IWIAQELRbEIGDbKFNAYYARR-NH2 
               
               
                   
               
               
                 324 
                 Ac-IWIAQELRbKIAibDbEFNAYYARR-NH2 
               
               
                   
               
               
                 325 
                 Ac-IWIAQELRbEIAibDbKFNAYYARR-NH2 
               
               
                   
               
               
                 326 
                 Ac-IWIAQELR#sIGD#sFNAYYARR-NH2 
               
               
                   
               
               
                 327 
                 Ac-IWIAQELR#sIAibD#sFNAYYARR-NH2 
               
               
                   
               
               
                 328 
                 Ac-IWIAQELR$sIGD$sFNAYYARR-NH2 
               
               
                   
               
               
                 329 
                 Ac-IAmWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 330 
                 Ac-IWIAQELR$r5IGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 331 
                 Ac-IWIA$r5ELR$r5IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 332 
                 Ac-IWIA$ELR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 333 
                 Ac-IWIAQ$r8LRRIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 334 
                 Ac-I$r8IAQELR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 335 
                 HepIAQ$LRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 336 
                 HepIAQ$LR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 337 
                 HepWIA$ELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 338 
                 HepWIA$ELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 339 
                 Ac-I$IAQ$LRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 340 
                 Ac-I$IAQ$LR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 341 
                 Ac-IWIAQALE$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 342 
                 Ac-IWIAQALR$IGR$ANAYYARR-NH2 
               
               
                   
               
               
                 343 
                 Ac-IWIAQAAE$IGR$ANAYYARR-NH2 
               
               
                   
               
               
                 344 
                 Ac-IWIAQAAE$IGE$ANAYYARR-NH2 
               
               
                   
               
               
                 345 
                 Ac-RWIAQALR$IGR$FNAFYARR-NH2 
               
               
                   
               
               
                 346 
                 Ac-RWIAQALE$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 347 
                 Ac-RWIAQAAR$IGR$ANAFYARR-NH2 
               
               
                   
               
               
                 348 
                 Ac-RWIAQAAE$IGD$ANAFYARR-NH2 
               
               
                   
               
               
                 349 
                 Ac-RWIAQAAD$IGD$ANAFYARR-NH2 
               
               
                   
               
               
                 350 
                 Ac-RWIAQAAE$IGR$ANAFYARR-NH2 
               
               
                   
               
               
                 351 
                 Ac-RWIAQAAR$IGD$ANAFYARR-NH2 
               
               
                   
               
               
                 352 
                 Ac-RWIAQALR$DIG$FNAFYARR-NH2 
               
               
                   
               
               
                 353 
                 Ac-RWIAQALR$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 354 
                 Ac-RWIAQAAR$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 355 
                 Ac-RWIAQAAE$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 356 
                 Ac-RWIAQAAE$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 357 
                 Ac-RWIAQAAE$NIG$ANAYYARR-NH2 
               
               
                   
               
               
                 358 
                 Ac-RWIAQAAR$NIG$ANAYYARR-NH2 
               
               
                   
               
               
                 359 
                 Ac-IWIAQALR$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 360 
                 Ac-IWIAQAAR$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 361 
                 Ac-IWIAQAAE$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 362 
                 Ac-IWIAQAAE$IGN$ANAYYARR-NH2 
               
               
                   
               
               
                 363 
                 Ac-IWIAQAAE$NIG$ANAYYARR-NH2 
               
               
                   
               
               
                 364 
                 Ac-IWIAQAAR$NIG$ANAYYARR-NH2 
               
               
                   
               
               
                 365 
                 Ac-RWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 366 
                 Ac-IWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 367 
                 Ac-RWIAQALR$IEN$FNAYYARR-NH2 
               
               
                   
               
               
                 368 
                 Ac-RWIAQALR$IED$FNAFYARR-NH2 
               
               
                   
               
               
                 369 
                 Ac-IWIAQALR$IED$FNAFYARR-NH2 
               
               
                   
               
               
                 370 
                 Ac-IWIAQELR$IGR$FNAYYARR-NH2 
               
               
                   
               
               
                 371 
                 Ac-IWIAQELRbKIGDbDFNAYYARR-NH2 
               
               
                   
               
               
                 372 
                 Ac-IWIAQELRbDIGDbKFNAYYARR-NH2 
               
               
                   
               
               
                 373 
                 FITC-AhxRWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 374 
                 FITC-AhxRWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 375 
                 FITC-AhxIWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 376 
                 FITC-AhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 377 
                 Ac-RWIAQALR$/IGN$/FNAYYARR-NH2 
               
               
                   
               
               
                 378 
                 Ac-IWIAQELR#cIGR#cFNAYYARR-NH2 
               
               
                   
               
               
                 379 
                 Ac-IWIAQELRCIGRCFNAYYARR-NH2 
               
               
                   
               
               
                 380 
                 FITC-AhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 381 
                 Ac-IWIAQQLR%IGD%FNAYYARR-NH2 
               
               
                   
               
               
                 382 
                 FITC-AhxRNIARHLA$VGD$NleAibRSI-NH2 
               
               
                   
               
               
                 383 
                 FITC-AhxIWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 384 
                 Ac-IWIAQELR#c4IGD#c4FNAYYARR-NH2 
               
               
                   
               
               
                 385 
                 Ac-IWIAQELR$c4IGD$c4FNAYYARR-NH2 
               
               
                   
               
               
                 386 
                 Ac-IWIAQELR#cIGD#cFNAYYARR-NH2 
               
               
                   
               
               
                 387 
                 Ac-IWIAQELR$cIGD$cFNAYYARR-NH2 
               
               
                   
               
               
                 388 
                 FITC-AhxIWIAQELR#IGD#FNAYYARR-NH2 
               
               
                   
               
               
                 389 
                 5-FAM-AhxIWIAQELR#c4IGD#c4FNAYYARR-NH2 
               
               
                   
               
               
                 390 
                 5-FAM-AhxIWIAQELR$c4IGD$c4INAYYARR-NH2 
               
               
                   
               
               
                 391 
                 FITC-AhxIWIAQELR#cIGD#cFNAYYARR-NH2 
               
               
                   
               
               
                 392 
                 FITC-AhxIWIAQELR#sIGD#sFNAYYARR-NH2 
               
               
                   
               
               
                 393 
                 FITC-AhxIWIAQELR$cIGD$cFNAYYARR-NH2 
               
               
                   
               
               
                 394 
                 Ac-IWIAQELR$4n4IGD$4a5FNAYYARR-NH2 
               
               
                   
               
               
                 395 
                 Ac-IWIAQELR$4a5IGD$4n4FNAYYARR-NH2 
               
               
                   
               
               
                 396 
                 Ac-IWIAQELR$5n3IGD$5a5FNAYYARR-NH2 
               
               
                   
               
               
                 397 
                 Ac-IWIAQELR$5a5IGD$5n3FNAYYARR-NH2 
               
               
                   
               
               
                 398 
                 Ac-IWIAQELR#5n3IGD#5a5FNAYYARR-NH2 
               
               
                   
               
               
                 399 
                 Ac-IWIAQELR#5a5IGD#5n3FNAYYARR-NH2 
               
               
                   
               
               
                 400 
                 FITC-AhxIWIAQELR$4n4IGD$4a5FNAYYARR-NH2 
               
               
                   
               
               
                 401 
                 FITC-AhxIWIAQELR$4a5IGD$4n4FNAYYARR-NH2 
               
               
                   
               
               
                 402 
                 FITC-AhxIWIAQELR$5n3IGD$5a5FNAYYARR-NH2 
               
               
                   
               
               
                 403 
                 FITC-AhxIWIAQELR$5a5IGD$5n3FNAYYARR-NH2 
               
               
                   
               
               
                 404 
                 FITC-AhxIWIAQELR#5n3IGD#5a5FNAYYARR-NH2 
               
               
                   
               
               
                 405 
                 FITC-AhxIWIAQELR#5a5IGD#5n3FNAYYARR-NH2 
               
               
                   
               
               
                 406 
                 Ac-IWIAQALR$IEN$FNAYYARR-NH2 
               
               
                   
               
               
                 407 
                 Ac-RWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 408 
                 Ac-IWIAQALR$/IGN$/FNAYYARR-NH2 
               
               
                   
               
               
                 409 
                 Ac-IWIAQALR$/IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 410 
                 Ac-RWIChaQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 411 
                 Ac-RWIAQALR$IChaD$FNAFYARR-NH2 
               
               
                   
               
               
                 412 
                 Ac-RWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 413 
                 Ac-RWIAQALR$IGD$FNChaFYARR-NH2 
               
               
                   
               
               
                 414 
                 Ac-RWIAQALR$IGD$FNAFYChaRR-NH2 
               
               
                   
               
               
                 415 
                 Ac-IWIChaQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 416 
                 Ac-IWIAQALR$IChaN$FNAYYARR-NH2 
               
               
                   
               
               
                 417 
                 Ac-IWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 418 
                 Ac-IWIAQALR$IGN$FNChaYYARR-NH2 
               
               
                   
               
               
                 419 
                 Ac-IWIAQALR$IGN$FNAYYChaRR-NH2 
               
               
                   
               
               
                 420 
                 HepIAQ$LR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 421 
                 Ac-YGRKKRRQRRRIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 422 
                 FITC-AhxYGRKKRRQRRRIWIAQELRRIGDEFNAYYARR- 
               
               
                   
                 NH2 
               
               
                   
               
               
                 423 
                 Ac-RWIAQALR$IGD$FNAFYAHR-NH2 
               
               
                   
               
               
                 424 
                 Ac-RWIAQALR$IGD$FNAFYARH-NH2 
               
               
                   
               
               
                 425 
                 Ac-RWIAQSLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 426 
                 Ac-IWIAQELR#4n4IGD#4a5FNAYYARR-NH2 
               
               
                   
               
               
                 427 
                 FITC-AhxRWIAQALR$/IGN$/FNAYYARR-NH2 
               
               
                   
               
               
                 428 
                 FITC-AhxRWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 429 
                 FITC-AhxIWIAQALR$/IGN$/FNAYYARR-NH2 
               
               
                   
               
               
                 430 
                 FITC-AhxIWIAQALR$/IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 431 
                 FITC-AhxIWIAQELR$sIGD$sFNAYYARR-NH2 
               
               
                   
               
               
                 432 
                 Biotin-AhxRWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 433 
                 Biotin-AhxRWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 434 
                 Biotin-AhxIWIAQALRRIGNEFNAYYARR-NH2 
               
               
                   
               
               
                 435 
                 Biotin-AhxIWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 436 
                 FITC-AhxIWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 437 
                 Biotin-AhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 438 
                 Biotin-AhxRWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 439 
                 Biotin-AhxIWIAQALR$IGN$FNAYYARR-NH2 
               
               
                   
               
               
                 440 
                 Biotin-AhxIWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 441 
                 Biotin-AhxIWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 442 
                 5-FAM-AhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 443 
                 DuIAQDprLRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 444 
                 DuIAQDprLRRIGDQFNAYYARR-NH2 
               
               
                   
               
               
                 445 
                 DuWIADprALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 446 
                 DuWIADprALRRIGDQFNAYYARR-NH2 
               
               
                   
               
               
                 447 
                 5-FAM-AhxIWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 448 
                 5-FAM-AhxIWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 449 
                 5-FAM-AhxIWIAQAARRDIGEANAYYARR-NH2 
               
               
                   
               
               
                 450 
                 5-FAM-AhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 451 
                 5-FAM-AhxIWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 452 
                 Ac-IWIAQEAmLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 453 
                 Ac-IWIAQELR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 454 
                 Ac-IWIAQELR$IGD$FNAAmfYARR-NH2 
               
               
                   
               
               
                 455 
                 Ac-IWIAQELR$IGD$FNAYAmfARR-NH2 
               
               
                   
               
               
                 456 
                 Ac-IWIAQELR$IGD$FNAAmyeYARR-NH2 
               
               
                   
               
               
                 457 
                 Ac-IWIAQELR$IGD$FNAYAmyeARR-NH2 
               
               
                   
               
               
                 458 
                 Ac-IWIAQELR$IGD$FNAYYAAmrR-NH2 
               
               
                   
               
               
                 459 
                 Ac-IWIAQELR$IGD$FNAYFARR-NH2 
               
               
                   
               
               
                 460 
                 Ac-IWIAQELR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 461 
                 Ac-RWIAQELR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 462 
                 Ac-RWIAQALR$IGD$FNAAmfYARR-NH2 
               
               
                   
               
               
                 463 
                 Ac-RWIAQALR$IGD$FNAFYAAmrR-NH2 
               
               
                   
               
               
                 464 
                 Ac-IWIA$r5ALRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 465 
                 Ac-IWIA$ALRStIGDEFN$s8YYARR-NH2 
               
               
                   
               
               
                 466 
                 Ac-IWIAQALR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 467 
                 5-FAM-AhxIWIAQELRbKIGDbDFNAYYARR-NH2 
               
               
                   
               
               
                 468 
                 5-FAM-AhxIWIAQELRbDIGDbKFNAYYARR-NH2 
               
               
                   
               
               
                 469 
                 5-FAM-AhxIWIAQELR#IGD#FNAYYARR-NH2 
               
               
                   
               
               
                 470 
                 5-FAM-AhxIWIAQELR#cmlIGD#cmlFNAYYARR-NH2 
               
               
                   
               
               
                 471 
                 5-FAM-AhxRWIAQALR$IGD$FNAFYAHR-NH2 
               
               
                   
               
               
                 472 
                 5-FAM-AhxRWIAQALRRIGDEFNAFYAHR-NH2 
               
               
                   
               
               
                 473 
                 5-FAM-AhxRWIAQALR$IGD$FNAFYARH-NH2 
               
               
                   
               
               
                 474 
                 5-FAM-AhxRWIAQALRRIGDEFNAFYARH-NH2 
               
               
                   
               
               
                 475 
                 Ac-RWIAQALR$IGD$FNAFYAAR-NH2 
               
               
                   
               
               
                 476 
                 Ac-RWIAQALR$IGD$FNAFYARA-NH2 
               
               
                   
               
               
                 477 
                 Ac-RWIAQAAR$DIG$ANAFYARR-NH2 
               
               
                   
               
               
                 478 
                 Ac-IWIAQAAR$DIG$ANAFYARR-NH2 
               
               
                   
               
               
                 479 
                 5-FAM-AhxIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 480 
                 5-FAM-AhxIWIAQELRRIEDEFNAYYARR-NH2 
               
               
                   
               
               
                 481 
                 Ac-IWIAQELRNleIGDNleFNAYYARR-NH2 
               
               
                   
               
               
                 482 
                 Ac-IWIAQELRAibIGDAibFNAYYARR-NH2 
               
               
                   
               
               
                 483 
                 5-FAM-AhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 484 
                 5-FAM-AhxRWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 485 
                 H-CAhxIWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 486 
                 H-CAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 487 
                 5-FAM-AhxIWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 488 
                 OVA-CAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 489 
                 OVA-CAhxRWIAQQLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 490 
                 H-CAhxRWIAQAAR$IGR$ANAFYARR-NH2 
               
               
                   
               
               
                 491 
                 H-CAhxRWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 492 
                 H-CAhxIWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 493 
                 OVA-CAhxRWIAQAAR$IGD$ANAYYARR-NH2 
               
               
                   
               
               
                 494 
                 OVA-CAhxRWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 495 
                 OVA-CAhxIWIAQALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 496 
                 Ac-6xhAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 497 
                 Ac-FlagAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 498 
                 5-FAM-6xhAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 499 
                 5-FAM-FlagAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 500 
                 Ac-6xhAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 501 
                 Ac-FlagAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 502 
                 5-FAM-6xhAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 503 
                 5-FAM-FlagAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 504 
                 5-FAM-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 505 
                 5-FAM-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 506 
                 Ac-IWIAQELR%OcoIGD%OcoFNAYYARR-NH2 
               
               
                   
               
               
                 507 
                 Ac-AhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 508 
                 Ac-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 509 
                 H-CAhxIWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 510 
                 5-FAM-AhxIWIAQELR$/IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 511 
                 Ac-RWIAQALRRIGDEFNAFYAHH-NH2 
               
               
                   
               
               
                 512 
                 5-FAM-AhxRWIAQALR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 513 
                 5-FAM-AhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 514 
                 Ac-TatAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 515 
                 5-FAM-TatAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 516 
                 Ac-TatAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 517 
                 5-FAM-TatAhxIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 518 
                 Ac-TatAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 519 
                 5-FAM-TatAhxRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 520 
                 Ac-TatAhxRWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 521 
                 5-FAM-TatAhxRWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 522 
                 5-FAM-AhxRWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 523 
                 5-FAM-AhxIWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 524 
                 Ac-TatAhxIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 525 
                 5-FAM-TatAhxIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 526 
                 Ac-IWIAQELRRIEDDFNAYYARR-NH2 
               
               
                   
               
               
                 527 
                 Ac-TatAhxIWIAQELRRIEDDFNAYYARR-NH2 
               
               
                   
               
               
                 528 
                 5-FAM-TatAhxIWIAQELRRIEDDFNAYYARR-NH2 
               
               
                   
               
               
                 529 
                 Ac-IWIAQELR$/IED$/FNAYYARR-NH2 
               
               
                   
               
               
                 530 
                 5-FAM-AhxIWIAQELR$/IED$/FNAYYARR-NH2 
               
               
                   
               
               
                 531 
                 5-FAM-AhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 532 
                 Ac-TatAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 533 
                 5-FAM-TatAhxIWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 534 
                 Ac-IWIAQAARRDIGEANAYYARR-NH2 
               
               
                   
               
               
                 535 
                 Ac-TatAhxIWIAQAARRDIGEANAYYARR-NH2 
               
               
                   
               
               
                 536 
                 5-FAM-TatAhxIWIAQAARRDIGEANAYYARR-NH2 
               
               
                   
               
               
                 537 
                 Ac-IWIAQAAR$DIG$ANAYYARR-NH2 
               
               
                   
               
               
                 538 
                 5-FAM-AhxIWIAQAAR$/DIG$/ANAYYARR-NH2 
               
               
                   
               
               
                 539 
                 Ac-IWIAQELRRIEDEFNAYYARR-NH2 
               
               
                   
               
               
                 540 
                 Ac-IWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 541 
                 Ac-RWIAQALR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 542 
                 TatAhxIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 543 
                 5-FAM-TatAhxIWIAQELRRIEDEFNAYYARR-NH2 
               
               
                   
               
               
                 544 
                 Ac-IWIAQALRRI$DEF$AYYARR-NH2 
               
               
                   
               
               
                 545 
                 Ac-IWIAQALR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 546 
                 Ac-IWIAQELRRIEDEFNAYYARR-NH2 
               
               
                   
               
               
                 547 
                 Ac-IWIAQELR$/IED$/FNAYYARR-NH2 
               
               
                   
               
               
                 548 
                 Ac-IWIAQAARRDIGEANAYYARR-NH2 
               
               
                   
               
               
                 549 
                 Ac-IWIAQAAR$/DIG$/ANAYYARR-NH2 
               
               
                   
               
               
                 550 
                 Ac-IWIAQALR$/IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 551 
                 Ac-RWIAQALR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 552 
                 Ac-IWIAQALRRIGDEFNAFYARR-NH2 
               
               
                   
               
               
                 553 
                 5-FAM-AhxIWIAQALR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 554 
                 Ac-RWIAQALR$IGD$FNA-OH 
               
               
                   
               
               
                 555 
                 Ac-RWIAQALR$IGD$FNAFYA-OH 
               
               
                   
               
               
                 556 
                 Ac-RWIAQALR$IGD$FNAF-OH 
               
               
                   
               
               
                 557 
                 Ac-RWIAQALR$IGD$FNAFYARAmr-NH2 
               
               
                   
               
               
                 558 
                 5-FAM-AhxIWIAQALR$/r8IGDEFN$/YYARR-NH2 
               
               
                   
               
               
                 559 
                 Ac-IWIAQALR$/r8IGDEFN$/YYARR-NH2 
               
               
                   
               
               
                 560 
                 OVA-CAhxIWIAQALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 561 
                 Ac-IWIA$ALR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 562 
                 Ac-IWIA$/ALR$/IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 563 
                 5-FAM-AhxIWIA$/r5ALRSt//IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 564 
                 5-FAM-AhxIWIA$ALRStIGDEFN$s8YYARR-NH2 
               
               
                   
               
               
                 565 
                 HepIAQ$LR$IGD$FNAYYARRTag5-FAM 
               
               
                   
               
               
                 566 
                 5-FAM-AhxIWIA$/ALRSt//IGDEFN$/s8YYARR-NH2 
               
               
                   
               
               
                 567 
                 5-FAM-AhxIWIA$r5ALRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 568 
                 Ac-AAARAAARAAA$AAA$AAAAA-NH2 
               
               
                   
               
               
                 569 
                 Ac-AAAAAAAR$AAA$AAAAAARA-NH2 
               
               
                   
               
               
                 570 
                 Ac-AAARAAARAAAKAAAEAAAAA-NH2 
               
               
                   
               
               
                 571 
                 Ac-AAAAAAARKAAAEAAAAAARA-NH2 
               
               
                   
               
               
                 572 
                 Ac-AAARAAAAAARAAAAA-NH2 
               
               
                   
               
               
                 573 
                 Ac-IWIAQELR%OIGD%OFNAYYARR-NH2 
               
               
                   
               
               
                 574 
                 Ac-IWIA$/r5ALRSt//IGD$/FNAYYARR-NH2 
               
               
                   
               
               
                 575 
                 Ac-IWIA$/ALRSt//IGDEFN$/s8YYARR-NH2 
               
               
                   
               
               
                 576 
                 Ac-I$r8IAQALR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 577 
                 Ac-IWIAQALRRIG$r8EFNAYY$RR-NH2 
               
               
                   
               
               
                 578 
                 Ac-I$/r8IAQALR$/IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 579 
                 Ac-IWIAQALRRIG$/r8EFNAYY$/RR-NH2 
               
               
                   
               
               
                 580 
                 Ac-RWIAQALR$IGD$FNAFYAibRR-NH2 
               
               
                   
               
               
                 581 
                 Ac-RWIAQALR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 582 
                 Ac-RWIAQALR$r5IGD$r5FNAFYARR-NH2 
               
               
                   
               
               
                 583 
                 Ac-IWIAQALRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 584 
                 Ac-RWIAEALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 585 
                 Ac-RWIAEALR$IGD$FDAFYARR-NH2 
               
               
                   
               
               
                 586 
                 Ac-RWIAQALR$/r5IGD$/FNAFYARR-NH2 
               
               
                   
               
               
                 587 
                 Ac-RWIAQALR$/IGD$/r5FNAFYARR-NH2 
               
               
                   
               
               
                 588 
                 Ac-IWIAQALRRIG$EFN$YYARR-NH2 
               
               
                   
               
               
                 589 
                 Ac-IWIAQALRRIGD$FNA$YARR-NH2 
               
               
                   
               
               
                 590 
                 Ac-IWIAQALRRIGDE$NAY$ARR-NH2 
               
               
                   
               
               
                 591 
                 Ac-IWIAQALRRIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 592 
                 %HepIAQ%LR%IGD%FNAYYARR-NH2 
               
               
                   
               
               
                 593 
                 Ac-SYDDALLMLRSIGDSL-NH2 
               
               
                   
               
               
                 594 
                 Ac-TEMMLAIMLRGIGDSL-NH2 
               
               
                   
               
               
                 595 
                 Ac-WVSEFLAIGDYVDFHY-NH2 
               
               
                   
               
               
                 596 
                 Ac-DLPVFILRNIGDSLIG-NH2 
               
               
                   
               
               
                 597 
                 Ac-VSDFDDFLTSVLDIYL-NH2 
               
               
                   
               
               
                 598 
                 5-FAM-AhxIWIA$ALR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 599 
                 5-FAM-AhxIWIAQALRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 600 
                 5-FAM-AhxI$IAQ$LRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 601 
                 5-FAM-AhxI$IAQ$LR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 602 
                 5-FAM-AhxIWIAQALRRIG$EFN$YYARR-NH2 
               
               
                   
               
               
                 603 
                 5-FAM-AhxIWIAQALRRIGD$FNA$YARR-NH2 
               
               
                   
               
               
                 604 
                 5-FAM-AhxIWIAQALRRIGDE$NAY$ARR-NH2 
               
               
                   
               
               
                 605 
                 5-FAM-AhxI$r8IAQALR$IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 606 
                 5-FAM-AhxIWIAQALRRIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 607 
                 5-FAM-AhxIWIAQALRRIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 608 
                 Ac-RWIAQALR$IGD$FDAFYARR-NH2 
               
               
                   
               
               
                 609 
                 Ac-IWIA$ALRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 610 
                 Ac-IWIAQALR$IGDStFNA$r5YARR-NH2 
               
               
                   
               
               
                 611 
                 Ac-RWIA$ALRStIGD$r5FNAFYARR-NH2 
               
               
                   
               
               
                 612 
                 Ac-RWIAQALR$IGDStFNA$r5YARR-NH2 
               
               
                   
               
               
                 613 
                 Ac-TENleNleLAINleLR$IGD$L-NH2 
               
               
                   
               
               
                 614 
                 Ac-WVSEFL$IGD$VDFHY-NH2 
               
               
                   
               
               
                 615 
                 Ac-DLPVFILR$IGD$LIG-NH2 
               
               
                   
               
               
                 616 
                 Ac-VSDFDDFLT$VLD$YL-NH2 
               
               
                   
               
               
                 617 
                 Ac-RWIAQALR$trIGD$trFNAFYARR-NH2 
               
               
                   
               
               
                 618 
                 Ac-RWIAQALR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 619 
                 Ac-RWIAQALR$IGD$FNAibFYARR-NH2 
               
               
                   
               
               
                 620 
                 Ac-RWIAQALR$IGD$FNAibFYAibRR-NH2 
               
               
                   
               
               
                 621 
                 Ac-PEG3RWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 622 
                 Ac-RWIAQALR$IGD$FNAFYAibHH-NH2 
               
               
                   
               
               
                 623 
                 Ac-RWIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 624 
                 Ac-RWIAQALR$IGD$FNAibFYAibHH-NH2 
               
               
                   
               
               
                 625 
                 Ac-RWIAQALR$IGD$FNAAmfYAHH-NH2 
               
               
                   
               
               
                 626 
                 Ac-RWIAQALR$r5IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 627 
                 Ac-RWIAQALR$IGD$r5FNAFYARR-NH2 
               
               
                   
               
               
                 628 
                 Ac-RWIAQALR$IGD$FNAFYARRPEG3-NH2 
               
               
                   
               
               
                 629 
                 Ac-RWIAQ$r8LRRIGDStFNAFYA$s8R-NH2 
               
               
                   
               
               
                 630 
                 Ac-R$r8IAQALRStIGDEFN$s8FYARR-NH2 
               
               
                   
               
               
                 631 
                 Ac-RWIAQALR$IGD$FNADamfYARR-NH2 
               
               
                   
               
               
                 632 
                 Ac-RWIAQALRbDIGDbKFNAFYARR-NH2 
               
               
                   
               
               
                 633 
                 Ac-RWIAQALRbKIGDbDFNAFYARR-NH2 
               
               
                   
               
               
                 634 
                 Ac-RWIAQALR$IAibD$FNAFYARR-NH2 
               
               
                   
               
               
                 635 
                 Ac-R$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 636 
                 Ac-RWIA$ALRStIGD$r5FNAAmfYARR-NH2 
               
               
                   
               
               
                 637 
                 Ac-RWIA$r5ALRStIGD$FNAAmfYARR-NH2 
               
               
                   
               
               
                 638 
                 Ac-IWIA$ALRStIGD$r5FNAAmfYARR-NH2 
               
               
                   
               
               
                 639 
                 Ac-IWIA$r5ALRStIGD$FNAAmfYARR-NH2 
               
               
                   
               
               
                 640 
                 Ac-RWIAQQLR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 641 
                 Ac-RWIAQALR#c4IGD#c4FNAFYARR-NH2 
               
               
                   
               
               
                 642 
                 Ac-RWIAQALR#c4eIGD#c4eFNAFYARR-NH2 
               
               
                   
               
               
                 643 
                 Ac-RWIAQLLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 644 
                 Ac-RWIAQALR$IGD$FNAhFYARR-NH2 
               
               
                   
               
               
                 645 
                 Ac-RWIAQALR$IGD$FNAAmfYAAmrR-NH2 
               
               
                   
               
               
                 646 
                 Biotin-IWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 647 
                 5-FAM-AhxIWIA$/ALR$/IGDEFNAYYARR-NH2 
               
               
                   
               
               
                 648 
                 5-FAM-AhxRWIAQALR$DIG$FNAFYARR-NH2 
               
               
                   
               
               
                 649 
                 Ac-RWIAQALR$IGD$FNAFYARR-OH 
               
               
                   
               
               
                 650 
                 Ac-IWIAQALR$5a5IGD$5n3FNAYYARR-NH2 
               
               
                   
               
               
                 651 
                 Ac-RWIAQQFR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 652 
                 Ac-RWIAQQLR$IGD$FNAFYAHR-NH2 
               
               
                   
               
               
                 653 
                 Ac-RWIAQQLR$IGD$FNAFYARH-NH2 
               
               
                   
               
               
                 654 
                 Ac-RWIAQQLRRIGDEFNAFYAHH-NH2 
               
               
                   
               
               
                 655 
                 Pr-WIAQQLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 656 
                 Ac-WIAQQLR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 657 
                 Ac-WIAQQLR$IGD$FNAFYAR-NH2 
               
               
                   
               
               
                 658 
                 Ac-IWIAQELD$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 659 
                 Ac-RWIAQALD$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 660 
                 Ac-IWIAQLLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 661 
                 Ac-RWIAQQLR$IGD$1NalNAYYARR-NH2 
               
               
                   
               
               
                 662 
                 Ac-RWIAQLLR$IGD$1NalNAYYARR-NH2 
               
               
                   
               
               
                 663 
                 Ac-RWIAQALR$IGD$1NalNAFYARR-NH2 
               
               
                   
               
               
                 664 
                 Ac-RWIAQALR$5n3IGD$5a5FNAFYARR-NH2 
               
               
                   
               
               
                 665 
                 Ac-RWIAQALR$5a5IGD$5n3FNAFYARR-NH2 
               
               
                   
               
               
                 666 
                 Ac-RWIAQALR$/n3IGD$/a5FNAFYARR-NH2 
               
               
                   
               
               
                 667 
                 Ac-RWIAQALR$/a5IGD$/n3FNAFYARR-NH2 
               
               
                   
               
               
                 668 
                 Pr-WIAQQLR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 669 
                 Pr-NIAQQLR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 670 
                 Pr-SIAQQLR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 671 
                 Pr-WIAQQLR$IGD$FNASYAR-NH2 
               
               
                   
               
               
                 672 
                 Ac-RWIAQNLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 673 
                 Ac-RWIAQRLR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 674 
                 Pr-WIAQ$LRR$GDAFNASYARR-NH2 
               
               
                   
               
               
                 675 
                 Ac-RWIAQQLR$IGD$FNAYYAHR-NH2 
               
               
                   
               
               
                 676 
                 Ac-RWIAQQLR$IGD$FNAYYARH-NH2 
               
               
                   
               
               
                 677 
                 Ac-RWIAQQLR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 678 
                 Pr-WIAQQLR$IGD$FNASIARR-NH2 
               
               
                   
               
               
                 679 
                 Ac-IWIAQQLR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 680 
                 FITC-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 681 
                 FITC-BaIWIAQELD$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 682 
                 FITC-BaRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 683 
                 FITC-BaRWIAQALD$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 684 
                 HBS-IWAarAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 685 
                 FITC-BaBaRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 686 
                 5-TAMRA-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 687 
                 5-TAMRA-BaRWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 688 
                 5-TAMRA-BaIWIAQELR$IED$FNAYYARR-NH2 
               
               
                   
               
               
                 689 
                 Ac-RWIAQQLR$IGD$FNASYARR-NH2 
               
               
                   
               
               
                 690 
                 Ac-RWIAQQLR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 691 
                 Ac-RWIAQALR$IGD$FNAC13FYARR-NH2 
               
               
                   
               
               
                 692 
                 Ac-WIAQQLR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 693 
                 Ac-RIAQELR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 694 
                 Ac-RIAQQLR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 695 
                 Ac-RWIA4QAL7R$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 696 
                 Ac-IWIAQELR#cIGR#cFNAYYARR-NH2 
               
               
                   
               
               
                 697 
                 Ac-IWIAQELR#cIGD#cFNAYYARR-NH2 
               
               
                   
               
               
                 698 
                 Ac-IWIAQELR#5n3IGD#5a5FNAYYARR-NH2 
               
               
                   
               
               
                 699 
                 FITC-AhxIWIAQELR#5n3IGD#5a5FNAYYARR-NH2 
               
               
                   
               
               
                 700 
                 HepIAQ$LR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 701 
                 IAQDprLRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 702 
                 IAQDprLRRIGDQFNAYYARR-NH2 
               
               
                   
               
               
                 703 
                 WIADprALRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 704 
                 WIADprALRRIGDQFNAYYARR-NH2 
               
               
                   
               
               
                 705 
                 HepIAQ$LR$IGD$FNAYYARRTag5-FAM- 
               
               
                   
               
               
                 706 
                 Ac-TENleNleLAINleLR$IGD$L-NH2 
               
               
                   
               
               
                 707 
                 5-TAMRA-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 708 
                 Ac-RWIAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 709 
                 Ac-IWIAQELR#sIGD#sFNAYYARR-NH2 
               
               
                   
               
               
                 710 
                 Ac-IWIAQELR#sIAibD#sFNAYYARR-NH2 
               
               
                   
               
               
                 711 
                 Ac-IWIAQELR$sIGD$sFNAYYARR-NH2 
               
               
                   
               
               
                 712 
                 HepIAQ$LR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 713 
                 Ac-RWIAQALR$IGD$VNAFYARR-NH2 
               
               
                   
               
               
                 714 
                 Pr-WIAQQLR$IGD$VNAFYARR-NH2 
               
               
                   
               
               
                 715 
                 Ac-RWIAQALR$IGD$VNASYARR-NH2 
               
               
                   
               
               
                 716 
                 Ac-RWIAQQLR$IGD$VNAFYARR-NH2 
               
               
                   
               
               
                 717 
                 Ac-RWIAQQLR$IGD$VNASYARR-NH2 
               
               
                   
               
               
                 718 
                 Ac-RWIAQALR$IGD$LNAFYARR-NH2 
               
               
                   
               
               
                 719 
                 Ac-RWIAQQLR$IGD$LNAFYARR-NH2 
               
               
                   
               
               
                 720 
                 Ac-KALETLRRVGDGV$RNH$TA-NH2 
               
               
                   
               
               
                 721 
                 Pr-WIAQQLR$IGD$VNAFYARR-NH2 
               
               
                   
               
               
                 722 
                 Pr-WIAQQLR$IGD$VNASYARR-NH2 
               
               
                   
               
               
                 723 
                 Ac-RWIAQQLR$IGD$VNAFYAHH-NH2 
               
               
                   
               
               
                 724 
                 Pr-WIAQQLR$IGD$VNAFYAR-NH2 
               
               
                   
               
               
                 725 
                 Pr-WIAQQLR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 726 
                 Pr-WIAQQLR$IGD$FNAFYARH-NH2 
               
               
                   
               
               
                 727 
                 Pr-WIAQQLR$IGD$FNAFYAHR-NH2 
               
               
                   
               
               
                 728 
                 Ac-RWIA4QAL7R$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 729 
                 Pr-WIAQQLR$IGD$LNAYYARR-NH2 
               
               
                   
               
               
                 730 
                 Pr-WIAQQLR$IGD$LNASYARR-NH2 
               
               
                   
               
               
                 731 
                 Pr-WIAQQLR$IGD$LNAYYARH-NH2 
               
               
                   
               
               
                 732 
                 Pr-WIAQQLR$IGD$LNAYYAHR-NH2 
               
               
                   
               
               
                 733 
                 Pr-RIAQQLR$IGD$LNAYYARH-NH2 
               
               
                   
               
               
                 734 
                 Pr-RIAQQLR$IGD$LNAYYAHR-NH2 
               
               
                   
               
               
                 735 
                 Pr-RIAQQLR$IGD$LNAYYAHH-NH2 
               
               
                   
               
               
                 736 
                 Pr-SIAQQLR$IGD$LNAYYARR-NH2 
               
               
                   
               
               
                 737 
                 Pr-AibIAQQLR$IGD$LNAYYARR-NH2 
               
               
                   
               
               
                 738 
                 Pr-YIAQQLR$IGD$LNAYYARR-NH2 
               
               
                   
               
               
                 739 
                 Pr-RIAQQLR$IGD$LNAYYAR-NH2 
               
               
                   
               
               
                 740 
                 Ac-RSIAQQLR$IGD$LNAYYARR-NH2 
               
               
                   
               
               
                 741 
                 Ac-IWIAQELR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 742 
                 Pr-SIAQQLR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 743 
                 Ac-RWIA$r5ALRStDIL$FNAFYARR-NH2 
               
               
                   
               
               
                 744 
                 Ac-RWIAQALR$5a5DIL$5n3FNAFYARR-NH2 
               
               
                   
               
               
                 745 
                 Ac-RWIAQQLR$IGD$FNAYYAH-NH2 
               
               
                   
               
               
                 746 
                 Ac-RWIA$r5ALRStIDL$FNAFYARR-NH2 
               
               
                   
               
               
                 747 
                 Ac-RWIAQALR$5a5ILL$5n3FNAFYARR-NH2 
               
               
                   
               
               
                 748 
                 Pr-RIAQQLR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 749 
                 Pr-WIAQQLR$IGD$VNAYYAHR-NH2 
               
               
                   
               
               
                 750 
                 Pr-WIAQQLR$IGD$VNAFYAHR-NH2 
               
               
                   
               
               
                 751 
                 Pr-RIAQQLR$IGD$VNAYYAHR-NH2 
               
               
                   
               
               
                 752 
                 Ac-RWIAQALR$5n3DIL$5a5FNAFYARR-NH2 
               
               
                   
               
               
                 753 
                 Ac-R$r8IAQALRStIGDLFN$s8FYARR-NH2 
               
               
                   
               
               
                 754 
                 Pr-RIAQQLR$IGD$FNAYYAH-NH2 
               
               
                   
               
               
                 755 
                 Ac-RWIAQALR$5n3ILL$5a5FNAFYARR-NH2 
               
               
                   
               
               
                 756 
                 Ac-RAIAQQLR$IGD$FNAYYAH-NH2 
               
               
                   
               
               
                 757 
                 Pr-WIAQQLR$IGD$LNAYYAHH-NH2 
               
               
                   
               
               
                 758 
                 Pr-SIAQQLR$IGD$LNAYYAHR-NH2 
               
               
                   
               
               
                 759 
                 Ac-RWIAQQLR$IGD$VNAFYAHR-NH2 
               
               
                   
               
               
                 760 
                 Ac-IWIA$QLRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 761 
                 Ac-RWIA$QLRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 762 
                 Ac-RWIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 763 
                 Ac-RWIAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 764 
                 Ac-IWIA$ALRStIGD$r5LNAYYARR-NH2 
               
               
                   
               
               
                 765 
                 Ac-IWIAQALR$IGDStFNA$r5YAHH-NH2 
               
               
                   
               
               
                 766 
                 Ac-RWIA$ALRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 767 
                 Pr-WIAQQLR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 768 
                 Pr-SIAQQLR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 769 
                 Ac-WIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 770 
                 Ac-RWIAQALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 771 
                 Ac-IWIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 772 
                 Ac-IWIAQALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 773 
                 Ac-IWIAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 774 
                 Ac-ELR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 775 
                 Ac-QELR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 776 
                 Ac-AQELR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 777 
                 Ac-IAQELR$r5IGDStFNA$YARR-NH2 
               
               
                   
               
               
                 778 
                 Ac-RWIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 779 
                 Ac-RWIAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 780 
                 Ac-RWIAQALR$IGDStFNA$r5YAHH-NH2 
               
               
                   
               
               
                 781 
                 Ac-RWIAQQLR$IGDStFNA$r5YAHH-NH2 
               
               
                   
               
               
                 782 
                 Ac-IWIAQQFR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 783 
                 Ac-RWIAQQFR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 784 
                 Ac-IWIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 785 
                 Ac-RWIAQQLR$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 786 
                 Ac-IWIAQALR$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 787 
                 Ac-RWIAQALR$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 788 
                 Ac-RWIAQALR$IGD$LNAibYYAHH-NH2 
               
               
                   
               
               
                 789 
                 Ac-RIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 790 
                 Pr-WIAQQLR$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 791 
                 Pr-RIAQQLR$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 792 
                 Pr-NIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 793 
                 Pr-SIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 794 
                 Pr-NIAQQLR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 795 
                 Pr-SIAQQLR$IGD$FNAibYYARR-NH2 
               
               
                   
               
               
                 796 
                 Ac-IWIA$r5QLRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 797 
                 Ac-IWIA$ALDStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 798 
                 Ac-RWIAQALD$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 799 
                 Ac-RWIAQQLR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 800 
                 Ac-IWIAQQLR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 801 
                 Ac-RAIAQQLR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 802 
                 Ac-IRIAQQLR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 803 
                 Ac-RAIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 804 
                 Ac-IRIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 805 
                 Ac-RWIAQALR$IGA$FNAibFYAHH-NH2 
               
               
                   
               
               
                 806 
                 Ac-RWIAQQLR$IGA$FNAFYAHH-NH2 
               
               
                   
               
               
                 807 
                 Pr-RIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 808 
                 Pr-WIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 809 
                 Ac-RWIAQALR$IGD$INAibFYAHH-NH2 
               
               
                   
               
               
                 810 
                 Ac-RWIAQALR$IGD$ChgNAibFYAHH-NH2 
               
               
                   
               
               
                 811 
                 Ac-IWIAQQLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 812 
                 Ac-IWIAQQLR$IGD$INAibFYAHH-NH2 
               
               
                   
               
               
                 813 
                 Ac-RWIAQQLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 814 
                 Ac-RWIAQQLR$IGD$INAibFYAHH-NH2 
               
               
                   
               
               
                 815 
                 Pr-WIAQQLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 816 
                 Ac-RWIAQAFR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 817 
                 Ac-RWIAQANleR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 818 
                 Ac-RWIAQAChgR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 819 
                 Ac-RWIAQALR$IGD$LNAFYAibHH-NH2 
               
               
                   
               
               
                 820 
                 Ac-RWIAQALR$IGD$VNAFYAibHH-NH2 
               
               
                   
               
               
                 821 
                 Ac-RWIAQALD$IGD$FNAibYYAHH-NH2 
               
               
                   
               
               
                 822 
                 Ac-RWIA$r5ALRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 823 
                 Ac-IWIA$r5ALDStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 824 
                 Ac-IWIA$r5ALRStIGD$FNAYYAibRR-NH2 
               
               
                   
               
               
                 825 
                 Ac-IWIA$r5ALRStIGD$VNAYYARR-NH2 
               
               
                   
               
               
                 826 
                 Ac-IRIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 827 
                 Ac-INIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 828 
                 Ac-IFIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 829 
                 Ac-ISIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 830 
                 Ac-IAibIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 831 
                 Ac-IWNleAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 832 
                 Ac-IWIAQANleR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 833 
                 Ac-IWIAibQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 834 
                 Pr-IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 835 
                 Ac-IWIAQAibLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 836 
                 Ac-IWIAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 837 
                 Ac-IWIAQFLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 838 
                 Ac-IAIAAFLR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 839 
                 Ac-IWIAQALR$IGD$FNAibYYAibHH-NH2 
               
               
                   
               
               
                 840 
                 Ac-IWIAQALR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 841 
                 Ac-RWIAQALR$r8IGDAibFN$FYAHH-NH2 
               
               
                   
               
               
                 842 
                 Ac-RWIAQALR$r8IGDAFN$FYAHH-NH2 
               
               
                   
               
               
                 843 
                 Ac-RWIA$r8ALRAibIG$AFNAibYYAHH-NH2 
               
               
                   
               
               
                 844 
                 Ac-RWIA$r8ALRAIG$AFNAibYYAHH-NH2 
               
               
                   
               
               
                 845 
                 Ac-IWIAQALR$IGD$ChaNAibFYAHH-NH2 
               
               
                   
               
               
                 846 
                 5-FAM-BaIWIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 847 
                 5-FAM-BaRWIAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 848 
                 Ac-IWILQALR$IAibD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 849 
                 Ac-IAIAQFLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 850 
                 Ac-IWIAQALR$r8IGDAFN$FYAHH-NH2 
               
               
                   
               
               
                 851 
                 Ac-IWIAQALR$r8IGDAibFN$FYAHH-NH2 
               
               
                   
               
               
                 852 
                 Ac-IWIAQNLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 853 
                 Ac-IWIAQHLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 854 
                 Ac-RWIAAQLR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 855 
                 Ac-RNIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 856 
                 Ac-RFIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 857 
                 Ac-RAibIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 858 
                 Ac-RAIAQFLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 859 
                 Ac-RWIAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 860 
                 Ac-RWIAQFLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 861 
                 Ac-RWIAQAibLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 862 
                 Ac-RWIAQALR$IGD$FNAibFYQHH-NH2 
               
               
                   
               
               
                 863 
                 Ac-RWIAQHLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 864 
                 Ac-RWIAQALR$NleGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 865 
                 Pr-IAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 866 
                 Ac-RWIALALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 867 
                 Pr-WIALALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 868 
                 Ac-RAIAFALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 869 
                 Ac-WIAQALR$IGD$FNAibFYQHH-NH2 
               
               
                   
               
               
                 870 
                 Ac-CCPGCCBaIWIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 871 
                 Ac-CCPGCCBaRWIAQALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 872 
                 Ac-CCPGCCBaRWIAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 873 
                 Ac-IWIAQALR$IGD$FNAibFYQHH-NH2 
               
               
                   
               
               
                 874 
                 Ac-RWIAQAibLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 875 
                 Ac-IWIAQLLR$IGD$FNAibFYQHH-NH2 
               
               
                   
               
               
                 876 
                 Ac-RWIAQALR$IGD$FNRFYAHH-NH2 
               
               
                   
               
               
                 877 
                 Ac-RWIAQALR$IGD$FNAFYRHH-NH2 
               
               
                   
               
               
                 878 
                 Ac-RWIAQRLR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 879 
                 Ac-RWIAQALR$IGD$FNARYAHH-NH2 
               
               
                   
               
               
                 880 
                 Ac-RWIAERLR$IGD$FNAFYAHH-NH2 
               
               
                   
               
               
                 881 
                 Ac-RWIAQALR$IGD$FNQFYAHH-NH2 
               
               
                   
               
               
                 882 
                 Ac-RWIAQALR$IGD$FNAFYQHH-NH2 
               
               
                   
               
               
                 883 
                 Ac-RWIAQELR$IGD$FNARYAHH-NH2 
               
               
                   
               
               
                 884 
                 Ac-RWIAQALR$IGD$FNAQYAHH-NH2 
               
               
                   
               
               
                 885 
                 Ac-RWIAQQLR$IGD$QNQQYQHH-NH2 
               
               
                   
               
               
                 886 
                 Ac-IWIAAFLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 887 
                 Ac-IWIAQALR$IGD$FNleAibFYAHH-NH2 
               
               
                   
               
               
                 888 
                 Ac-IWIAQALR$IGD$FNleAibFYQHH-NH2 
               
               
                   
               
               
                 889 
                 Ac-IWIAQAibLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 890 
                 Ac-IWIAQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 891 
                 Ac-IWIAQAAR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 892 
                 Ac-IAIAFALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 893 
                 Ac-IWIALALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 894 
                 Ac-IWIAQALR$IGD$VNAibFYQHH-NH2 
               
               
                   
               
               
                 895 
                 Ac-IWIAQELR$4n4IGD$4a3FNAYYARR-NH2 
               
               
                   
               
               
                 896 
                 Ac-IWIAQELR$4a3IGD$4n4FNAYYARR-NH2 
               
               
                   
               
               
                 897 
                 Ac-IWIAQELR$4n3IGD$4a5FNAYYARR-NH2 
               
               
                   
               
               
                 898 
                 Ac-IWIAQELR$4a5IGD$4n3FNAYYARR-NH2 
               
               
                   
               
               
                 899 
                 Ac-IWIAQELR$4n5IGD$4a5FNAYYARR-NH2 
               
               
                   
               
               
                 900 
                 Ac-IWIAQELR$4a5IGD$4n5FNAYYARR-NH2 
               
               
                   
               
               
                 901 
                 Ac-RCouIAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 902 
                 Ac-RCouIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 903 
                 Ac-ICouIAQALRRIGDELNAibFYAHH-NH2 
               
               
                   
               
               
                 904 
                 Ac-RCouIAQALRRIGDEFNAFYAHH-NH2 
               
               
                   
               
               
                 905 
                 Ac-IWIAQALR$IGD$FNAFYAibHH-NH2 
               
               
                   
               
               
                 906 
                 Ac-IWIALALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 907 
                 Ac-IAIAFALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 908 
                 Ac-RWIAQHLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 909 
                 Ac-IWIAQHLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 910 
                 Ac-RWIAQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 911 
                 Ac-IWIAQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 912 
                 Ac-IWIAQFLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 913 
                 Ac-IWIAQALR$IGD$HNAibFYAHH-NH2 
               
               
                   
               
               
                 914 
                 Ac-IWIAHLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 915 
                 Ac-IWIAQALR$IGD$INAibFYAHH-NH2 
               
               
                   
               
               
                 916 
                 Ac-IWIAQLLR$IGD$INAibFYAHH-NH2 
               
               
                   
               
               
                 917 
                 Ac-IHIAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 918 
                 Ac-IHIAQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 919 
                 Ac-IWIAQLLR$IGD$VNAibFYAHA-NH2 
               
               
                   
               
               
                 920 
                 Ac-IWIAQLLR$IGD$VNAibFYAAH-NH2 
               
               
                   
               
               
                 921 
                 Ac-RWIAQALD$IGR$VNAibFYAHH-NH2 
               
               
                   
               
               
                 922 
                 Ac-RWIAQALD$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 923 
                 Ac-IWIAQALD$IGR$VNAibFYAHH-NH2 
               
               
                   
               
               
                 924 
                 Ac-RWIAQAAR$IAibD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 925 
                 Ac-IWIAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 926 
                 Ac-IWIAQALD$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 927 
                 Ac-IWIAQAAR$IAibD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 928 
                 Ac-RWIAQALD$r5IGRStFNA$YAHH-NH2 
               
               
                   
               
               
                 929 
                 Ac-IWIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 930 
                 Ac-RWIAAQLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 931 
                 Ac-IWIAAQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 932 
                 Ac-IWNleAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 933 
                 Ac-RWNleAQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 934 
                 Ac-IWNleAibQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 935 
                 Ac-RWNleAibQLLR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 936 
                 Ac-IRIAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 937 
                 Ac-ISIAQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 938 
                 Ac-IRIAibQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 939 
                 Ac-ISIAibQLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 940 
                 Ac-IWIA$r5ALDStIGR$FNAYYARR-NH2 
               
               
                   
               
               
                 941 
                 Pr-WIAibQLLR$IGD$FNAibFYAibHH-NH2 
               
               
                   
               
               
                 942 
                 Ac-IWIAibQLLR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 943 
                 Pr-WIAQLLR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 944 
                 Pr-WIAibQALR$IGD$FNAibFYAibHH-NH2 
               
               
                   
               
               
                 945 
                 Ac-IWIAibQALR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 946 
                 Ac-RWIAibQALR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 947 
                 Ac-IWIAQAibLR$IGD$FNAibFYAibHH-NH2 
               
               
                   
               
               
                 948 
                 Ac-IWIAQAibLR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 949 
                 Ac-RWIAQAibLR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 950 
                 Ac-IWIAQALR$IGD$VNAibFYAibHH-NH2 
               
               
                   
               
               
                 951 
                 FITC-BaIWIAQELR$IGD$F 
               
               
                   
               
               
                 952 
                 Ac-I$IAQ$LRRIGDEF$AYY$R-NH2 
               
               
                   
               
               
                 953 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$R-NH2 
               
               
                   
               
               
                 954 
                 Ac-I$IAQ$LRRIGDEF$AYY$HH-NH2 
               
               
                   
               
               
                 955 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$HH-NH2 
               
               
                   
               
               
                 956 
                 Ac-IWIA$ALR$IGD$FNA$YARR-NH2 
               
               
                   
               
               
                 957 
                 Ac-IWIA$ALR$IGD$FNA$YAHH-NH2 
               
               
                   
               
               
                 958 
                 Ac-IWIA$ALR$IGD$FNA$YAR-NH2 
               
               
                   
               
               
                 959 
                 Ac-IWIAQ$LRA$GDAFNAYYAR-NH2 
               
               
                   
               
               
                 960 
                 Ac-IWIAQ$LRA$GDAFNAYYAHH-NH2 
               
               
                   
               
               
                 961 
                 Ac-IWIAQALR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 962 
                 Ac-IWIAQALR$r8IGDNleFN$YYARR-NH2 
               
               
                   
               
               
                 963 
                 Ac-IWIAQALR$r8IGDAibFN$YYARR-NH2 
               
               
                   
               
               
                 964 
                 Ac-IWIAQALR$r8IGDAFN$YYAHH-NH2 
               
               
                   
               
               
                 965 
                 Ac-IWIAQALR$r8IGDNleFN$YYAHH-NH2 
               
               
                   
               
               
                 966 
                 Ac-IWIAQALR$r8IGDAibFN$YYAHH-NH2 
               
               
                   
               
               
                 967 
                 Ac-IWIAQALR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 968 
                 Ac-ICouIAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 969 
                 Ac-ICouIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 970 
                 Ac-ICouIAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 971 
                 Ac-ICouIAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 972 
                 Ac-ICouIAQALR$IGD$FNAibFYAAA-NH2 
               
               
                   
               
               
                 973 
                 Ac-ICouIAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 974 
                 Ac-RCou2IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 975 
                 Ac-RCou2IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 976 
                 Ac-RCou2IAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 977 
                 Ac-ICou2IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 978 
                 Ac-ICou2IAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 979 
                 Ac-RWIAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 
               
               
                   
               
               
                 980 
                 Ac-RCou3IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 981 
                 Ac-RCou3IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 982 
                 Ac-RCou3IAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 983 
                 Ac-ICou3IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 984 
                 Ac-ICou3IAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 985 
                 Ac-IWIAQALR$IGD$FNAibFYAAA-NH2 
               
               
                   
               
               
                 986 
                 Ac-IWIAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 987 
                 Ac-IWIAQALR$r8IGAAibFN$FYAHH-NH2 
               
               
                   
               
               
                 988 
                 Ac-IWIAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 989 
                 Ac-ICou2IA$ALRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 990 
                 Ac-IDprIA$ALRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 991 
                 Ac-ICou2IA$QLRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 992 
                 Ac-IDprIA$QLRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 993 
                 Ac-IWIAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 994 
                 Ac-ICou2IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 995 
                 Ac-IDprIAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 996 
                 Ac-RDprIAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 997 
                 Ac-IWIAQALR$IGD$FNAibCou2YAHH-NH2 
               
               
                   
               
               
                 998 
                 Ac-IWIAQALR$IGD$FNAibCou3YAHH-NH2 
               
               
                   
               
               
                 999 
                 Ac-IWIAQALR$IGD$FNAibDprYAHH-NH2 
               
               
                   
               
               
                 1000 
                 Ac-IRIAQALR$IGD$FNAibCou2YAHH-NH2 
               
               
                   
               
               
                 1001 
                 Ac-IRIAQALR$IGD$FNAibCou3YAHH-NH2 
               
               
                   
               
               
                 1002 
                 Ac-IRIAQALR$IGD$FNAibDprYAHH-NH2 
               
               
                   
               
               
                 1003 
                 Ac-IAibIAQALR$IGD$FNAibCou2YAHH-NH2 
               
               
                   
               
               
                 1004 
                 Ac-IAibIAQALR$IGD$FNAibCou3YAHH-NH2 
               
               
                   
               
               
                 1005 
                 Ac-IAibIAQALR$IGD$FNAibDprYAHH-NH2 
               
               
                   
               
               
                 1006 
                 Ac-ICou2IAQALR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 1007 
                 Ac-ICou3IAQALR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 1008 
                 Ac-IDprIAQALR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 1009 
                 Pam-IWIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1010 
                 Pam-ICou2IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1011 
                 Pam-ICou3IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1012 
                 Pam-IDprIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1013 
                 Ac-IWIAQALR$5n3IGD$5a5FNAibFYAHH-NH2 
               
               
                   
               
               
                 1014 
                 Ac-IWIAQALR$5a5IGD$5n3FNAibFYAHH-NH2 
               
               
                   
               
               
                 1015 
                 Ac-IWIAQALR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1016 
                 Ac-ICou2IAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1017 
                 Ac-ICou2IAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1018 
                 Ac-ICou2IAQALR$IGD$FNAibFYAAA-NH2 
               
               
                   
               
               
                 1019 
                 Ac-ICou2IAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1020 
                 Ac-RCou2IAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1021 
                 Ac-RCou2IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1022 
                 Ac-RCou2IAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1023 
                 Ac-RCou2IAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1024 
                 Ac-RCou2IAQALR$IGD$FNAibFYAAA-NH2 
               
               
                   
               
               
                 1025 
                 Ac-RCou2IAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1026 
                 Ac-IWIAQALR$r8IGAAibFN$FYAHH-NH2 
               
               
                   
               
               
                 1027 
                 Ac-IWIA$ALRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 1028 
                 Pr-Cou2IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1029 
                 Pr-Cou2IAQALR$IGD$FNAibFYQHH-NH2 
               
               
                   
               
               
                 1030 
                 Ac-RWIAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1031 
                 Ac-RWIAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1032 
                 Ac-RWIAQALR$IGD$FNAibFYAAA-NH2 
               
               
                   
               
               
                 1033 
                 Ac-RWIAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1034 
                 Ac-ICou2IAQALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1035 
                 Ac-ICou2IAQELR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1036 
                 Ac-ICou2IAQALD$IGR$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1037 
                 Ac-ICou4IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1038 
                 Ac-RCou4IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1039 
                 Ac-ICou4IAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1040 
                 Ac-ICou4IAQQLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1041 
                 Ac-RCou4IAQALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1042 
                 Ac-IWIAQALR$5a5IGD$5n3FNAibFYAHH-NH2 
               
               
                   
               
               
                 1043 
                 Ac-RWIAQALR$/rn3IGDSta/FNA$/n3YAHH-NH2 
               
               
                   
               
               
                 1044 
                 Ac-ICou2IA$r5ALRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1045 
                 Ac-ICou2IA$r5QLRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1046 
                 Ac-ICou4IA$r5ALRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1047 
                 Ac-ICou4IA$r5QLRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1048 
                 Ac-RCou2IAQALR$IGDStFNA$r5YAHH-NH2 
               
               
                   
               
               
                 1049 
                 Ac-RCou4IAQALR$IGDStFNA$r5YAHH-NH2 
               
               
                   
               
               
                 1050 
                 Ac-ICou7IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1051 
                 Ac-RCou7IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1052 
                 Ac-IWIAQALR$IGD$FNAibCou7YAHH-NH2 
               
               
                   
               
               
                 1053 
                 Ac-IRIAQALR$IGD$FNAibCou7YAHH-NH2 
               
               
                   
               
               
                 1054 
                 Ac-ICou2IAQQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1055 
                 Ac-AAIAQALR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1056 
                 Ac-AAIAQALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1057 
                 Ac-IWIAQALR$IGD$FNAibFYAAAAa-NH2 
               
               
                   
               
               
                 1058 
                 Ac-IWIAQALR$IGD$FNAibAAAAAa-NH2 
               
               
                   
               
               
                 1059 
                 Ac-IWIAQALR$IGD$FNAibFYAHHAAAAa-NH2 
               
               
                   
               
               
                 1060 
                 Ac-IWIAQALA$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1061 
                 Ac-IWIAQALR$IGD$FAAibFYA-NH2 
               
               
                   
               
               
                 1062 
                 Ac-IWIALALR$IGD$FAAibFYA-NH2 
               
               
                   
               
               
                 1063 
                 Ac-IWIALALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1064 
                 Ac-IWIALALR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 1065 
                 Ac-IWIALALR$IGD$FAAAAA-NH2 
               
               
                   
               
               
                 1066 
                 Ac-IWIALALR$IGD$FNAAAA-NH2 
               
               
                   
               
               
                 1067 
                 Ac-IWIALLLR$IGD$FAAibFYAHH-NH2 
               
               
                   
               
               
                 1068 
                 Ac-IWIALLLR$IGD$FNAibFYAHH-NH2 
               
               
                   
               
               
                 1069 
                 Ac-IWIALLLR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1070 
                 Ac-IWIALLLR$IGD$FNAibFYAAAAAa-NH2 
               
               
                   
               
               
                 1071 
                 Ac-RWIALQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1072 
                 Ac-RWIAQQLR$r5IGDStFNA$YA-NH2 
               
               
                   
               
               
                 1073 
                 Ac-RWIAQQLR$r5IGDStFNA$YAAa-NH2 
               
               
                   
               
               
                 1074 
                 Ac-RWIALQLR$r5IGDStFNA$YAAa-NH2 
               
               
                   
               
               
                 1075 
                 Ac-RCou2IALQLR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1076 
                 Ac-RCou2IAQQLR$r5IGDStFNA$YA-NH2 
               
               
                   
               
               
                 1077 
                 Ac-RCou2IAQQLR$r5IGDStFNA$YAAa-NH2 
               
               
                   
               
               
                 1078 
                 Ac-RCou2IALQLR$r5IGDStFNA$YAAa-NH2 
               
               
                   
               
               
                 1079 
                 Ac-RCou2IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 
               
               
                   
               
               
                 1080 
                 RCou4IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 
               
               
                   
               
               
                 1081 
                 5-FAM-BaRWIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1082 
                 Ac-RCou2IAQQLRAibIGDAibFNAAibYAHH-NH2 
               
               
                   
               
               
                 1083 
                 Ac-RWIAQQLRAibIGDAibFNAAibYAHH-NH2 
               
               
                   
               
               
                 1084 
                 Ac-RCou2IAQELR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1085 
                 Ac-RWIAQELR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1086 
                 Ac-ICou2IAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1087 
                 Ac-IWIAQALR4Me$5a5IGD$5n3FNAibFYAHH-NH2 
               
               
                   
               
               
                 1088 
                 Ac-IWIAQALR4Ph$5a5IGD$5n3FNAibFYAHH-NH2 
               
               
                   
               
               
                 1089 
                 Ac-NleWIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1090 
                 Ac-KWIAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1091 
                 Ac-RWIAQALR$r5IGDStFNA$YQHH-NH2 
               
               
                   
               
               
                 1092 
                 Ac-IWIAQALR$r5IGDStFNA$YQHH-NH2 
               
               
                   
               
               
                 1093 
                 Ac-NleCou2IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1094 
                 Ac-KCou2IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1095 
                 Ac-IWIAQELRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1096 
                 Ac-IWIAQELRRIGDEFN$YYA$R-NH2 
               
               
                   
               
               
                 1097 
                 Ac-IWIAQEL$r8RIGDEF$AYYARR-NH2 
               
               
                   
               
               
                 1098 
                 Ac-IWIAQELR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1099 
                 Ac-IWIAQELRRIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1100 
                 Ac-I$IAQStLRRIGD$s8FNAYYARR-NH2 
               
               
                   
               
               
                 1101 
                 Ac-I$r8IAQELRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 1102 
                 Ac-I$r8IAQELRStIGDEFN$s8YYARR-NH2 
               
               
                   
               
               
                 1103 
                 Ac-IWI$QELStRIGDEF$s8AYYARR-NH2 
               
               
                   
               
               
                 1104 
                 Ac-IWIA$ELRStIGD$r5FNAYYARR-NH2 
               
               
                   
               
               
                 1105 
                 Ac-IWIA$r5ELRStIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1106 
                 Ac-IWIA$ELRStIGDEFN$s8YYARR-NH2 
               
               
                   
               
               
                 1107 
                 Ac-IWIAQ$r8LRRIGDStFNAYYA$s8R-NH2 
               
               
                   
               
               
                 1108 
                 Ac-IWIAQEL$r8RIGDEFStAYY$r5RR-NH2 
               
               
                   
               
               
                 1109 
                 Ac-IWIAQELR$IGDStFNAYYA$s8R-NH2 
               
               
                   
               
               
                 1110 
                 Ac-IWIAQELR$r8IGDEFNStYYA$r5R-NH2 
               
               
                   
               
               
                 1111 
                 Ac-I$IAQ$LRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1112 
                 Ac-I$IAQ$LRRIGDEFN$YYA$R-NH2 
               
               
                   
               
               
                 1113 
                 Ac-IWI$QEL$RIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1114 
                 Ac-IWI$QEL$RIGDEFN$YYA$R-NH2 
               
               
                   
               
               
                 1115 
                 Ac-IWIA$ELR$IGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1116 
                 Ac-IWIA$ELR$IGDEFN$YYA$R-NH2 
               
               
                   
               
               
                 1117 
                 Ac-I$r8IAQELR$IGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1118 
                 Ac-I$r8IAQELR$IGDEFN$YYA$R-NH2 
               
               
                   
               
               
                 1119 
                 Ac-IWIAQ$r8LRRIGD$F$AYY$RR-NH2 
               
               
                   
               
               
                 1120 
                 Ac-IWIAQ$r8LRRIGD$FN$YYA$R-NH2 
               
               
                   
               
               
                 1121 
                 Ac-I$IAQ$L$r8RIGDEF$AYYARR-NH2 
               
               
                   
               
               
                 1122 
                 Ac-I$IAQ$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1123 
                 Ac-I$IAQ$LRRIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1124 
                 Ac-IWI$QEL$RIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1125 
                 Ac-IWIA$ELR$IGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1126 
                 5-FAM-BaIWIAQELRRIGDEFNAYYARR-NH2 
               
               
                   
               
               
                 1127 
                 5-FAM-BaIWIAQELR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1128 
                 5-FAM-BaNLWAAQRYGRELR$NleSD$FVDSFKK-NH2 
               
               
                   
               
               
                 1129 
                 5-FAM-BaKALETLR$VGD$VQRNHETAF-NH2 
               
               
                   
               
               
                 1130 
                 Ac-RCou2IAQALR$IGD$FNAFYARR-NH2 
               
               
                   
               
               
                 1131 
                 Ac-RCou2IAQALR$5rn3IGDSta5FNA$5n3YAHH-NH2 
               
               
                   
               
               
                 1132 
                 Ac-IWI$QEL$RIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1133 
                 Ac-IWIAQ$r8LRRIGD$F$AYY$RR-NH2 
               
               
                   
               
               
                 1134 
                 Ac-IWIAQ$r8LRRIGD$FN$YYA$R-NH2 
               
               
                   
               
               
                 1135 
                 Ac-IWI$QEL$RIGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1136 
                 Ac-IWIA$ELR$IGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1137 
                 Ac-IWI$QELStRIGDEF$s8AYYARR-NH2 
               
               
                   
               
               
                 1138 
                 Ac-IWIAQ$r8LRRIGDStFNAYYA$s8R-NH2 
               
               
                   
               
               
                 1139 
                 Ac-IWIAQEL$r8RIGDEFStAYY$r5RR-NH2 
               
               
                   
               
               
                 1140 
                 Ac-I$r8IAQELR$IGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1141 
                 Ac-IWIAQ$r8LRRIGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1142 
                 Ac-IWIAQELRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1143 
                 Ac-IWIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1144 
                 Ac-WIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1145 
                 Ac-IAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1146 
                 Ac-IAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1147 
                 Ac-IAQALA$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1148 
                 Ac-IAQALR$r8IADAFN$YYA-NH2 
               
               
                   
               
               
                 1149 
                 Ac-IAQALR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1150 
                 Ac-IAQALR$r8IGDAFA$YYA-NH2 
               
               
                   
               
               
                 1151 
                 Ac-IAQALR$r8IGDAFN$AYA-NH2 
               
               
                   
               
               
                 1152 
                 Ac-IAQALR$r8IGDAFN$YAA-NH2 
               
               
                   
               
               
                 1153 
                 Ac-IAQALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1154 
                 Ac-IAQALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1155 
                 Ac-IWIAQALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1156 
                 Ac-IWIAQALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1157 
                 Ac-I$IAQ$LR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1158 
                 HepIAQ$LRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1159 
                 HepIAQ$LR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1160 
                 HepIA$ALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1161 
                 HepIA$ALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1162 
                 Ac-I$IAQ$LRRIGDEF$AYY$AA-NH2 
               
               
                   
               
               
                 1163 
                 Ac-I$IAQ$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1164 
                 Ac-I$IAA$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1165 
                 Ac-I$IAV$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1166 
                 Ac-I$IAL$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1167 
                 Ac-I$IAI$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1168 
                 Ac-I$IAF$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1169 
                 Ac-I$IAY$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1170 
                 Ac-I$IAG$LRRIGDEF$AYY$A-NH2 
               
               
                   
               
               
                 1171 
                 Ac-I$IAQ$LRAIGDAF$AYY$A-NH2 
               
               
                   
               
               
                 1172 
                 Ac-I$IAQ$LRAIGDAibF$AYY$A-NH2 
               
               
                   
               
               
                 1173 
                 Ac-I$IAQ$LRAibIGDAF$AYY$A-NH2 
               
               
                   
               
               
                 1174 
                 Ac-I$IAQ$LRAibIGDAibF$AYY$A-NH2 
               
               
                   
               
               
                 1175 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$A-NH2 
               
               
                   
               
               
                 1176 
                 Ac-I$IAQ$LRNleIGDAibF$AYY$A-NH2 
               
               
                   
               
               
                 1177 
                 Ac-I$IAQ$LRAibIGDNleF$AYY$A-NH2 
               
               
                   
               
               
                 1178 
                 Ac-I$IAQ$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1179 
                 Ac-I$IAA$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1180 
                 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1181 
                 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1182 
                 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1183 
                 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1184 
                 Ac-I$IAY$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1185 
                 Ac-I$IAG$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1186 
                 Ac-I$IAQ$LR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1187 
                 Ac-I$IAQ$LR$r8IGDNleFN$YYA-NH2 
               
               
                   
               
               
                 1188 
                 Ac-I$IAQ$LR$r8IGDAibFN$YYA-NH2 
               
               
                   
               
               
                 1189 
                 Ac-IWIA$ELR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1190 
                 Ac-IWIA$ALR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1191 
                 Ac-IWIA$VLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1192 
                 Ac-IWIA$LLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1193 
                 Ac-IWIA$ILR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1194 
                 Ac-IWIA$FLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1195 
                 Ac-IWIA$YLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1196 
                 Ac-IWIA$GLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1197 
                 Ac-IWIA$SLR$IGD$r8FNAYYA$A-NH2 
               
               
                   
               
               
                 1198 
                 Ac-I$IAQ$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1199 
                 Ac-IWIA$ELR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1200 
                 Ac-WIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1201 
                 Ac-IAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1202 
                 Ac-IAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1203 
                 Ac-IAQALA$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1204 
                 Ac-IAQALR$r8IADAFN$YYA-NH2 
               
               
                   
               
               
                 1205 
                 Ac-IAQALR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1206 
                 Ac-IAQALR$r8IGDAFA$YYA-NH2 
               
               
                   
               
               
                 1207 
                 Ac-IAQALR$r8IGDAFN$AYA-NH2 
               
               
                   
               
               
                 1208 
                 Ac-IAQALR$r8IGDAFN$YAA-NH2 
               
               
                   
               
               
                 1209 
                 Ac-I$IAL$LR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1210 
                 Ac-I$IALALR$IGDAFN$YYA$A-NH2 
               
               
                   
               
               
                 1211 
                 Ac-IWIA$ALR$IGDAFN$YYA$A-NH2 
               
               
                   
               
               
                 1212 
                 Ac-IWIA$ALRStIGDAFN$s8YYA-NH2 
               
               
                   
               
               
                 1213 
                 Ac-IWIA$ALRStIGDNleFN$s8YYA-NH2 
               
               
                   
               
               
                 1214 
                 Ac-I$r8IALALRStIGDAFN$s8YYA-NH2 
               
               
                   
               
               
                 1215 
                 Ac-I$r8IALALRStIGD$r5FNAYYA-NH2 
               
               
                   
               
               
                 1216 
                 Ac-IWIALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1217 
                 Ac-IWIAQALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1218 
                 Ac-I$IAA$LRAibIGDAibF$AYY$A-NH2 
               
               
                   
               
               
                 1219 
                 Ac-I$IAL$LRAibIGDAibF$AYY$A-NH2 
               
               
                   
               
               
                 1220 
                 Ac-I$r8IALALR$IGDAF$AYY$A-NH2 
               
               
                   
               
               
                 1221 
                 Ac-I$r8IAQELRStIGDAFN$s8YYARR-NH2 
               
               
                   
               
               
                 1222 
                 Ac-I$r8IAQALRStIGDAFN$s8YYA-NH2 
               
               
                   
               
               
                 1223 
                 HBS-IAAarALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1224 
                 HBS-IAAarALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1225 
                 HBS-IWAarAQALRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1226 
                 HBS-IWAarAQALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1227 
                 HepIAQ$LRRIGDEFNAYYAHH-NH2 
               
               
                   
               
               
                 1228 
                 HepIAQ$LR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1229 
                 HepIA$ALR$IGD$FNAYYAHH-NH2 
               
               
                   
               
               
                 1230 
                 Ac-I$IAQ$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1231 
                 Ac-I$IAA$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1232 
                 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1233 
                 Ac-I$IAV$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1234 
                 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1235 
                 Ac-I$IAI$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1236 
                 Ac-I$IAY$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1237 
                 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1238 
                 Ac-I$IAL$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1239 
                 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1240 
                 Ac-I$IAF$LR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1241 
                 Ac-I$IAQ$LR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1242 
                 Ac-I$IAQ$LR$r8IGDNleFN$YYA-NH2 
               
               
                   
               
               
                 1243 
                 Ac-I$IAQ$LR$r8IGDAibFN$YYA-NH2 
               
               
                   
               
               
                 1244 
                 Ac-I$IAQ$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1245 
                 Ac-I$IAA$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1246 
                 Ac-I$IAV$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1247 
                 Ac-I$IAL$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1248 
                 Ac-I$IAI$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1249 
                 Ac-I$IAF$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1250 
                 Ac-I$IAY$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1251 
                 Ac-I$IAG$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1252 
                 Ac-I$IAQ$LRAIGDAF$AYY$-NH2 
               
               
                   
               
               
                 1253 
                 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1254 
                 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 
               
               
                   
               
               
                 1255 
                 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1256 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 
               
               
                   
               
               
                 1257 
                 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1258 
                 Ac-I$IAQ$LRAibIGDNleF$AYY$-NH2 
               
               
                   
               
               
                 1259 
                 Ac-IWIA$ALR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1260 
                 Ac-IWIA$VLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1261 
                 Ac-IWIA$LLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1262 
                 Ac-IWIA$ILR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1263 
                 Ac-IWIA$FLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1264 
                 Ac-IWIA$YLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1265 
                 Ac-IWIA$GLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1266 
                 Ac-IWIA$SLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1267 
                 Ac-I$r8IALALR$IGDAFN$YYA$A-NH2 
               
               
                   
               
               
                 1268 
                 Ac-IWIA$r5ALRStIGDNleFN$r8YYA-NH2 
               
               
                   
               
               
                 1269 
                 Ac-I$IAL$LR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1270 
                 Ac-ICou2IAQALR$r5IGDStFNA$YAHH-NH2 
               
               
                   
               
               
                 1271 
                 Ac-I$IAQ$LRAIGDAF$AYY$-NH2 
               
               
                   
               
               
                 1272 
                 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1273 
                 Ac-I$IAQ$LRAIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1274 
                 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 
               
               
                   
               
               
                 1275 
                 Ac-I$IAQ$LRAibIGDAF$AYY$-NH2 
               
               
                   
               
               
                 1276 
                 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1277 
                 Ac-I$IAQ$LRAibIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1278 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 
               
               
                   
               
               
                 1279 
                 Ac-I$IAQ$LRNleIGDNleF$AYY$-NH2 
               
               
                   
               
               
                 1280 
                 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1281 
                 Ac-I$IAQ$LRNleIGDAibF$AYY$-NH2 
               
               
                   
               
               
                 1282 
                 Ac-IWIA$VLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1283 
                 Ac-IWIA$LLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1284 
                 Ac-IWIA$FLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1285 
                 Ac-IWIA$SLR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1286 
                 Ac-IWIA$ELR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1287 
                 Ac-IWIA$ALR$IGD$r8FNAYYA$-NH2 
               
               
                   
               
               
                 1288 
                 Ac-I$IAA$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1289 
                 Ac-I$IAA$LRRIGDEF$AYY$-NH2 
               
               
                   
               
               
                 1290 
                 Ac-I$IAL$LRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1291 
                 Ac-I$IAQ$LRAibIGDAF$AYY$RR-NH2 
               
               
                   
               
               
                 1292 
                 Ac-I$IAL$LRAibIGDAF$AYY$RR-NH2 
               
               
                   
               
               
                 1293 
                 Ac-I$IAL$LRRIGDEF$AYY$R-NH2 
               
               
                   
               
               
                 1294 
                 Ac-I$IAQ$LRAibIGDAF$AYY$R-NH2 
               
               
                   
               
               
                 1295 
                 Ac-I$IAL$LRAibIGDAF$AYY$R-NH2 
               
               
                   
               
               
                 1296 
                 Ac-I$IAY$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1297 
                 Ac-I$IAL$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1298 
                 Ac-I$IAF$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1299 
                 Ac-I$IAQ$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1300 
                 Ac-I$IAY$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1301 
                 Ac-I$IAL$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1302 
                 Ac-I$IAF$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1303 
                 Ac-IWIA$ALR$IGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1304 
                 Ac-IWIALALR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1305 
                 Ac-IWIAYALR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1306 
                 Ac-IWIAQALR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1307 
                 Ac-IWIALALR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1308 
                 Ac-IWIAYALR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1309 
                 Ac-IWIALALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1310 
                 Ac-IWIAYALR$IGD$FNAYYARR-NH2 
               
               
                   
               
               
                 1311 
                 Ac-IWIALALR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 1312 
                 Ac-IWIAYALR$IGD$FNAYYAR-NH2 
               
               
                   
               
               
                 1313 
                 Ac-IWIALALR$IGD$FNAYYAH-NH2 
               
               
                   
               
               
                 1314 
                 Ac-IWIAQALR%r8IGDAFN%YYA-NH2 
               
               
                   
               
               
                 1315 
                 Ac-I$IAL$LRRIGDEF$AYY$RR-NH2 
               
               
                   
               
               
                 1316 
                 Ac-I$IAL$LRRIGDEF$AYY$R-NH2 
               
               
                   
               
               
                 1317 
                 Ac-I$IAQ$LRAibIGDAF$AYY$R-NH2 
               
               
                   
               
               
                 1318 
                 Ac-I$IAL$LRAibIGDAF$AYY$R-NH2 
               
               
                   
               
               
                 1319 
                 Ac-I$IAY$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1320 
                 Ac-I$IAL$LR$r8IGDEFN$YYARR-NH2 
               
               
                   
               
               
                 1321 
                 Ac-IWIA$ALR$IGD$r8FNAYYA$R-NH2 
               
               
                   
               
               
                 1322 
                 Ac-I$IAY$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1323 
                 Ac-I$IAL$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1324 
                 Ac-I$IAF$LR$r8IGDEFN$YYAR-NH2 
               
               
                   
               
               
                 1325 
                 Ac-I$IAQ$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1326 
                 Ac-I$IAY$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1327 
                 Ac-I$IAL$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1328 
                 Ac-I$IAF$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1329 
                 Ac-I$IAQ$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1330 
                 Ac-I$IAY$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1331 
                 Ac-I$IAL$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1332 
                 Ac-I$IAF$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1333 
                 Ac-IWIAQALR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1334 
                 Ac-IWIAQALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1335 
                 Ac-IWIAAALR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1336 
                 Ac-IWIAAALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1337 
                 Ac-IWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1338 
                 Ac-IWIAQALR$r8IGDEFA$YYA-NH2 
               
               
                   
               
               
                 1339 
                 Ac-IWIAQALR$r8IGDQFA$YYA-NH2 
               
               
                   
               
               
                 1340 
                 Ac-IWIAQALR$r8IGDAFA$YYA-NH2 
               
               
                   
               
               
                 1341 
                 Ac-IWIAQALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1342 
                 Ac-IWIAQALCit$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1343 
                 Ac-IWIAQALH$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1344 
                 Ac-IWIAQALH$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1345 
                 Ac-IWIAQALQ$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1346 
                 Ac-IWIAQALQ$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1347 
                 Ac-IWIAQALR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1348 
                 Ac-IWIAQALR$r8IGDQAN$YYA-NH2 
               
               
                   
               
               
                 1349 
                 Ac-IWIAQALR$r8IGDAIN$YYA-NH2 
               
               
                   
               
               
                 1350 
                 Ac-IWIAQALR$r8IGDQIN$YYA-NH2 
               
               
                   
               
               
                 1351 
                 Ac-IWIAQAAR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1352 
                 Ac-IWIAQALR$r8IADAFN$YYA-NH2 
               
               
                   
               
               
                 1353 
                 Ac-IWIAQALR$r8IADQFN$YYA-NH2 
               
               
                   
               
               
                 1354 
                 Ac-IWIAQALR$r8AGDAFN$YYA-NH2 
               
               
                   
               
               
                 1355 
                 Ac-IWIAQALR$r8AGDQFN$YYA-NH2 
               
               
                   
               
               
                 1356 
                 Ac-IWIAQALR$r8FGDAFN$YYA-NH2 
               
               
                   
               
               
                 1357 
                 Ac-IWIAQALR$r8FGDQFN$YYA-NH2 
               
               
                   
               
               
                 1358 
                 Ac-IWFAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1359 
                 Ac-IWFAQALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1360 
                 Ac-IAIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1361 
                 Ac-IWIAQALA$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1362 
                 Ac-IWIAQALR$r8IGNAFN$YYA-NH2 
               
               
                   
               
               
                 1363 
                 Ac-IWIAQAAR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1364 
                 FITC-BaIWIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1365 
                 5-FAM-BaIWIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1366 
                 5-FAM-BaIWIAQALR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1367 
                 Ac-WLAQLLR$IGD$IN-NH2 
               
               
                   
               
               
                 1368 
                 Ac-ICou2IALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1369 
                 Ac-ICou2IALALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1370 
                 Ac-I$IAY$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1371 
                 Ac-I$IAL$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1372 
                 Ac-I$IAF$LR$r8IGDAFN$YYARR-NH2 
               
               
                   
               
               
                 1373 
                 Ac-I$IAQ$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1374 
                 Ac-I$IAY$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1375 
                 Ac-I$IAL$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1376 
                 Ac-I$IAF$LR$r8IGDAFN$YYAR-NH2 
               
               
                   
               
               
                 1377 
                 Ac-IAIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1378 
                 Ac-IWIAQALR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1379 
                 Ac-IWIAQALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1380 
                 Ac-IWIAAALR$r8IGDEFN$YYA-NH2 
               
               
                   
               
               
                 1381 
                 Ac-IWIAAALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1382 
                 Ac-IWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1383 
                 Ac-IWIAQALR$r8IGDAFA$YYA-NH2 
               
               
                   
               
               
                 1384 
                 Ac-IWIAQALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1385 
                 Ac-IWIAQALCit$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1386 
                 Ac-IWIAQALH$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1387 
                 Ac-IWIAQALH$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1388 
                 Ac-IWIAQALQ$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1389 
                 Ac-IWIAQALQ$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1390 
                 Ac-IWIAQALR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1391 
                 Ac-IWIAQALR$r8IGDAIN$YYA-NH2 
               
               
                   
               
               
                 1392 
                 Ac-IWIAQALR$r8IGDQIN$YYA-NH2 
               
               
                   
               
               
                 1393 
                 Ac-IWIAQAAR$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1394 
                 Ac-IWIAQALR$r8IADAFN$YYA-NH2 
               
               
                   
               
               
                 1395 
                 Ac-IWIAQALR$r8IADQFN$YYA-NH2 
               
               
                   
               
               
                 1396 
                 Ac-IWIAQALR$r8AGDAFN$YYA-NH2 
               
               
                   
               
               
                 1397 
                 Ac-IWIAQALR$r8AGDQFN$YYA-NH2 
               
               
                   
               
               
                 1398 
                 Ac-IWIAQALR$r8FGDAFN$YYA-NH2 
               
               
                   
               
               
                 1399 
                 Ac-IWIAQALR$r8FGDQFN$YYA-NH2 
               
               
                   
               
               
                 1400 
                 Ac-IWFAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1401 
                 Ac-IWFAQALR$r8IGDQFN$YYA-NH2 
               
               
                   
               
               
                 1402 
                 Ac-IWIAQALA$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1403 
                 Ac-IWIAQALR$r8IGNAFN$YYA-NH2 
               
               
                   
               
               
                 1404 
                 Ac-IWIAQAAR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1405 
                 Ac-IWIALALG$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1406 
                 Ac-IWIALALG$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1407 
                 Ac-IWIALALG$IGN$VNAYYA-NH2 
               
               
                   
               
               
                 1408 
                 Ac-IWIALALG$IGN$INAYYA-NH2 
               
               
                   
               
               
                 1409 
                 Ac-IWIALALN$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1410 
                 Ac-IWIALALN$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1411 
                 Ac-IWIALALN$IGN$VNAYYA-NH2 
               
               
                   
               
               
                 1412 
                 Ac-IWIALALN$IGN$INAYYA-NH2 
               
               
                   
               
               
                 1413 
                 Ac-IWIALALR$IGD$VNAFYA-NH2 
               
               
                   
               
               
                 1414 
                 Ac-IWIALALR$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1415 
                 Ac-IWIALALR$IGD$VNAibFYA-NH2 
               
               
                   
               
               
                 1416 
                 Ac-IWIALALR$IGD$VNAibYYA-NH2 
               
               
                   
               
               
                 1417 
                 Ac-IWFALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1418 
                 Ac-IWYALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1419 
                 Ac-IWVALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1420 
                 Ac-IWLALALR$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1421 
                 Ac-IWIAQALR$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1422 
                 Ac-IWIAQALR$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1423 
                 Ac-IWIALALR$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1424 
                 Ac-IWIALLLR$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1425 
                 Ac-IWIALLLR$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1426 
                 Ac-IWIALALG$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1427 
                 Ac-IWIALALS$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1428 
                 Ac-IWIALALH$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1429 
                 Ac-IWIALALN$IGD$FNAYYA-NH2 
               
               
                   
               
               
                 1430 
                 Ac-IWIALAIG$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1431 
                 Ac-IWIALAIG$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1432 
                 Ac-IWIALAIN$IGD$VNAYYA-NH2 
               
               
                   
               
               
                 1433 
                 Ac-IWIALAIN$IGD$INAYYA-NH2 
               
               
                   
               
               
                 1434 
                 Ac-IWIALALN$IGD$VNAYYAHH-NH2 
               
               
                   
               
               
                 1435 
                 Ac-IWIALALN$IGD$INAYYAHH-NH2 
               
               
                   
               
               
                 1436 
                 Ac-IWIALALN$IGN$VNAYYAHH-NH2 
               
               
                   
               
               
                 1437 
                 Ac-IWIALALN$IGN$INAYYAHH-NH2 
               
               
                   
               
               
                 1438 
                 Ac-IWIA$r5ALGStIGD$VNAYYA-NH2 
               
               
                   
               
               
                 1439 
                 Ac-IWIA$r5ALGStIGD$INAYYA-NH2 
               
               
                   
               
               
                 1440 
                 Ac-IWIA$r5ALGStIGN$VNAYYA-NH2 
               
               
                   
               
               
                 1441 
                 Ac-IWIA$r5ALGStIGN$INAYYA-NH2 
               
               
                   
               
               
                 1442 
                 Ac-IWIALALR$IGD$VNAAAA-NH2 
               
               
                   
               
               
                 1443 
                 Ac-IWIALALG$IGD$VNAAAA-NH2 
               
               
                   
               
               
                 1444 
                 Ac-IWIALALD$IGD$VNAAAA-NH2 
               
               
                   
               
               
                 1445 
                 Ac-IWIALALN$IGD$VNAAAA-NH2 
               
               
                   
               
               
                 1446 
                 Ac-IWIALALR$IGD$VN-NH2 
               
               
                   
               
               
                 1447 
                 Ac-IWIALALG$IGD$VN-NH2 
               
               
                   
               
               
                 1448 
                 Ac-IWIALALD$IGD$VN-NH2 
               
               
                   
               
               
                 1449 
                 Ac-IWIALALN$IGD$VN-NH2 
               
               
                   
               
               
                 1450 
                 5-FAM-BaIWIA$r5ALGStIGD$VNAYYA-NH2 
               
               
                   
               
               
                 1451 
                 5-FAM-BaIWIALALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1452 
                 5-FAM-BaIWIA$r5ALGStIGN$INAYYA-NH2 
               
               
                   
               
               
                 1453 
                 5-FAM-BaIWIALALG$IGN$INAYYA-NH2 
               
               
                   
               
               
                 1454 
                 FITC-BaIWIA$r5ALGStIGD$VNAYYA-NH2 
               
               
                   
               
               
                 1455 
                 FITC-BaIWIALALR$IGD$FNAibFYA-NH2 
               
               
                   
               
               
                 1456 
                 5-FAM-BaIWIA$r5ALGStIGD$INAYYA-NH2 
               
               
                   
               
               
                 1457 
                 Ac-IWIAQALR$r8IGDQFA$YYA-NH2 
               
               
                   
               
               
                 1458 
                 Ac-RWIAQALR$IGD$LNAFYAHH-NH2 
               
               
                   
               
               
                 1459 
                 Ac-RWIAQELR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1460 
                 Ac-RWIAQALR$IGD$LNAibFYA-NH2 
               
               
                   
               
               
                 1461 
                 Ac-RWIAQAAR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1462 
                 Ac-RWIAQALA$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1463 
                 Ac-RWIAQALR$IGN$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1464 
                 Ac-RWIAQALCit$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1465 
                 Ac-RWIAQALR$IGD$ANAibFYAHH-NH2 
               
               
                   
               
               
                 1466 
                 Ac-RCou2IAQAAR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1467 
                 Ac-RCou2IAQALA$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1468 
                 Ac-RCou2IAQALR$IGN$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1469 
                 Ac-RCou2IAQALCit$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1470 
                 Ac-IWIAMOALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1471 
                 Ac-IWIAMO2ALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1472 
                 Ac-RWIAMOALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1473 
                 Ac-RWIAMO2ALR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1474 
                 Ac-RWIAQALR$IGN$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1475 
                 Ac-RWIAQAAR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1476 
                 Ac-RWIAQALA$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1477 
                 Ac-RWIAQALCit$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1478 
                 Ac-RCou2IAQALR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1479 
                 Ac-RCou2IAQALR$IGN$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1480 
                 Ac-RCou2IAQAAR$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1481 
                 Ac-RCou2IAQALA$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1482 
                 Ac-RCou2IAQALCit$IGD$VNAibFYAHH-NH2 
               
               
                   
               
               
                 1483 
                 Ac-IWChaAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1484 
                 Ac-IWhhLAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1485 
                 Ac-IWAdmAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1486 
                 Ac-IWhChaAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1487 
                 Ac-IWhFAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1488 
                 Ac-IWIglAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1489 
                 Ac-IWF4CF3AQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1490 
                 Ac-IWF4tBuAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1491 
                 Ac-IW2NalAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1492 
                 Ac-IWBipAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1493 
                 Ac-IWIAQAChaR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1494 
                 Ac-IWIAQAhhLR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1495 
                 Ac-IWIAQAAdmR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1496 
                 Ac-IWIAQAhChaR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1497 
                 Ac-IWIAQAhAdmR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1498 
                 Ac-IWIAQAhFR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1499 
                 Ac-IWIAQAIglR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1500 
                 Ac-IWIAQAF4CF3R$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1501 
                 Ac-IWIAQAF4tBuR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1502 
                 Ac-IWIAQA2NalR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1503 
                 Ac-IWIAQABipR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1504 
                 Ac-IWIAQALR$r8CbaGDAFN$YYA-NH2 
               
               
                   
               
               
                 1505 
                 Ac-IWIAQALR$r8hLGDAFN$YYA-NH2 
               
               
                   
               
               
                 1506 
                 Ac-IWIAQALR$r8ChaGDAFN$YYA-NH2 
               
               
                   
               
               
                 1507 
                 Ac-IWIAQALR$r8TbaGDAFN$YYA-NH2 
               
               
                   
               
               
                 1508 
                 Ac-IWIAQALR$r8hhLGDAFN$YYA-NH2 
               
               
                   
               
               
                 1509 
                 Ac-IAmWIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1510 
                 Ac-IAibIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1511 
                 Ac-AmLWIAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1512 
                 Ac-IWAmLAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1513 
                 Ac-IWIAibQALR$r8IGAmDAFN$YYA-NH2 
               
               
                   
               
               
                 1514 
                 Ac-IWIAAibALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1515 
                 Ac-IWIAQAAmLR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1516 
                 Ac-IWIAQALR$r8IGAmDAFN$YYA-NH2 
               
               
                   
               
               
                 1517 
                 Ac-IWIAQALR$r8IGDAFN$F4FYA-NH2 
               
               
                   
               
               
                 1518 
                 Ac-IWIAQALR$r8IGDAFN$AYA-NH2 
               
               
                   
               
               
                 1519 
                 Ac-IWIAQALR$r8IGDAFN$YF4FA-NH2 
               
               
                   
               
               
                 1520 
                 Ac-IWIAQALR$r8IGDAFN$YYAib-NH2 
               
               
                   
               
               
                 1521 
                 Ac-I$r8IAQALRStIGDEFN$s8YYA-NH2 
               
               
                   
               
               
                 1522 
                 Ac-IWIA$ALRStIGDEFN$s8YYA-NH2 
               
               
                   
               
               
                 1523 
                 Ac-IWIAQALR$r8IGDEFNStYYA$r5A-NH2 
               
               
                   
               
               
                 1524 
                 Ac-IWIAQAACit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1525 
                 Ac-IWIAQALCit$r8IGNAFN$YYA-NH2 
               
               
                   
               
               
                 1526 
                 Ac-IWIAQALCit$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1527 
                 Ac-IWIAQALCit$r8IGDAVN$YYA-NH2 
               
               
                   
               
               
                 1528 
                 Ac-RWIAQAChaR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1529 
                 Ac-RWIAQAhhLR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1530 
                 Ac-RWIAQAAdmR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1531 
                 Ac-RWIAQAhChaR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1532 
                 Ac-RWIAQAhFR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1533 
                 Ac-RWIAQAIglR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1534 
                 Ac-RWIAQAF4CF3R$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1535 
                 Ac-RWIAQAF4tBuR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1536 
                 Ac-RWIAQA2NalR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1537 
                 Ac-RWIAQABipR$IGD$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1538 
                 Ac-IWIAQ$r8LRRIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1539 
                 Ac-IWIAQ$r8LRAIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1540 
                 Ac-IWIAQ$r8LCitRIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1541 
                 Ac-IWIAQ$r8LCitAIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1542 
                 Ac-IWIAMOALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1543 
                 Ac-IWIAMO2ALCit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1544 
                 Ac-IWIAQALD$r8IGRAFN$YYA-NH2 
               
               
                   
               
               
                 1545 
                 Ac-RWIAQALD$IGR$LNAibFYAHH-NH2 
               
               
                   
               
               
                 1546 
                 Ac-RPEIWIAQAID$r8IGDAVN$YYAR-NH2 
               
               
                   
               
               
                 1547 
                 Ac-RPEIWIAQAID$IGD$VNAYYAR-NH2 
               
               
                   
               
               
                 1548 
                 Ac-DWIAQALR$r8IGDAFN$YYR-NH2 
               
               
                   
               
               
                 1549 
                 Ac-IWAAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1550 
                 Ac-IWTbaAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1551 
                 Ac-IWhLAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1552 
                 Ac-IWChgAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1553 
                 Ac-IWAc6cAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1554 
                 Ac-IWAc5cAQALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1555 
                 Ac-EWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1556 
                 Ac-RWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1557 
                 Ac-KWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1558 
                 Ac-HWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1559 
                 Ac-SWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1560 
                 Ac-QWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1561 
                 Ac-AWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1562 
                 Ac-AibWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1563 
                 Ac-FWIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1564 
                 Ac-IDIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1565 
                 Ac-IRIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1566 
                 Ac-IHIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1567 
                 Ac-ISIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1568 
                 Ac-INIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1569 
                 Ac-ILIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1570 
                 Ac-IFIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1571 
                 Ac-I2NalIAAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1572 
                 Ac-IWISAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1573 
                 Ac-IWILAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1574 
                 Ac-IWIFAALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1575 
                 Ac-IWIALALR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1576 
                 Ac-IWIAAALF4g$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1577 
                 Ac-IWIAAALK$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1578 
                 Ac-IWIAAALR$r8IAbuDAFN$YYA-NH2 
               
               
                   
               
               
                 1579 
                 Ac-IWIAAALR$r8IVDAFN$YYA-NH2 
               
               
                   
               
               
                 1580 
                 Ac-IWIAAALR$r8IGEAFN$YYA-NH2 
               
               
                   
               
               
                 1581 
                 Ac-IWIAAALR$r8IGDAGN$YYA-NH2 
               
               
                   
               
               
                 1582 
                 Ac-IWIAQALR$r8IGDAWN$YYA-NH2 
               
               
                   
               
               
                 1583 
                 Ac-IWIAQALR$r8IGDAhFN$YYA-NH2 
               
               
                   
               
               
                 1584 
                 Ac-IWIAQALR$r8IGDAF4CF3N$YYA-NH2 
               
               
                   
               
               
                 1585 
                 Ac-IWIAQALR$r8IGDAF4tBuN$YYA-NH2 
               
               
                   
               
               
                 1586 
                 Ac-IWIAQALR$r8IGDA2NalN$YYA-NH2 
               
               
                   
               
               
                 1587 
                 Ac-IWIAQALR$r8IGDABipN$YYA-NH2 
               
               
                   
               
               
                 1588 
                 Ac-IWIAAALR$r8IGDAFD$YYA-NH2 
               
               
                   
               
               
                 1589 
                 Ac-IWIAAALR$r8IGDAFE$YYA-NH2 
               
               
                   
               
               
                 1590 
                 Ac-IWIAAALR$r8IGDAFQ$YYA-NH2 
               
               
                   
               
               
                 1591 
                 Ac-IWIAAALR$r8IGDAFS$YYA-NH2 
               
               
                   
               
               
                 1592 
                 Ac-IWIAAALR$r8IGDAFH$YYA-NH2 
               
               
                   
               
               
                 1593 
                 Ac-IWIAAALR$r8IGDAFN$LYA-NH2 
               
               
                   
               
               
                 1594 
                 Ac-IWIAQALR$r8IGDAFN$YAA-NH2 
               
               
                   
               
               
                 1595 
                 Ac-IWIAQALR$r8IGDAFN$YLA-NH2 
               
               
                   
               
               
                 1596 
                 Ac-IWIAQALR$r8IGDAFN$YChaA-NH2 
               
               
                   
               
               
                 1597 
                 Ac-IWIAQALR$r8IGDAFN$YhFA-NH2 
               
               
                   
               
               
                 1598 
                 Ac-IWIAQALR$r8IGDAFN$YWA-NH2 
               
               
                   
               
               
                 1599 
                 Ac-IWIAQALR$r8IGDAFN$Y2NalA-NH2 
               
               
                   
               
               
                 1600 
                 Ac-IWIAAALR$r8IGDAFN$YYD-NH2 
               
               
                   
               
               
                 1601 
                 Ac-IWIAAALR$r8IGDAFN$YYE-NH2 
               
               
                   
               
               
                 1602 
                 Ac-IWIAAALR$r8IGDAFN$YYQ-NH2 
               
               
                   
               
               
                 1603 
                 Ac-IWIAAALR$r8IGDAFN$YYS-NH2 
               
               
                   
               
               
                 1604 
                 Ac-IWIAAALR$r8IGDAFN$YYH-NH2 
               
               
                   
               
               
                 1605 
                 Ac-IWIAAALR$r8IGDAFN$YYR-NH2 
               
               
                   
               
               
                 1606 
                 Ac-IWIAAALR$r8IGDAFN$YYK-NH2 
               
               
                   
               
               
                 1607 
                 Ac-IWIAQALR$rda6IGDAFN$da5YYA-NH2 
               
               
                   
               
               
                 1608 
                 Ac-IWIAQAAmLR$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1609 
                 Ac-IWIAQALR$r8IGAmDAFN$YYA-NH2 
               
               
                   
               
               
                 1610 
                 Ac-IWIAQALR$r8IGDAFN$F4FYA-NH2 
               
               
                   
               
               
                 1611 
                 Ac-IWIAQALR$r8IGDAFN$YYAib-NH2 
               
               
                   
               
               
                 1612 
                 Ac-IWIAQAACit$r8IGDAFN$YYA-NH2 
               
               
                   
               
               
                 1613 
                 Ac-IWIAQALCit$r8IGNAFN$YYA-NH2 
               
               
                   
               
               
                 1614 
                 Ac-IWIAQALCit$r8IGDAAN$YYA-NH2 
               
               
                   
               
               
                 1615 
                 Ac-IWIAQALCit$r8IGDAVN$YYA-NH2 
               
               
                   
               
               
                 1616 
                 Ac-IWIAQ$r8LRAIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1617 
                 Ac-IWIAQ$r8LCitAIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1618 
                 Ac-IWIAQALR$r8IGDAFN$AYA-NH2 
               
               
                   
               
               
                 1619 
                 Ac-IWIAQ$r8LRRIGD$FNAYYA-NH2 
               
               
                   
               
               
                 1620 
                 Ac-IWIAQALR$r8hLGDAFN$F4FYA-NH2 
               
               
                   
               
               
                 1621 
                 Ac-IWIAQALR$r8hLGDAFN$YF4FA-NH2 
               
               
                   
               
               
                 1622 
                 Ac-IWIAQALR$r8hLGDAFN$F4FF4FA-NH2 
               
               
                   
               
               
                 1623 
                 Ac-AWIAAALR$r8hLGDAFN$YF4FA-NH2 
               
               
                   
               
               
                 1624 
                 Ac-AWIAAALR$r8hLGDAFN$AF4FA-NH2 
               
               
                   
               
               
                 1625 
                 Ac-IWIAQAAR$r8hLGDAFN$F4FF4FA-NH2 
               
               
                   
               
            
           
         
       
     
     In the sequences shown above and elsewhere, the following abbreviations are used: “Nle” represents norleucine, “Aib” represents 2-aminoisobutyric acid, “Ac” represents acetyl, and “Pr” represents propionyl. Amino acids represented as “$” are alpha-Me S5-pentenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. Amino acids represented as “$r5” are alpha-Me R5-pentenyl-alanine olefin amino acids connected by an all-carbon comprising one double bond. Amino acids represented as “$s8” are alpha-Me S8-octenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. Amino acids represented as “$r8” are alpha-Me R8-octenyl-alanine olefin amino acids connected by an all-carbon crosslinker comprising one double bond. “Ahx” represents an aminocyclohexyl linker. The crosslinkers are linear all-carbon crosslinker comprising eight or eleven carbon atoms between the alpha carbons of each amino acid. Amino acids represented as “$/” are alpha-Me S5-pentenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/r5” are alpha-Me R5-pentenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/s8” are alpha-Me S8-octenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “$/r8” are alpha-Me R8-octenyl-alanine olefin amino acids that are not connected by any crosslinker. Amino acids represented as “Amw” are alpha-Me tryptophan amino acids. Amino acids represented as “Aml” are alpha-Me leucine amino acids. Amino acids represented as “Amf” are alpha-Me phenylalanine amino acids. Amino acids represented as “2ff” are 2-fluoro-phenylalanine amino acids. Amino acids represented as “3ff” are 3-fluoro-phenylalanine amino acids. Amino acids represented as “St” are amino acids comprising two pentenyl-alanine olefin side chains, each of which is crosslinked to another amino acid as indicated. Amino acids represented as “St//” are amino acids comprising two pentenyl-alanine olefin side chains that are not crosslinked. Amino acids represented as “% St” are amino acids comprising two pentenyl-alanine olefin side chains, each of which is crosslinked to another amino acid as indicated via fully saturated hydrocarbon crosslinks. Amino acids represented as “Ba” are beta-alanine. The lower-case character “e” or “z” within the designation of a crosslinked amino acid (e.g., “$er8” or “$zr8”) represents the configuration of the double bond (E or Z, respectively). In other contexts, lower-case letters such as “a” or “f” represent D amino acids (e.g., D-alanine, or D-phenylalanine, respectively). Amino acids designated as “NmW” represent N-methyltryptophan. Amino acids designated as “NmY” represent N-methyltyrosine. Amino acids designated as “NmA” represent N-methylalanine. “Kbio” represents a biotin group attached to the side chain amino group of a lysine residue. Amino acids designated as “Sar” represent sarcosine. Amino acids designated as “Cha” represent cyclohexyl alanine. Amino acids designated as “Cpg” represent cyclopentyl glycine. Amino acids designated as “Chg” represent cyclohexyl glycine. Amino acids designated as “Cba” represent cyclobutyl alanine. Amino acids designated as “F 4 I” represent 4-iodo phenylalanine. “7L” represents N15 isotopic leucine. Amino acids designated as “F 3 Cl” represent 3-chloro phenylalanine. Amino acids designated as “F4cooh” represent 4-carboxy phenylalanine. Amino acids designated as “F 3 4F 2 ” represent 3,4-difluoro phenylalanine. Amino acids designated as “6clW” represent 6-chloro tryptophan. Amino acids designated as “$rda6” represent alpha-Me R6-hexynyl-alanine alkynyl amino acids, crosslinked via a dialkyne bond to a second alkynyl amino acid. Amino acids designated as “$da5” represent alpha-Me S5-pentynyl-alanine alkynyl amino acids, wherein the alkyne forms one half of a dialkyne bond with a second alkynyl amino acid. Amino acids designated as “$ra9” represent alpha-Me R9-nonynyl-alanine alkynyl amino acids, crosslinked via an alkyne metathesis reaction with a second alkynyl amino acid. Amino acids designated as “$a6” represent alpha-Me S6-hexynyl-alanine alkynyl amino acids, crosslinked via an alkyne metathesis reaction with a second alkynyl amino acid. The designation “iso1” or “iso2” indicates that the peptidomimetic macrocycle is a single isomer. Amino acids designated as “Cit” represent citrulline. 
     Amino acids which are used in the formation of triazole crosslinkers are represented according to the legend indicated below. Stereochemistry at the alpha position of each amino acid is S unless otherwise indicated. For azide amino acids, the number of carbon atoms indicated refers to the number of methylene units between the alpha carbon and the terminal azide. For alkyne amino acids, the number of carbon atoms indicated is the number of methylene units between the alpha position and the triazole moiety plus the two carbon atoms within the triazole group derived from the alkyne. 
     
       
         
           
               
               
               
             
               
                   
                   
               
             
            
               
                   
                 $5a5 
                 Alpha-Me alkyne 1,5 triazole (5 carbon) 
               
               
                   
                 $5n3 
                 Alpha-Me azide 1,5 triazole (3 carbon) 
               
               
                   
                 $4rn6 
                 Alpha-Me R-azide 1,4 triazole (6 carbon) 
               
               
                   
                 $4a5 
                 Alpha-Me alkyne 1,4 triazole (5 carbon) 
               
               
                   
                   
               
            
           
         
       
     
     In some embodiments, peptidomimetic macrocycles are provided which are derived from BIM. In some embodiments, the present invention provides a peptidomimetic macrocycle comprising an amino acid sequence which is at least about 60% identical to BIM, further comprising at least two macrocycle-forming linkers, wherein the first of said two macrocycle-forming linkers connects a first amino acid to a second amino acid, and the second of said two macrocycle-forming linkers connects a third amino acid to a fourth amino acid. 
     Two or more peptides can share a degree of homology. In some embodiments, the pair of peptides is a peptidomimetic macrocycle of the present disclosure and a peptide identical to BIM. A pair of peptides can have, for example, up to about 20% pairwise homology, up to about 25% pairwise homology, up to about 30% pairwise homology, up to about 35% pairwise homology, up to about 40% pairwise homology, up to about 45% pairwise homology, up to about 50% pairwise homology, up to about 55% pairwise homology, up to about 60% pairwise homology, up to about 65% pairwise homology, up to about 70% pairwise homology, up to about 75% pairwise homology, up to about 80% pairwise homology, up to about 85% pairwise homology, up to about 90% pairwise homology, up to about 95% pairwise homology, up to about 96% pairwise homology, up to about 97% pairwise homology, up to about 98% pairwise homology, up to about 99% pairwise homology, up to about 99.5% pairwise homology, or up to about 99.9% pairwise homology. A pair of peptides can have, for example, at least about 20% pairwise homology, at least about 25% pairwise homology, at least about 30% pairwise homology, at least about 35% pairwise homology, at least about 40% pairwise homology, at least about 45% pairwise homology, at least about 50% pairwise homology, at least about 55% pairwise homology, at least about 60% pairwise homology, at least about 65% pairwise homology, at least about 70% pairwise homology, at least about 75% pairwise homology, at least about 80% pairwise homology, at least about 85% pairwise homology, at least about 90% pairwise homology, at least about 95% pairwise homology, at least about 96% pairwise homology, at least about 97% pairwise homology, at least about 98% pairwise homology, at least about 99% pairwise homology, at least about 99.5% pairwise homology, at least about 99.9% pairwise homology. 
     Various methods and software programs can be used to determine the homology between two or more peptides, such as NCBI BLAST, Clustal W, MAFFT, Clustal Omega, AlignMe, Praline, or another suitable method or algorithm. 
     In some embodiments, a peptidomimetic macrocycle of the invention comprises a helix, for example an α-helix. In some embodiments, a peptidomimetic macrocycle of the invention comprises an α,α-disubstituted amino acid. In some embodiments, each amino acid connected by the macrocycle-forming linker is an α,α-disubstituted amino acid. 
     In some embodiments, a peptidomimetic macrocycle of the invention has the Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently an amino acid (including natural or non-natural amino acids and amino acid analogues) and the terminal D and E independently optionally include a capping group; 
     each B is independently an amino acid (including natural or non-natural amino acids and amino acid analogues), 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each R 1  and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R 1  and R 2  forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ;
         each L and L′ is independently a macrocycle-forming linker of the formula -L 1 -L 2 -,       

     
       
         
         
             
             
         
       
     
     or -L 1 -S-L 2 -S-L 3 -; 
     each L 1 , L 2  and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; when L is not 
     
       
         
         
             
             
         
       
     
     or -L 1 -S-L 2 -S-L 3 -, L 1  and L 2  are alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each R 9  is independently absent, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with R a  or R b ; 
     each R a  and R b  is independently alkyl, OCH 3 , CF 3 , NH 2 , CH 2 NH 2 , F, Br, I, 
     
       
         
         
             
             
         
       
     
     each v and w is independently an integer from 0-1000, for example 0-500, 0-200, 0-100, 0-50, 0-30, 0-20, or 0-10; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example 1-5, 1-3 or 1-2; 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example the sum of x+y+z is 2, 3, or 6; 
     each n is independently 1, 2, 3, 4, or 5; and 
     wherein A, B, C, D, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker, -L 1 -L 2 -, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to BIM 1-44, BIM 1-29 or to an amino acid sequence chosen from the group consisting of the amino acid sequences in Table 1; 
     In some embodiments, u is 1. 
     In some embodiments, the sum of x+y+z is 2, 3, 6, or 10, for example 2, 3 or 6, for example 3 or 6. 
     In some embodiments, the sum of x+y+z is 3. 
     In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25. 
     In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 
     In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6. 
     In some embodiments, w is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, w is 3, 4, 5, or 6. In some embodiments, w is 3, 4, 5, 6, 7, or 8. In some embodiments, w is 6, 7, 8, 9, or 10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2. 
     In some embodiments, L 1  and L 2  are independently alkylene, alkenylene or alkynylene. 
     In some embodiments, L 1  and L 2  are independently C 3 -C 10  alkylene or alkenylene. 
     In some embodiments, L 1  and L 2  are independently C 3 -C 6  alkylene or alkenylene. 
     In some embodiments, L or L′ is: 
     
       
         
         
             
             
         
       
     
     In some embodiments, L or L′ is 
     
       
         
         
             
             
         
       
     
     For example, L or L′ is 
     
       
         
         
             
             
         
       
     
     In some embodiments, R 1  and R 2  are H. 
     In some embodiments, R 1  and R 2  are independently alkyl. 
     In some embodiments, R 1  and R 2  are methyl. 
     In some embodiments, the present invention provides a peptidomimetic macrocycle having the Formula (Ia): 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 8 ′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with a E residue; 
     v′ and w′ are independently integers from 0-100; and 
     x′, y′ and z′ are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example, x′+y′+z′ is 2, 3, 6 or 10. 
     In some embodiments, u is 2. 
     In some embodiments, the peptidomimetic macrocycle of Formula (I) has the Formula (Ib): 
     
       
         
         
             
             
         
       
     
     wherein: 
     R 7 ′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     R 8 ′ is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     v′ and w′ are independently integers from 0-100; and 
     x′, y′ and z′ are independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 
     In some embodiments, the sum of x+y+z is 2, 3 or 6, for example 3 or 6. 
     In some embodiments, the sum of x′+y′+z′ is 2, 3 or 6, for example 3 or 6. 
     In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25. 
     In some embodiments, each v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6. 
     In some embodiments, w is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, w is 3, 4, 5, or 6. In some embodiments, w is 3, 4, 5, 6, 7, or 8. In some embodiments, w is 6, 7, or 8. In some embodiments, w is 6, 7, 8, 9, or 10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2. 
     In some embodiments, a peptidomimetic macrocycle of the invention comprises an amino acid sequence which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of Table 1, and comprising at least one macrocycle-forming linker, wherein the macrocycle-forming linker connects amino acids 14 and 18. 
     In some embodiments, a peptidomimetic macrocycle of Formula (I) has Formula (Ic): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each L is independently a macrocycle-forming linker; 
     each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 1  and the atom to which both R 1  and L′ are bound forms a ring; 
     each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 2  and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 1  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L′ and the atom to which both R 1  and L′ are bound forms a ring; 
     each R 2  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-, or together with L″ and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, optionally substituted with R 5 ; 
     each L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     n is 1, 2, 3, 4, or 5; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-40, 1-25, 1-20, 1-15, or 1-10; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 
     In some embodiments, the peptidomimetic macrocycle comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. 
     In some embodiments, w is at least about 1, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10. In some embodiments, w is from about 1 to about 2, from about 2 to about 3, from about 3 to about 4, from about 4 to about 5, from about 5 to about 6, from about 6 to about 7, from about 7 to about 8, from about 8 to about 9, or from about 9 to about 10. 
     In some embodiments, w is at least 2 and at least one of the last two E residues is a His residue. In some embodiments, w is at least 2 and at least one of the last two E residues is an Arg residue. In some embodiments, w is at least 2 and both of the last two E residues are His residues. In some embodiments, w is at least 2 and both of the last two E residues are Arg residues. The number of His residues at the peptide C-terminus, or at the E variable, can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The His residues can be contiguous, or interrupted by a gap of i, i+1, i+2, i+3, or i+4. 
     In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, each of v and w is independently 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, v is 8. In some embodiments, w is 6. In some embodiments, the crosslinked amino acid residues are at positions 9 and 13 of the peptidomimetic macrocycle. 
     In some embodiments, L is 
     
       
         
         
             
             
         
       
     
     In some embodiments, R 1  and R 2  are H. In some embodiments, R 1  and R 2  are independently alkyl. In some embodiments, R 1  and R 2  are methyl. 
     In some embodiments, the peptidomimetic macrocycles have the Formula (I): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each R 1  and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, optionally substituted with R 5 ; 
     each L is independently a macrocycle-forming linker of the formula 
     
       
         
         
             
             
         
       
     
     each L 1 , L 2  and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     n is 1, 2, 3, 4, or 5. 
     In other embodiments, provided are peptidomimetic macrocycles comprising Formula (II) or (IIa): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently a natural or non-natural amino acid, and the terminal D and E independently optionally include a capping group; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each R 1  and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R 1  and R 2  forms a macrocycle-forming linker U connected to the alpha position of one of said D or E amino acids; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ; 
     each L 1 , L 2 , and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ; 
     each v and w is independently an integer from 0-100; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 
     n is 1, 2, 3, 4, or 5; and 
     A, B, C, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker -L 1 -L 2 -, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of Table 1. 
     In some embodiments, a peptidomimetic macrocycle comprises Formula (IIIa) or (IIIb): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D and E is independently an amino acid, and the terminal D and E independently optionally include a capping group; 
     each B is independently an amino acid, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each R 1 ′ and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or R 2  forms a macrocycle-forming linker L′ connected to the alpha position of one of said E amino acids; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ; 
     each L and L′ is independently a macrocycle-forming linker of the formula -L 1 -L 2 -, 
     
       
         
         
             
             
         
       
     
     or -L 1 -S-L 2 -S-L 3 -; 
     each L 1 , L 2  and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  or R 7 ′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  or R 8 ′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each R 9  is independently absent, hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with R a  or R b ; 
     each R a  and R b  is independently alkyl, OCH 3 , CF 3 , NH 2 , CH 2 NH 2 , F, Br, I, 
     
       
         
         
             
             
         
       
     
     each v′ and w is independently an integer from 0-1000, for example 0-500, 0-200, 0-100, 0-50, 0-30, 0-20, or 0-10; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example 1, 2, 3, 4, or 5; 1, 2, or 3; or 1 or 2; 
     each x, y, z, x′, y′ and z′ is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example the sum of x+y+z is 2, 3, 6 or 10, or the sum of x′+y′+z′ is 2, 3, 6, or 10; 
     n is 1, 2, 3, 4, or 5; 
     X is C═O, CHR c , or C═S; 
     R c  is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl; and 
     A, B, C, and E, taken together with the crosslinked amino acids connected by the macrocycle-forming linker -L 1 -L 2 -, form an amino acid sequence of the peptidomimetic macrocycle which is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence of Table 1. 
     In some embodiments, the peptidomimetic macrocycle has the Formula: 
     
       
         
         
             
             
         
       
     
     wherein: 
     each R 1 ′ or R 2 ′ is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; and 
     each v, w, v′ or w′ is independently an integer from 0-100. 
     In some embodiments, the notation “Hep” is used for a macrocycle of Formula Ma, which represents an N-terminal heptenoic capping group of the following formula: 
     
       
         
         
             
             
         
       
     
     wherein AA 1 , AA 2 , AA 3  and AA 4  are amino acids. 
     In other embodiments, a C-terminal macrocycle of Formula IIIb forms the structure: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the peptidomimetic macrocycle has the Formula IV: 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently an amino acid; 
     each B is independently an amino acid, 
     
       
         
         
             
             
         
       
     
     [—NH-L 4 -CO—], [—NH-L 4 -SO 2 —], or [—NH-L 4 -]; 
     each R 1  and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or at least one of R 1  and R 2  forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids; 
     each R 3  is independently hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 ; 
     each L 1 , L 2 , L 3  and L 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [—R 4 —K—R 4 ] n , each being unsubstituted or substituted with R 5 ; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20 or 1-10; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example 1, 2, 3, 4, or 5; 1, 2, or 3; or 1 or 2; 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, for example the sum of x+y+z is 2, 3, 6 or 10, for example sum of x+y+z is 2, 3 or 6; and 
     n is 1, 2, 3, 4, or 5. 
     In some embodiments, the peptidomimetic macrocycle has the Formula (V): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each D and E is independently an amino acid residue; 
     R 1  and R 2  are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or at least one of R 1  and R 2  forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues; 
     each L or L′ is independently a macrocycle-forming linker of the formula -L 1 -L 2 - or -L 1 -L 2 -L 3 -; 
     each L 1 , L 2 , and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 ; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     R 7  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     R 8  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each of Xaa 1  and Xaa 2  is independently an amino acid residue or absent; 
     Xaa 3  is Ala, Aib, Asp, Asn, Cys, Glu, Gln, His, Ile, Lys, Leu, Met, Arg, Ser, Thr, Val, Trp, Tyr, or an analogue of any of the foregoing; 
     v is an integer from 1-1000; 
     w is an integer from 0-1000; and 
     n is 1, 2, 3, 4, or 5. 
     In some embodiments, the peptidomimetic macrocycle of Formula (V) comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. In some embodiments, one of Xaa 1  and Xaa 2  is His. In some embodiments, both of Xaa 1  and Xaa 2  are His. In some embodiments, one of Xaa 1  and Xaa 2  is Arg. In some embodiments, both of Xaa 1  and Xaa 2  are Arg. In some embodiments, one of Xaa 1  and Xaa 2  is absent. In some embodiments, both of Xaa 1  and Xaa 2  are absent. 
     In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, v is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, v is 8. In some embodiments, w is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, w is 0, 1, 2, 3, 4, or 5. In some embodiments, w is 0, 1, 2, or 3. In some embodiments, wherein w is 0. 
     In some embodiments, each v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6. 
     In some embodiments, w is 3, 4, 5, 6, 7, 8, 9, or 10, for example 3, 4, 5, or 6; 3, 4, 5, 6, 7, or 8; 6, 7, or 8; or 6, 7, 8, 9, or 10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2. 
     In some embodiments, L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently alkylene, alkenylene, or alkynylene. In some embodiments, wherein L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently C 3 -C 10  alkylene or C 3 -C 10  alkenylene. In some embodiments, wherein L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently C 3 -C 6  alkylene or C 3 -C 6  alkenylene. In some embodiments, L is 
     
       
         
         
             
             
         
       
     
     In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently alkylene, alkenylene, or alkynylene, and L 2  is arylene or heteroarylene. In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently C 3 -C 10  alkylene, and L 2  is heteroarylene. In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently C 3 -C 6  alkylene, and L 2  is heteroarylene. 
     In some embodiments, R 1  and R 2  are H. In some embodiments, R 1  and R 2  are independently alkyl. In some embodiments, R 1  and R 2  are methyl. 
     In some embodiments, the peptidomimetic macrocycle has the Formula (VI) (SEQ ID NO: 1785): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each D and E is independently an amino acid residue; 
     R 1  and R 2  are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-; or at least one of R 1  and R 2  forms a macrocycle-forming linker L′ connected to the alpha position of one of the D or E amino acid residues; 
     each L or L′ is independently a macrocycle-forming linker of the formula -L 1 -L 2 - or -L 1 -L 2 -L 3 -; 
     each L 1 , L 2 , and L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 ; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     R 7  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     R 8  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each of Xaa 1  and Xaa 2  is independently an amino acid residue or absent; 
     v is an integer from 1-1000; 
     w is an integer from 0-1000; and 
     n is 1, 2, 3, 4, or 5. 
     In some embodiments, the peptidomimetic macrocycle of Formula (VI) comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. In some embodiments, the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. In some embodiments, one of Xaa 1  and Xaa 2  is His. In some embodiments, both of Xaa 1  and Xaa 2  are His. In some embodiments, one of Xaa 1  and Xaa 2  is Arg. In some embodiments, both of Xaa 1  and Xaa 2  are Arg. In some embodiments, one of Xaa 1  and Xaa 2  is absent. In some embodiments, both of Xaa 1  and Xaa 2  are absent. 
     In some embodiments, the peptidomimetic macrocycle comprises a helix. In some embodiments, the peptidomimetic macrocycle comprises an α-helix. In some embodiments, v is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, v is 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, v is 8. In some embodiments, w is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, w is 0, 1, 2, 3, 4, or 5. In some embodiments, w is 0, 1, 2, or 3. In some embodiments, wherein w is 0. 
     In some embodiments, each v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, w is an integer from 3-1000, for example 3-500, 3-200, 3-100, 3-50, 3-30, 3-20, or 3-10. In some embodiments, the sum of x+y+z is 3 or 6. In some embodiments, the sum of x+y+z is 3. In other embodiments, the sum of x+y+z is 6. 
     In some embodiments, w is 3, 4, 5, 6, 7, 8, 9, 10, for example 3, 4, 5, or 6; 3, 4, 5, 6, 7, or 8; 6, 7, or 8; or 6, 7, 8, 9, or 10. In some embodiments, w is 3. In other embodiments, w is 6. In some embodiments, v is an integer from 1-1000, for example 1-500, 1-200, 1-100, 1-50, 1-30, 1-20, or 1-10. In some embodiments, v is 2. 
     In some embodiments, L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently alkylene, alkenylene, or alkynylene. In some embodiments, wherein L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently C 3 -C 10  alkylene or C 3 -C 10  alkenylene. In some embodiments, wherein L is the formula -L 1 -L 2 -, and L 1  and L 2  are independently C 3 -C 6  alkylene or C 3 -C 6  alkenylene. In some embodiments, L is 
     
       
         
         
             
             
         
       
     
     In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently alkylene, alkenylene, or alkynylene, and L 2  is arylene or heteroarylene. In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently C 3 -C 10  alkylene, and L 2  is heteroarylene. In some embodiments, L is the formula -L 1 -L 2 -L 3 -, and L 1  and L 3  are independently C 3 -C 6  alkylene, and L 2  is heteroarylene. 
     In some embodiments, R 1  and R 2  are H. In some embodiments, R 1  and R 2  are independently alkyl. In some embodiments, R 1  and R 2  are methyl. 
     In one example, at least one of R 1  and R 2  is alkyl, unsubstituted or substituted with halo-. In another example, both R 1  and R 2  are independently alkyl, unsubstituted or substituted with halo-. In some embodiments, at least one of R 1  and R 2  is methyl. In other embodiments, R 1  and R 2  are methyl. 
     In some embodiments of the invention, the sum of the sum of x+y+z is at least 3, or the sum of x′+y′+z′ is at least 3. In other embodiments of the invention, the sum of the sum of x+y+z is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (for example 2, 3 or 6) or the sum of x′+y′+z′ is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (for example 2, 3 or 6). 
     Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula [A] x , when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gln-Asp-Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges. Similarly, when u is greater than 1, each compound of the invention may encompass peptidomimetic macrocycles which are the same or different. For example, a compound of the invention may comprise peptidomimetic macrocycles comprising different linker lengths or chemical compositions. 
     In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α-helix and R 8  is —H, allowing intrahelical hydrogen bonding. In some embodiments, at least one of A, B, C, D or E is an α,α-disubstituted amino acid. In one example, B is an α,α-disubstituted amino acid. For instance, at least one of A, B, C, D or E is 2-aminoisobutyric acid. In other embodiments, at least one of A, B, C, D or E is 
     
       
         
         
             
             
         
       
     
     In other embodiments, the length of the macrocycle-forming linker L as measured from a first Cα to a second Cα is selected to stabilize a desired secondary peptide structure, such as an α-helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first Cα to a second Cα. 
     In one embodiment, the peptidomimetic macrocycle of Formula (I) is: 
     
       
         
         
             
             
         
       
     
     wherein each R 1  and R 2  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. 
     In related embodiments, the peptidomimetic macrocycle comprises a structure of Formula (I) which is: 
     
       
         
         
             
             
         
       
     
     In other embodiments, the peptidomimetic macrocycle of Formula (I) is a compound of any of the formulas shown below: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     wherein “AA” represents any natural or non-natural amino acid side chain and “ ” is [D] v , [E] w  as defined above, and n is an integer between 0 and 20, 50, 100, 200, 300, 400 or 500. In some embodiments, the substituent “n” shown in the preceding paragraph is 0. In other embodiments, the substituent “n” shown in the preceding paragraph is less than 50, 40, 30, 20, 10, or 5. 
     Exemplary embodiments of the macrocycle-forming linker L are shown below. 
     
       
         
         
             
             
         
       
     
     In other embodiments, D or E in the compound of Formula I are further modified in order to facilitate cellular uptake. In some embodiments, lipidating or PEGylating a peptidomimetic macrocycle facilitates cellular uptake, increases bioavailability, increases blood circulation, alters pharmacokinetics, decreases immunogenicity or decreases the needed frequency of administration. 
     In other embodiments, at least one of [D] and [E] in the compound of Formula I represents a moiety comprising an additional macrocycle-forming linker such that the peptidomimetic macrocycle comprises at least two macrocycle-forming linkers. In a specific embodiment, a peptidomimetic macrocycle comprises two macrocycle-forming linkers. 
     In the peptidomimetic macrocycles of the invention, any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown in Tables 1-2 and also with any of the R— substituents indicated herein. 
     In some embodiments, the peptidomimetic macrocycle comprises at least one α-helix motif. For example, A, B or C in the compound of Formula I include one or more α-helices. As a general matter, α-helices include between 3 and 4 amino acid residues per turn. In some embodiments, the α-helix of the peptidomimetic macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid residues. In specific embodiments, the α-helix includes 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns. In some embodiments, the macrocycle-forming linker stabilizes an α-helix motif included within the peptidomimetic macrocycle. Thus, in some embodiments, the length of the macrocycle-forming linker L from a first Cα to a second Cα is selected to increase the stability of an α-helix. In some embodiments, the macrocycle-forming linker spans from 1 turn to 5 turns of the α-helix. In some embodiments, the macrocycle-forming linker spans approximately 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns of the α-helix. In some embodiments, the length of the macrocycle-forming linker is approximately 5 Å to 9 Å per turn of the α-helix, or approximately 6 Å to 8 Å per turn of the α-helix. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the length is equal to approximately 5 carbon-carbon bonds to 13 carbon-carbon bonds, approximately 7 carbon-carbon bonds to 11 carbon-carbon bonds, or approximately 9 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 2 turns of an α-helix, the length is equal to approximately 8 carbon-carbon bonds to 16 carbon-carbon bonds, approximately 10 carbon-carbon bonds to 14 carbon-carbon bonds, or approximately 12 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 3 turns of an α-helix, the length is equal to approximately 14 carbon-carbon bonds to 22 carbon-carbon bonds, approximately 16 carbon-carbon bonds to 20 carbon-carbon bonds, or approximately 18 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 4 turns of an α-helix, the length is equal to approximately 20 carbon-carbon bonds to 28 carbon-carbon bonds, approximately 22 carbon-carbon bonds to 26 carbon-carbon bonds, or approximately 24 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 5 turns of an α-helix, the length is equal to approximately 26 carbon-carbon bonds to 34 carbon-carbon bonds, approximately 28 carbon-carbon bonds to 32 carbon-carbon bonds, or approximately 30 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the linkage contains approximately 4 atoms to 12 atoms, approximately 6 atoms to 10 atoms, or approximately 8 atoms. Where the macrocycle-forming linker spans approximately 2 turns of the α-helix, the linkage contains approximately 7 atoms to 15 atoms, approximately 9 atoms to 13 atoms, or approximately 11 atoms. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the linkage contains approximately 13 atoms to 21 atoms, approximately 15 atoms to 19 atoms, or approximately 17 atoms. Where the macrocycle-forming linker spans approximately 4 turns of the α-helix, the linkage contains approximately 19 atoms to 27 atoms, approximately 21 atoms to 25 atoms, or approximately 23 atoms. Where the macrocycle-forming linker spans approximately 5 turns of the α-helix, the linkage contains approximately 25 atoms to 33 atoms, approximately 27 atoms to 31 atoms, or approximately 29 atoms. Where the macrocycle-forming linker spans approximately 1 turn of the α-helix, the resulting macrocycle forms a ring containing approximately 17 members to 25 members, approximately 19 members to 23 members, or approximately 21 members. Where the macrocycle-forming linker spans approximately 2 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 29 members to 37 members, approximately 31 members to 35 members, or approximately 33 members. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 44 members to 52 members, approximately 46 members to 50 members, or approximately 48 members. Where the macrocycle-forming linker spans approximately 4 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 59 members to 67 members, approximately 61 members to 65 members, or approximately 63 members. Where the macrocycle-forming linker spans approximately 5 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 74 members to 82 members, approximately 76 members to 80 members, or approximately 78 members. 
     In some embodiments, L is a macrocycle-forming linker of the formula: 
     
       
         
         
             
             
         
       
     
     Exemplary embodiments of such macrocycle-forming linkers L are shown below. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     In some embodiments, the peptidomimetic macrocycle comprises an amino acid sequence of formula: 
     X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21 
     wherein: 
     In some embodiments, X1 is Ile, Arg, Ala, Lys, Pro, Leu, Asp, Glu, His, Ser, Gln, Phe, an analogue thereof, or absent. 
     In some embodiments, X2 is Trp, Arg, Ala, Asn, Phe, Pro, Leu, Ser, Lys, Tyr, His, Cou, Cou2, Cou4, Cou7, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X3 is Ile, Ala, Leu, Phe, Tyr, Val, Asp, Trp, Pro, Gln, Chg, Ac5c, Ac6c, Tba, Bip, Cha, Adm, hCha, an analogue thereof, or absent. 
     In some embodiments, X4 is Ala, Gln, Asp, Val, Gly, Ser, Leu, Phe, Cha, A4, an analogue, thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X5 is Gln, Ala, Leu, Phe, Tyr, Gly, Ile, Val, Arg, Glu, Pro, Asp, MO, MO2, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X6 is Glu, Gln, His, Ala, Ser, Arg, Ile, Leu, Thr, Phe, Val, Tyr, Gly, Nle, St, an analogue thereof, or absent. 
     In some embodiments, X7 is Ala, Leu, Phe, Ile, 2Nal, 1Nal, 3cf, Chg, Cha, Adm, hCha, Igl, Bip, an analogue thereof, or absent. 
     In some embodiments, X8 is Arg, Ala, Asp, Glu, Thr, His, Gln, Gly, Asn, Phe, Cit, St, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X9 is Arg, Ala, Asp, Lys, Asn, Gly, Ser, Gln, Cys, Nle, St, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X10 is Ile, Val, Ala, Asp, Asn, Phe, Tba, hL, hhL, Nle, Chg, Cha, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X11 is Gly, Val, Ala, Leu, Ile, Asp, Glu, Cha, Aib, Abu, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X12 is Asp, Ala, Asn, Gly, Arg, Glu, Lys, Leu, Nle, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X13 is Ala, Glu, Gln, Leu, Lys, Asp, Tyr, Ile, Ser, Cys, St, Sta5, Aib, Nle, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X14 is Phe, Ala, Leu, Val, Tyr, Glu, His, Ile, Nle, 1Nal, 2Nal, Chg, Cha, BiP, an analogue thereof, or a crosslinked amino acid. 
     In some embodiments, X15 is Asn, Gln, Ser, His, Glu, Asp, Ala, Leu, Ile, St, Nle, Aib, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X16 is Ala, Glu, Asp, Arg, Lys, Phe, Gly, Gln, Aib, Cha, St, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X17 is Phe, Tyr, Ala, Leu, Asn, Ser, Gln, Arg, His, Thr, Cou2, Cou3, Cou7, Dpr, Amf, Damf, Amye, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X18 is Tyr, Ala, Ile, Phe, His, Arg, Lys, Trp, Orn, Amf, Amye, Cha, 2Nal, an analogue thereof, or absent. 
     In some embodiments, X19 is Ala, Lys, Arg, His, Ser, Gln, Glu, Asp, Thr, Aib, Cha, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X20 is Arg, His, Ala, Thr, Lys, Amr, an analogue thereof, a crosslinked amino acid, or absent. 
     In some embodiments, X21 is Arg, His, Ala, Amr, an analogue thereof, or absent. 
     In some embodiments, the peptidomimetic macrocycle comprises a helix. 
     In some embodiments, the peptidomimetic macrocycle comprises an α-helix. 
     In some embodiments, the peptidomimetic macrocycle comprises an α,α-disubstituted amino acid. 
     In some embodiments, each amino acid connected by the macrocycle-forming linker is an α,α-disubstituted amino acid. 
     Warhead-Containing Peptidomimetic Macrocycles 
     The binding sites of the target proteins can be populated with amino acids that are capable of covalent modification with suitable reactive ligands. In some embodiments, the peptidomimetic macrocycles of the invention contain at least one warhead that can covalently modify a target protein. Non-limiting examples of a target protein include Bfl-1 and Bcl-2 family proteins. 
     In some embodiments, amino acids that are capable of covalent modification with suitable reactive ligands can be located near or in the binding regions of the peptidomimetic macrocycles of the invention. Amino acids capable of covalent modification are amino acids with heteroatoms in the side chain, such as threonine, cysteine, histidine, serine, tyrosine, and lysine. Amino acids such as lysine are unreactive and do not react in vivo. In some embodiments, a hydrogen bond donor amino acid in proximity to a lysine moiety can enhance the nucleophilicity of the lysine nitrogen by lowering the pKa, and make lysine reactive toward an electrophilic warhead. 
     Amino acids with hydrogen donor capability include arginine, threonine, serine, histidine, tyrosine, and lysine. In some embodiments, hydrogen bond donation by a side chain or a main chain amide can enhance the electrophilicity of a warhead. The compounds of the invention can incorporate an amino acid warhead to be proximal to a lysine or cysteine amino acid of a target protein to facilitate the formation of a covalent bond and irreversibly inhibit the target protein. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention are designed to be proximal to a Lys or Cys amino acid of the target protein to form a covalent bond for the irreversible inhibition of the target protein. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention act as irreversible inhibitors that covalently bind to their target proteins. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can permanently eliminate existing drug target activity, which can return when the target protein is newly synthesized. In some embodiments, the therapeutic plasma concentration of a compound can irreversibly suppress the activity of a target protein. In some embodiments, the plasma levels of a target protein can decline while the target protein remains inactivated. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can lower the minimal blood plasma concentration required for therapeutic activity. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can minimize dosing requirements. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can eliminate the requirement for long plasma-half lives. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can reduce toxicity resulting from any nonspecific off-target interactions that can occur at high or prolonged blood plasma levels. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can inactivate target proteins that have resistance mutations. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention can have enhanced potency, which may lower the dose of inhibitor required to silence the target protein. 
     In some embodiments, the peptidomimetic macrocycles of the invention comprise at least one warhead. In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention comprise an amino acid sequence that is about 60%, about 70%, about 80%, about 90%, about 95%, and about 99% identical to an amino acid sequence identified as binding to the binding site of a target protein. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention are of the formula: 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, and E is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each L is independently a macrocycle-forming linker; 
     each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 1  and the atom to which both R 1  and L′ are bound forms a ring; 
     each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 2  and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 1  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L′ and the atom to which both R 1  and L′ are bound forms a ring; 
     each R 2  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L″ and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each n is independently 1, 2, 3, 4, or 5; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or 
     a pharmaceutically-acceptable salt thereof, wherein the peptidomimetic macrocycle comprises an amino acid with an electron accepting group susceptible to attack by a nucleophile. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention are of the formula: 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, E, and F is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     each WH is an amino acid with an electron accepting group susceptible to attack by a nucleophile; 
     each L is independently a macrocycle-forming linker; 
     each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 1  and the atom to which both R 1  and L′ are bound forms a ring; 
     each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 2  and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 1  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L′ and the atom to which both R 1  and L′ are bound forms a ring; 
     each R 2  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L″ and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each n is independently 1, 2, 3, 4, or 5; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000; 
     t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or 
     a pharmaceutically-acceptable salt thereof. 
     In some embodiments, t is 0, 1, or 2. In some embodiments, t is 0. In some embodiments, u is 1 or 2. In some embodiments, t is 0, and u is 1. 
     In some embodiments, the warhead (WH)-containing peptidomimetic macrocycles of the invention are of the formula: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the warhead-containing peptidomimetic macrocycles are of the formula: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the invention comprise an amino acid of the formula: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the warhead of the amino acids are of the formula: 
     
       
         
         
             
             
         
       
     
     wherein:
         X is alkylene, CH, CH 2 , NR α , O, or S, wherein R α  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl;   R α  is H, CN, or C(O)CH 3 ;   R b  is H, methyl, ethyl, allyl, propyl, isopropyl, butyl, or isobutyl;   each R c , R d , and R e  is independently —H, C 1 -C 4  saturated or unsaturated, straight or branched, hydrocarbon chain, or an electron-withdrawing group, and in some embodiments, at least one of R c , R d , and R e  is an electron withdrawing group;   R f  is halogen, a C 2  alkynyl or alkenyl side chain optionally substituted with oxo, halogen, NO 2 , or CN; and   n′ iso, 1, 2, 3, 4, or 5.       

     In some embodiments, R d  and R e  are each independently —H, methyl, ethyl, allyl, propyl, isopropyl, butyl, or isobutyl. In some embodiments, R f  is —CH═CH 2  or —C≡CH. 
     In some embodiments, the warhead-containing peptidomimetic macrocycles of the formula comprise an amino acid with the side chain: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1-1625 and one Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1-500 and one Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1-10 and one Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1500-1625 and one Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1575-1625 and one Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1620-1625 and one Michael acceptor. 
     In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1-1625 and 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1575-1625 and 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NOs: 1-50 or 1620-1625 and 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NO 2 with 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NO 15 with 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NO 1620 with 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NO 1621 with 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. In some embodiments, the peptidomimetic macrocycles of the invention comprise SEQ ID NO 1625 with 
     
       
         
         
             
             
         
       
     
     as a Michael acceptor. 
     Non-limiting examples of warhead-containing peptidomimetic macrocycles include: 
     [WH]IAQELR$IGD$FNAYYARR-NH 2  (SEQ ID NO: 1626) and 
     [WH]IAQALR$r8hLGDAFN$YF4FA-NH 2 (SEQ ID NO: 1627). 
     Preparation of Peptidomimetic Macrocycles 
     Peptidomimetic macrocycles of the invention may be prepared by any of a variety of methods known in the art. For example, any of the residues indicated by “X”, “Z” or “XX” in Tables for 2 may be substituted with a residue capable of forming a crosslinker with a second residue in the same molecule or a precursor of such a residue. 
     Various methods to effect formation of peptidomimetic macrocycles are known in the art. For example, the preparation of peptidomimetic macrocycles of Formula I is described in Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000); Schafmeister &amp; Verdin, J. Am. Chem. Soc. 122:5891 (2005); Walensky et al., Science 305:1466-1470 (2004); U.S. Pat. No. 7,192,713 and PCT application WO 2008/121767. The α,α-disubstituted amino acids and amino acid precursors disclosed in the cited references may be employed in synthesis of the peptidomimetic macrocycle precursor polypeptides. For example, the “55-olefin amino acid” is (S)-α-(2′-pentenyl) alanine and the “R8 olefin amino acid” is (R)-α-(2′-octenyl) alanine. Following incorporation of such amino acids into precursor polypeptides, the terminal olefins are reacted with a metathesis catalyst, leading to the formation of the peptidomimetic macrocycle. In various embodiments, the following amino acids may be employed in the synthesis of the peptidomimetic macrocycle: 
     
       
         
         
             
             
         
       
     
     In some embodiments, x+y+z is 3, and A, B and C are independently natural or non-natural amino acids. In other embodiments, x+y+z is 6, and A, B and C are independently natural or non-natural amino acids. 
     In some embodiments, the contacting step is performed in a solvent selected from the group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof. For example, the solvent may be chosen from the group consisting of H 2 O, THF, THF/H 2 O, tBuOH/H 2 O, DMF, DIPEA, CH 3 CN or CH 2 Cl 2 , ClCH 2 CH 2 Cl or a mixture thereof. The solvent may be a solvent which favors helix formation. 
     Alternative but equivalent protecting groups, leaving groups or reagents are substituted, and certain of the synthetic steps are performed in alternative sequences or orders to produce the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein include, for example, those such as described in Larock, Comprehensive Organic Transformations, VCH Publishers (1989); Greene and Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); Fieser and Fieser, Fieser and Fieser&#39;s Reagents for Organic Synthesis, John Wiley and Sons (1994); and Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof. 
     The peptidomimetic macrocycles disclosed herein are made, for example, by chemical synthesis methods, such as described in Fields et al., Chapter 3 in  Synthetic Peptides: A User&#39;s Guide , ed. Grant, W. H. Freeman &amp; Co., New York, N.Y., 1992, p. 77. Hence, for example, peptides are synthesized using the automated Merrifield techniques of solid phase synthesis with the amine protected by either tBoc or Fmoc chemistry using side chain protected amino acids on, for example, an automated peptide synthesizer (e.g., Applied Biosystems (Foster City, Calif.), Model 430A, 431, or 433). 
     One manner of producing the peptidomimetic precursors and peptidomimetic macrocycles described herein uses solid phase peptide synthesis (SPPS). The C-terminal amino acid is attached to a cross-linked polystyrene resin via an acid labile bond with a linker molecule. This resin is insoluble in the solvents used for synthesis, making it relatively simple and fast to wash away excess reagents and by-products. The N-terminus is protected with the Fmoc group, which is stable in acid, but removable by base. Side chain functional groups are protected as necessary with base stable, acid labile groups. 
     Longer peptidomimetic precursors are produced, for example, by conjoining individual synthetic peptides using native chemical ligation. Alternatively, the longer synthetic peptides are biosynthesized by well-known recombinant DNA and protein expression techniques. Such techniques are provided in well-known standard manuals with detailed protocols. To construct a gene encoding a peptidomimetic precursor of this invention, the amino acid sequence is reverse translated to obtain a nucleic acid sequence encoding the amino acid sequence, preferably with codons that are optimum for the organism in which the gene is to be expressed. Next, a synthetic gene is made, typically by synthesizing oligonucleotides which encode the peptide and any regulatory elements, if necessary. The synthetic gene is inserted in a suitable cloning vector and transfected into a host cell. The peptide is then expressed under suitable conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods. 
     The peptidomimetic precursors are made, for example, in a high-throughput, combinatorial fashion using, for example, a high-throughput polychannel combinatorial synthesizer (e.g., Thuramed TETRAS multichannel peptide synthesizer from CreoSalus, Louisville, Ky. or Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, Ky.). 
     In some embodiments, the peptidomimetic macrocycles of the invention comprise triazole macrocycle-forming linkers. For example, the synthesis of such peptidomimetic macrocycles involves a multi-step process that features the synthesis of a peptidomimetic precursor containing an azide moiety and an alkyne moiety; followed by contacting the peptidomimetic precursor with a macrocyclization reagent to generate a triazole-linked peptidomimetic macrocycle. Such a process is described, for example, in U.S. application Ser. No. 12/037,041, filed on Feb. 25, 2008. Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, “The Non-Protein Amino Acids” in  Chemistry and Biochemistry of the Amino Acids , edited by G. C. Barrett, Chapman and Hall, 1985. 
     In some embodiments, an azide is linked to the α-carbon of a residue and an alkyne is attached to the α-carbon of another residue. In some embodiments, the azide moieties are azido-analogues of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, alpha-methyl-D-lysine, L-ornithine, D-ornithine, alpha-methyl-L-ornithine or alpha-methyl-D-ornithine. In another embodiment, the alkyne moiety is L-propargylglycine. In yet other embodiments, the alkyne moiety is an amino acid selected from the group consisting of L-propargylglycine, D-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, (R)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-2-methyl-5-hexynoic acid, (R)-2-amino-2-methyl-5-hexynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, (R)-2-amino-2-methyl-6-heptynoic acid, (S)-2-amino-2-methyl-7-octynoic acid, (R)-2-amino-2-methyl-7-octynoic acid, (S)-2-amino-2-methyl-8-nonynoic acid and (R)-2-amino-2-methyl-8-nonynoic acid. 
     The following synthetic schemes are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein. To simplify the drawings, the illustrative schemes depict azido amino acid analogues ε-azido-α-methyl-L-lysine and ε-azido-α-methyl-D-lysine, and alkyne amino acid analogues L-propargylglycine, (S)-2-amino-2-methyl-4-pentynoic acid, and (S)-2-amino-2-methyl-6-heptynoic acid. Thus, in the following synthetic schemes, each R 1 , R 2 , R 7  and R 8  is —H; each L 1  is —(CH 2 ) 4 —; and each L 2  is —(CH 2 )—. However, as noted throughout the detailed description above, many other amino acid analogues can be employed in which R 1 , R 2 , R 7 , R 8 , L 1  and L 2  can be independently selected from the various structures disclosed herein. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     Synthetic Scheme 1 describes the preparation of several compounds of the invention. Ni(II) complexes of Schiff bases derived from the chiral auxiliary (S)-2-[N—(N′-benzylprolyl)amino]benzophenone (BPB) and amino acids such as glycine or alanine are prepared as described in Belokon et al. (1998),  Tetrahedron Asymm.  9:4249-4252. The resulting complexes are subsequently reacted with alkylating reagents comprising an azido or alkynyl moiety to yield enantiomerically enriched compounds of the invention. If desired, the resulting compounds can be protected for use in peptide synthesis. 
     
       
         
         
             
             
         
       
     
     In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 2, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Cu(I) in organic or aqueous solutions (Rostovtsev et al. (2002),  Angew. Chem. Int. Ed.  41:2596-2599; Tornoe et al. (2002),  J. Org. Chem.  67:3057-3064; Deiters et al. (2003),  J. Am. Chem. Soc.  125:11782-11783; Punna et al. (2005),  Angew. Chem. Int. Ed.  44:2215-2220). In one embodiment, the triazole forming reaction is performed under conditions that favor α-helix formation. In one embodiment, the macrocyclization step is performed in a solvent chosen from the group consisting of H 2 O, THF, CH 3 CN, DMF, DIPEA, tBuOH or a mixture thereof. In another embodiment, the macrocyclization step is performed in DMF. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent. 
     
       
         
         
             
             
         
       
     
     In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 3, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Cu(I) reagent on the resin as a crude mixture (Rostovtsev et al. (2002),  Angew. Chem. Int. Ed.  41:2596-2599; Tornoe et al. (2002),  J. Org. Chem.  67:3057-3064; Deiters et al. (2003),  J. Am. Chem. Soc.  125:11782-11783; Punna et al. (2005),  Angew. Chem. Int. Ed.  44:2215-2220). The resultant triazole-containing peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH 2 Cl 2 , ClCH 2 CH 2 Cl, DMF, THF, NMP, DIPEA, 2,6-lutidine, pyridine, DMSO, H 2 O or a mixture thereof. In some embodiments, the macrocyclization step is performed in a buffered aqueous or partially aqueous solvent. 
     
       
         
         
             
             
         
       
     
     In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 4, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solution-phase or solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The peptidomimetic precursor is reacted as a crude mixture or is purified prior to reaction with a macrocyclization reagent such as a Ru(II) reagents, for example Cp*RuCl(PPh 3 ) 2  or [Cp*RuCl] 4  (Rasmussen et al. (2007),  Org. Lett.  9:5337-5339; Zhang et al. (2005),  J. Am. Chem. Soc.  127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of DMF, CH 3 CN and THF. 
     
       
         
         
             
             
         
       
     
     In the general method for the synthesis of peptidomimetic macrocycles shown in Synthetic Scheme 5, the peptidomimetic precursor contains an azide moiety and an alkyne moiety and is synthesized by solid-phase peptide synthesis (SPPS) using the commercially available amino acid N-α-Fmoc-L-propargylglycine and the N-α-Fmoc-protected forms of the amino acids (S)-2-amino-2-methyl-4-pentynoic acid, (S)-2-amino-6-heptynoic acid, (S)-2-amino-2-methyl-6-heptynoic acid, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. The peptidomimetic precursor is reacted with a macrocyclization reagent such as a Ru(II) reagent on the resin as a crude mixture. For example, the reagent can be Cp*RuCl(PPh 3 ) 2  or [Cp*RuCl] 4  (Rasmussen et al. (2007),  Org. Lett.  9:5337-5339; Zhang et al. (2005),  J. Am. Chem. Soc.  127:15998-15999). In some embodiments, the macrocyclization step is performed in a solvent chosen from the group consisting of CH 2 Cl 2 , ClCH 2 CH 2 Cl, CH 3 CN, DMF, and THF. 
     In some embodiments, a peptidomimetic macrocycle of Formula I comprises a halogen group substitution on a triazole moiety, for example an iodo substitution. Such peptidomimetic macrocycles may be prepared from a precursor having the partial structure and using the cross-linking methods taught herein. Crosslinkers of any length, as described herein, may be prepared comprising such substitutions. In one embodiment, the peptidomimetic macrocycle is prepared according to the scheme shown below. The reaction is performed, for example, in the presence of CuI and an amine ligand such as TEA or TTTA. See, e.g., Hein et al. Angew. Chem., Int. Ed. 2009, 48, 8018-8021. 
     
       
         
         
             
             
         
       
     
     In other embodiments, an iodo-substituted triazole is generated according to the scheme shown below. For example, the second step in the reaction scheme below is performed using, for example, CuI and N-bromosuccinimide (NBS) in the presence of THF (see, e.g. Zhang et al., J. Org. Chem. 2008, 73, 3630-3633). In other embodiments, the second step in the reaction scheme shown below is performed, for example, using CuI and an iodinating agent such as ICl (see, e.g. Wu et al., Synthesis 2005, 1314-1318.) 
     
       
         
         
             
             
         
       
     
     In some embodiments, an iodo-substituted triazole moiety is used in a cross-coupling reaction, such as a Suzuki or Sonogashira coupling, to afford a peptidomimetic macrocycle comprising a substituted crosslinker. Sonogashira couplings using an alkyne as shown below may be performed, for example, in the presence of a palladium catalyst such as Pd(PPh 3 ) 2 Cl 2 , CuI, and in the presence of a base such as triethylamine. Suzuki couplings using an arylboronic or substituted alkenyl boronic acid as shown below may be performed, for example, in the presence of a catalyst such as Pd(PPh 3 ) 4 , and in the presence of a base such as K 2 CO 3 . 
     
       
         
         
             
             
         
       
     
     Any suitable triazole substituent groups which reacts with the iodo-substituted triazole can be used in Suzuki couplings described herein. Example triazole substituents for use in Suzuki couplings are shown below: 
     
       
         
         
             
             
         
       
     
     wherein “Cyc” is a suitable aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with an R a  or R b  group as described below. 
     In some embodiments, the substituent is: 
     
       
         
         
             
             
         
       
     
     Any suitable substituent group which reacts with the iodo-substituted triazole can be used in Sonogashira couplings described herein. Example triazole substituents for use in Sonogashira couplings are shown below: 
     
       
         
         
             
             
         
       
     
     wherein “Cyc” is a suitable aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocyclyl group, unsubstituted or optionally substituted with an R a  or R b  group as described below. 
     In some embodiments, the triazole substituent is: 
     
       
         
         
             
             
         
       
     
     In some embodiments, the Cyc group shown above is further substituted by at least one R a  or R b  substituent. In some embodiments, at least one of R a  and R b  is independently: 
     
       
         
         
             
             
         
       
     
     In other embodiments, the triazole substituent is 
     
       
         
         
             
             
         
       
     
     and at least one of R a  and R b  is alkyl (including hydrogen, methyl, or ethyl), or: 
     
       
         
         
             
             
         
       
     
     The present invention contemplates the use of non-naturally-occurring amino acids and 
     The present invention contemplates the use of non-naturally-occurring amino acids and amino acid analogues in the synthesis of the peptidomimetic macrocycles described herein. Any amino acid or amino acid analogue amenable to the synthetic methods employed for the synthesis of stable triazole containing peptidomimetic macrocycles can be used in the present invention. For example, L-propargylglycine is contemplated as a useful amino acid in the present invention. However, other alkyne-containing amino acids that contain a different amino acid side chain are also useful in the invention. For example, L-propargylglycine contains one methylene unit between the α-carbon of the amino acid and the alkyne of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α-carbon and the alkyne. Also, the azido-analogues of amino acids L-lysine, D-lysine, alpha-methyl-L-lysine, and alpha-methyl-D-lysine are contemplated as useful amino acids in the present invention. However, other terminal azide amino acids that contain a different amino acid side chain are also useful in the invention. For example, the azido-analogue of L-lysine contains four methylene units between the α-carbon of the amino acid and the terminal azide of the amino acid side chain. The invention also contemplates the use of amino acids with fewer than or greater than four methylene units between the α-carbon and the terminal azide. Table 2 shows some amino acids useful in the preparation of peptidomimetic macrocycles disclosed herein. 
     
       
         
           
               
             
               
                 TABLE 2 
               
               
                   
               
             
            
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
            
           
         
       
     
     In some embodiments the amino acids and amino acid analogues are of the D-configuration. In other embodiments they are of the L-configuration. In some embodiments, some of the amino acids and amino acid analogues contained in the peptidomimetic are of the D-configuration while some of the amino acids and amino acid analogues are of the L-configuration. In some embodiments the amino acid analogues are α,α-disubstituted, such as α-methyl-L-propargylglycine, α-methyl-D-propargylglycine, ε-azido-alpha-methyl-L-lysine, and ε-azido-alpha-methyl-D-lysine. In some embodiments the amino acid analogues are N-alkylated, e.g., N-methyl-L-propargylglycine, N-methyl-D-propargylglycine, N-methyl-ε-azido-L-lysine, and N-methyl-ε-azido-D-lysine. 
     In some embodiments, the —NH moiety of the amino acid is protected using a protecting group, including without limitation -Fmoc and -Boc. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle. 
     In some embodiments, the —NH moiety of the amino acid is protected using a protecting group, including without limitation -Fmoc and -Boc. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle. 
     The preparation of macrocycles of Formula IV is described, for example, in U.S. application Ser. No. 11/957,325, filed on Dec. 17, 2007 and herein incorporated by reference. Synthetic Schemes 6-9 describe the preparation of such compounds of Formula IV. To simplify the drawings, the illustrative schemes depict amino acid analogues derived from L- or D-cysteine, in which L 1  and L 3  are both —(CH 2 )—. However, as noted throughout the detailed description above, many other amino acid analogues can be employed in which L 1  and L 3  can be independently selected from the various structures disclosed herein. The symbols “[AA] m ”, “[AA] n ”, “[AA] o ” represent a sequence of amide bond-linked moieties such as natural or unnatural amino acids. As described previously, each occurrence of “AA” is independent of any other occurrence of “AA”, and a formula such as “[AA] m ” encompasses, for example, sequences of non-identical amino acids as well as sequences of identical amino acids. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     In Scheme 6, the peptidomimetic precursor contains two —SH moieties and is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-trityl-L-cysteine or N-α-Fmoc-S-trityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996),  Angew. Chem. Int. Ed. Engl.  35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-trityl monomers by known methods (“Bioorganic Chemistry: Peptides and Proteins”, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The precursor peptidomimetic is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L 2 -Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH 3  (Mosberg et al. (1985), J. Am. Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40:233-242), NH 3 /MeOH, or NH 3 /DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the solvent used for the alkylation reaction is DMF or dichloroethane. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     In Scheme 7, the precursor peptidomimetic contains two or more —SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The precursor peptidomimetic is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-p-methoxytrityl-L-cysteine or N-α-Fmoc-S-p-methoxytrityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996),  Angew. Chem. Int. Ed. Engl.  35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-p-methoxytrityl monomers by known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The Mmt protecting groups of the peptidomimetic precursor are then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM). The precursor peptidomimetic is then reacted on the resin with X-L 2 -Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH 3  (Mosberg et al. (1985),  J. Am. Chem. Soc.  107:2986-2987; Szewczuk et al. (1992),  Int. J. Peptide Protein Res.  40:233-242), NH 3 /MeOH or NH 3 /DMF (Or et al. (1991),  J. Org. Chem.  56:3146-3149). In other embodiments, the alkylation reaction is performed in DMF or dichloroethane. The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). 
     
       
         
         
             
             
         
       
     
     In Scheme 8, the peptidomimetic precursor contains two or more —SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The peptidomimetic precursor is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-p-methoxytrityl-L-cysteine, N-α-Fmoc-S-p-methoxytrityl-D-cysteine, N-α-Fmoc-S—S-t-butyl-L-cysteine, and N-α-Fmoc-S—S-t-butyl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996),  Angew. Chem. Int. Ed. Engl.  35:2708-2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-p-methoxytrityl or N-α-Fmoc-S—S-t-butyl monomers by known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The S—S-tButyl protecting group of the peptidomimetic precursor is selectively cleaved by known conditions (e.g., 20% 2-mercaptoethanol in DMF, reference: Galande et al. (2005),  J. Comb. Chem.  7:174-177). The precursor peptidomimetic is then reacted on the resin with a molar excess of X-L 2 -Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. The Mmt protecting group of the peptidomimetic precursor is then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM). The peptidomimetic precursor is then cyclized on the resin by treatment with a hindered base in organic solutions. In some embodiments, the alkylation reaction is performed in organic solutions such as NH 3 /MeOH or NH 3 /DMF (Or et al. (1991),  J. Org. Chem.  56:3146-3149). The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). 
     
       
         
         
             
             
         
       
     
     In Scheme 9, the peptidomimetic precursor contains two L-cysteine moieties. The peptidomimetic precursor is synthesized by known biological expression systems in living cells or by known in vitro, cell-free, expression methods. The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH 3  (Mosberg et al. (1985), J. Am. Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40:233-242), NH 3 /MeOH, or NH 3 /DMF (Or et al. (1991), J. Org. Chem. 56:3146-3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunel et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the alkylation is performed in DMF or dichloroethane. In another embodiment, the alkylation is performed in non-denaturing aqueous solutions, and in yet another embodiment the alkylation is performed under conditions that favor α-helical structure formation. In yet another embodiment, the alkylation is performed under conditions that favor the binding of the precursor peptidomimetic to another protein, so as to induce the formation of the bound α-helical conformation during the alkylation. 
     Various embodiments for X and Y are envisioned which are suitable for reacting with thiol groups. In general, each X or Y is independently be selected from the general category shown in Table 3. For example, X and Y are halides such as —Cl, —Br or —I. Any of the macrocycle-forming linkers described herein may be used in any combination with any of the sequences shown and also with any of the R-substituents indicated herein. 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Examples of Reactive Groups Capable of Reacting 
               
               
                 with Thiol Groups and Resulting Linkages 
               
            
           
           
               
               
               
            
               
                   
                   
                 Resulting Covalent 
               
               
                   
                 X or Y 
                 Linkage 
               
               
                   
                   
               
               
                   
                 acrylamide 
                 Thioether 
               
               
                   
                 halide (e.g. alkyl or aryl halide) 
                 Thioether 
               
               
                   
                 sulfonate 
                 Thioether 
               
               
                   
                 aziridine 
                 Thioether 
               
               
                   
                 epoxide 
                 Thioether 
               
               
                   
                 haloacetamide 
                 Thioether 
               
               
                   
                 maleimide 
                 Thioether 
               
               
                   
                 sulfonate ester 
                 Thioether 
               
               
                   
                   
               
            
           
         
       
     
     The present invention contemplates the use of both naturally occurring and non-naturally-occurring amino acids and amino acid analogues in the synthesis of the peptidomimetic macrocycles of Formula IV. Any amino acid or amino acid analogue amenable to the synthetic methods employed for the synthesis of stable bis-sulfhydryl containing peptidomimetic macrocycles can be used in the present invention. For example, cysteine is contemplated as a useful amino acid in the present invention. However, sulfur containing amino acids other than cysteine that contain a different amino acid side chain are also useful. For example, cysteine contains one methylene unit between the α-carbon of the amino acid and the terminal-SH of the amino acid side chain. The invention also contemplates the use of amino acids with multiple methylene units between the α-carbon and the terminal —SH. Non-limiting examples include α-methyl-L-homocysteine and α-methyl-D-homocysteine. In some embodiments the amino acids and amino acid analogues are of the D-configuration. In other embodiments they are of the L-configuration. In some embodiments, some of the amino acids and amino acid analogues contained in the peptidomimetic are of the D-configuration while some of the amino acids and amino acid analogues are of the L-configuration. In some embodiments the amino acid analogues are α,α-disubstituted, such as α-methyl-L-cysteine and α-methyl-D-cysteine. 
     The invention includes macrocycles in which macrocycle-forming linkers are used to link two or more —SH moieties in the peptidomimetic precursors to form the peptidomimetic macrocycles disclosed herein. As described above, the macrocycle-forming linkers impart conformational rigidity, increased metabolic stability or increased cell penetrability. Furthermore, in some embodiments, the macrocycle-forming linkages stabilize the α-helical secondary structure of the peptidomimetic macrocycles. The macrocycle-forming linkers are of the formula X-L 2 -Y, wherein both X and Y are the same or different moieties, as defined above. Both X and Y have the chemical characteristics that allow one macrocycle-forming linker-L 2 - to bis alkylate the bis-sulfhydryl containing peptidomimetic precursor. As defined above, the linker-L 2 -includes alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene, or —R 4 —K—R 4 —, all of which can be optionally substituted with an R 5  group, as defined above. Furthermore, one to three carbon atoms within the macrocycle-forming linkers-L 2 -, other than the carbons attached to the —SH of the sulfhydryl containing amino acid, are optionally substituted with a heteroatom such as N, S or O. 
     The L 2  component of the macrocycle-forming linker X-L 2 -Y may be varied in length depending on, among other things, the distance between the positions of the two amino acid analogues used to form the peptidomimetic macrocycle. Furthermore, as the lengths of L 1  or L 3  components of the macrocycle-forming linker are varied, the length of L 2  can also be varied in order to create a linker of appropriate overall length for forming a stable peptidomimetic macrocycle. For example, if the amino acid analogues used are varied by adding an additional methylene unit to each of L 1  and L 3 , the length of L 2  are decreased in length by the equivalent of approximately two methylene units to compensate for the increased lengths of L 1  and L 3 . 
     In some embodiments, L 2  is an alkylene group of the formula —(CH 2 ) n —, where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In other embodiments, L 2  is an alkenylene group. In still other embodiments, L 2  is an aryl group. 
     Table 4 shows additional embodiments of X-L 2 -Y groups. 
     
       
         
           
               
             
               
                 TABLE 4 
               
               
                   
               
               
                 Example X-L 2 -Y groups. 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
            
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 
                   
                     
                     
                         
                         
                     
                   
                 
               
               
                   
               
               
                 Each X and Y in this Table, is, for example, independently Cl—, Br—, I—. 
               
            
           
         
       
     
     Additional methods of forming peptidomimetic macrocycles which are envisioned as suitable to perform the present invention include those disclosed by Mustapa, M. Firouz Mohd et al., J. Org. Chem (2003), 68, pp. 8193-8198; Yang, Bin et al. Bioorg Med. Chem. Lett. (2004), 14, pp. 1403-1406; U.S. Pat. No. 5,364,851; U.S. Pat. No. 5,446,128; U.S. Pat. No. 5,824,483; U.S. Pat. No. 6,713,280; and U.S. Pat. No. 7,202,332. In such embodiments, amino acid precursors are used containing an additional substituent R— at the alpha position. Such amino acids are incorporated into the macrocycle precursor at the desired positions, which may be at the positions where the crosslinker is substituted or, alternatively, elsewhere in the sequence of the macrocycle precursor. Cyclization of the precursor is then performed according to the indicated method. 
     For example, a peptidomimetic macrocycle of Formula (II) is prepared as indicated: 
     
       
         
         
             
             
         
       
     
     wherein each AA1, AA2, AA3 is independently an amino acid side chain. 
     In other embodiments, a peptidomimetic macrocycle of Formula (II) is prepared as indicated: 
     
       
         
         
             
             
         
       
     
     wherein each AA1, AA2, AA3 is independently an amino acid side chain. 
     In some embodiments, a peptidomimetic macrocycle is obtained in more than one isomer, for example due to the configuration of a double bond within the structure of the crosslinker (E vs Z). Such isomers can or cannot be separable by conventional chromatographic methods. In some embodiments, one isomer has improved biological properties relative to the other isomer. In one embodiment, an E crosslinker olefin isomer of a peptidomimetic macrocycle has better solubility, better target affinity, better in vivo or in vitro efficacy, higher helicity, or improved cell permeability relative to its Z counterpart. In another embodiment, a Z crosslinker olefin isomer of a peptidomimetic macrocycle has better solubility, better target affinity, better in vivo or in vitro efficacy, higher helicity, or improved cell permeability relative to its E counterpart. 
     A compound described herein can be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure on a chemical, optical, isomeric, enantiomeric, or diastereomeric basis. Purity can be assessed, for example, by HPLC, MS, LC/MS, melting point, or NMR. 
     Assays 
     The properties of the peptidomimetic macrocycles of the invention are assayed, for example, by using the methods described below. In some embodiments, a peptidomimetic macrocycle of the invention has improved biological properties relative to a corresponding polypeptide lacking the substituents described herein. 
     In some embodiments, a peptidomimetic macrocycle disclosed herein selectively binds BFL-1, or a BCL-2 family protein, selectively over another protein that has a BH3 domain. In some embodiments, the selectivity is a ratio of about 2 to about 1, about 3 to about 1, about 4 to about 1, about 5 to about 1, about 6 to about 1, about 7 to about 1, about 8 to about 1, about 9 to about 1, about 10 to about 1, about 20 to about 1, about 30 to about 1, about 40 to about 1, about 50 to about 1, about 60 to about 1, about 70 to about 1, about 80 to about 1, about 90 to about 1, about 100 to about 1, about 200 to about 1, about 300 to about 1, about 400 to about 1, about 500 to about 1, about 600 to about 1, about 700 to about 1, about 800 to about 1, about 900 to about 1, or about 1000 to about 1. 
     In some embodiments, a peptidomimetic macrocycle disclosed herein non-selectively binds additional types of proteins that have a BH3 domain. In some embodiments, the non-selectivity is at least about 2 types of proteins, at least about 3 types of proteins, at least about 4 types of proteins, at least about 5 types of proteins, at least about 6 types of proteins, at least about 7 types of proteins, at least about 8 types of proteins, at least about 9 types of proteins, at least about 10 types of proteins, at least about 11 types of protein, at least about 12 types of proteins, at least about 13 types of proteins, at least about 14 types of proteins, at least about 15 types of proteins, at least about 16 types of proteins, at least about 17 types of proteins, at least about 18 types of proteins, at least about 19 types of proteins, or at least about 20 types of proteins. In some embodiments, the non-selectivity is from about 2 types of protein to about 3 types of protein, from about 3 types of protein to about 4 types of protein, from about 4 types of protein to about 5 types of protein, from about 5 types of protein to about 6 types of protein, from about 6 types of protein to about 7 types of protein, from about 7 types of protein to about 8 types of protein, from about 8 types of protein to about 9 types of protein, from about 9 types of protein to about 10 types of protein, from about 10 types of protein to about 11 types of protein, from about 11 types of protein to about 12 types of protein, from about 12 types of protein to about 13 types of protein, from about 13 types of protein to about 14 types of protein, from about 14 types of protein to about 15 types of protein, from about 15 types of protein to about 16 types of protein, from about 16 types of protein to about 17 types of protein, from about 17 types of protein to about 18 types of protein, from about 18 types of protein to about 19 types of protein, or from about 19 types of protein to about 20 types of protein. 
     Assay to Determine α-Helicity. 
     In solution, the secondary structure of polypeptides with α-helical domains will reach a dynamic equilibrium between random coil structures and α-helical structures, often expressed as a “percent helicity”. Thus, for example, alpha-helical domains are predominantly random coils in solution, with α-helical content usually under 25%. Peptidomimetic macrocycles with optimized linkers, on the other hand, possess, for example, an alpha-helicity that is at least two-fold greater than that of a corresponding uncrosslinked polypeptide. In some embodiments, macrocycles of the invention will possess an alpha-helicity of greater than 50%. To assay the helicity of peptidomimetic macrocycles of the invention, the compounds are dissolved in an aqueous solution (e.g. 50 mM potassium phosphate solution at pH 7, or distilled H 2 O, to concentrations of 25-50 μM). Circular dichroism (CD) spectra are obtained on a spectropolarimeter (e.g., Jasco J-710) using standard measurement parameters (e.g. temperature, 20° C.; wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm). The α-helical content of each peptide is calculated by dividing the mean residue ellipticity (e.g. [Φ]222obs) by the reported value for a model helical decapeptide (Yang et al. (1986),  Methods Enzymol.  130:208)). 
     Assay to Determine Melting Temperature (Tm). 
     A peptidomimetic macrocycle of the invention comprising a secondary structure such as an α-helix exhibits, for example, a higher melting temperature than a corresponding uncrosslinked polypeptide. Typically peptidomimetic macrocycles of the invention exhibit Tm of &gt;60° C. representing a highly stable structure in aqueous solutions. To assay the effect of macrocycle formation on melting temperature, peptidomimetic macrocycles or unmodified peptides are dissolved in distilled H 2 O (e.g. at a final concentration of 50 μM) and the Tm is determined by measuring the change in ellipticity over a temperature range (e.g. 4 to 95° C.) on a spectropolarimeter (e.g., Jasco J-710) using standard parameters (e.g. wavelength 222 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature increase rate: 1° C./min; path length, 0.1 cm). 
     Protease Resistance Assay. 
     The amide bond of the peptide backbone is susceptible to hydrolysis by proteases, thereby rendering peptidic compounds vulnerable to rapid degradation in vivo. Peptide helix formation, however, typically buries the amide backbone and therefore may shield it from proteolytic cleavage. The peptidomimetic macrocycles of the present invention may be subjected to in vitro trypsin proteolysis to assess for any change in degradation rate compared to a corresponding uncrosslinked polypeptide. For example, the peptidomimetic macrocycle and a corresponding uncrosslinked polypeptide are incubated with trypsin agarose and the reactions quenched at various time points by centrifugation and subsequent HPLC injection to quantitate the residual substrate by ultraviolet absorption at 280 nm. Briefly, the peptidomimetic macrocycle and peptidomimetic precursor (5 mcg) are incubated with trypsin agarose (Pierce) (S/E ˜125) for 0, 10, 20, 90, and 180 minutes. Reactions are quenched by tabletop centrifugation at high speed; remaining substrate in the isolated supernatant is quantified by HPLC-based peak detection at 280 nm. The proteolytic reaction displays first order kinetics and the rate constant, k, is determined from a plot of 1n[S] versus time (k=−1×slope). 
     Ex Vivo Stability Assay. 
     Peptidomimetic macrocycles with optimized linkers possess, for example, an ex vivo half-life that is at least two-fold greater than that of a corresponding uncrosslinked polypeptide, and possess an ex vivo half-life of 12 hours or more. For ex vivo serum stability studies, a variety of assays may be used. For example, a peptidomimetic macrocycle and a corresponding uncrosslinked polypeptide (2 mcg) are incubated with fresh mouse, rat or human serum (2 mL) at 37° C. for 0, 1, 2, 4, 8, and 24 hours. To determine the level of intact compound, the following procedure may be used: The samples are extracted by transferring 100 μl of sera to 2 ml centrifuge tubes followed by the addition of 10 μL of 50% formic acid and 500 μL acetonitrile and centrifugation at 14,000 RPM for 10 min at 4±2° C. The supernatants are then transferred to fresh 2 ml tubes and evaporated on Turbovap under N 2 &lt;10 psi, 37° C. The samples are reconstituted in 100 μL of 50:50 acetonitrile:water and submitted to LC-MS/MS analysis. 
     In Vitro Binding Assays. 
     To assess the binding and affinity of peptidomimetic macrocycles and peptidomimetic precursors to acceptor proteins, a fluorescence polarization assay (FPA) is used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (e.g., FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution). 
     For example, fluoresceinated peptidomimetic macrocycles (25 nM) are incubated with the acceptor protein (25-1000 nM) in binding buffer (140 mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (e.g. Perkin-Elmer LS50B). K d  values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, Calif.). A peptidomimetic macrocycle of the invention shows, in some instances, similar or lower Kd than a corresponding uncrosslinked polypeptide. 
     In Vitro Displacement Assays to Characterize Antagonists of Peptide-Protein Interactions. 
     To assess the binding and affinity of compounds that antagonize the interaction between a peptide and an acceptor protein, a fluorescence polarization assay (FPA) utilizing a fluoresceinated peptidomimetic macrocycle derived from a peptidomimetic precursor sequence is used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (e.g., FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution). A compound that antagonizes the interaction between the fluoresceinated peptidomimetic macrocycle and an acceptor protein will be detected in a competitive binding FPA experiment. 
     For example, putative antagonist compounds (1 nM to 1 mM) and a fluoresceinated peptidomimetic macrocycle (25 nM) are incubated with the acceptor protein (50 nM) in binding buffer (140 mM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Antagonist binding activity is measured, for example, by fluorescence polarization on a luminescence spectrophotometer (e.g. Perkin-Elmer LS50B). Kd values may be determined by nonlinear regression analysis using, for example, Graphpad Prism software (GraphPad Software, Inc., San Diego, Calif.). 
     Any class of molecule, such as small organic molecules, peptides, oligonucleotides or proteins can be examined as putative antagonists in this assay. 
     Assay for Protein-Ligand Binding by Affinity Selection-Mass Spectrometry. 
     To assess the binding and affinity of test compounds for proteins, an affinity-selection mass spectrometry assay is used, for example. Protein-ligand binding experiments are conducted according to the following representative procedure outlined for a system-wide control experiment using 1 μM peptidomimetic macrocycle plus 5 μM target protein. A 1 μL DMSO aliquot of a 40 μM stock solution of peptidomimetic macrocycle is dissolved in 19 μL of PBS (Phosphate-buffered saline: 50 mM, pH 7.5 Phosphate buffer containing 150 mM NaCl). The resulting solution is mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To a 4 μL aliquot of the resulting supernatant is added 4 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS plus 1 μM peptidomimetic macrocycle and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated for 60 min at room temperature, and then chilled to 4° C. prior to size-exclusion chromatography-LC-MS analysis of 5.0 μL injections. Samples containing a target protein, protein-ligand complexes, and unbound compounds are injected onto an SEC column, where the complexes are separated from non-binding component by a rapid SEC step. The SEC column eluate is monitored using UV detectors to confirm that the early-eluting protein fraction, which elutes in the void volume of the SEC column, is well resolved from unbound components that are retained on the column. After the peak containing the protein and protein-ligand complexes elutes from the primary UV detector, it enters a sample loop where it is excised from the flow stream of the SEC stage and transferred directly to the LC-MS via a valving mechanism. The (M+3H) 3+  ion of the peptidomimetic macrocycle is observed by ESI-MS at the expected m/z, confirming the detection of the protein-ligand complex. 
     Assay for Protein-Ligand K d  Titration Experiments. 
     To assess the binding and affinity of test compounds for proteins, a protein-ligand Kd titration experiment is performed. Protein-ligand K d  titrations experiments are conducted as follows: 2 μL DMSO aliquots of a serially diluted stock solution of titrant peptidomimetic macrocycle (5, 2.5, . . . , 0.098 mM) are prepared then dissolved in 38 μL of PBS. The resulting solutions are mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To 4.0 μL aliquots of the resulting supernatants is added 4.0 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS, varying concentrations (125, 62.5, . . . , 0.24 μM) of the titrant peptide, and 2.5% DMSO. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 30 min, then chilled to 4° C. prior to SEC-LC-MS analysis of 2.0 μL injections. The (M+H) 1+ , (M+2H) 2+ , (M+3H) 3+ , or (M+Na) 1+  ion is observed by ESI-MS; extracted ion chromatograms are quantified, then fit to equations to derive the binding affinity K d  as described in “ A General Technique to Rank Protein - Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures .” Annis, D. A.; Nazef, N.; Chuang, C. C.; Scott, M. P.; Nash, H. M. J. Am. Chem. Soc. 2004, 126, 15495-15503; also in “ ALIS: An Affinity Selection - Mass Spectrometry System for the Discovery and Characterization of Protein - Ligand Interactions ” D. A. Annis, C.-C. Chuang, and N. Nazef. In Mass Spectrometry in Medicinal Chemistry. Edited by Wanner K, Höfner G: Wiley-VCH; 2007:121-184. Mannhold R, Kubinyi H, Folkers G (Series Editors): Methods and Principles in Medicinal Chemistry. 
     Assay for Competitive Binding Experiments by Affinity Selection-Mass Spectrometry. 
     To determine the ability of test compounds to bind competitively to proteins, an affinity selection mass spectrometry assay is performed, for example. A mixture of ligands at 40 μM per component is prepared by combining 2 μL aliquots of 400 μM stocks of each of the three compounds with 14 μL of DMSO. Then, 1 μL aliquots of this 40 μM per component mixture are combined with 1 μL DMSO aliquots of a serially diluted stock solution of titrant peptidomimetic macrocycle (10, 5, 2.5, . . . , 0.078 mM). These 2 μL samples are dissolved in 38 μL of PBS. The resulting solutions were mixed by repeated pipetting and clarified by centrifugation at 10 000 g for 10 min. To 4.0 μL aliquots of the resulting supernatants is added 4.0 μL of 10 μM target protein in PBS. Each 8.0 μL experimental sample thus contains 40 pmol (1.5 μg) of protein at 5.0 μM concentration in PBS plus 0.5 μM ligand, 2.5% DMSO, and varying concentrations (125, 62.5, . . . , 0.98 μM) of the titrant peptidomimetic macrocycle. Duplicate samples thus prepared for each concentration point are incubated at room temperature for 60 min, then chilled to 4° C. prior to SEC-LC-MS analysis of 2.0 μL injections. Additional details on these and other methods are provided in “ A General Technique to Rank Protein - Ligand Binding Affinities and Determine Allosteric vs. Direct Binding Site Competition in Compound Mixtures .” Annis, D. A.; Nazef, N.; Chuang, C. C.; Scott, M. P.; Nash, H. M.  J. Am. Chem. Soc.  2004, 126, 15495-15503; also in “ ALIS: An Affinity Selection - Mass Spectrometry System for the Discovery and Characterization of Protein - Ligand Interactions ” D. A. Annis, C.-C. Chuang, and N. Nazef. In Mass Spectrometry in Medicinal Chemistry. Edited by Wanner K, Höfner G: Wiley-VCH; 2007:121-184. Mannhold R, Kubinyi H, Folkers G (Series Editors): Methods and Principles in Medicinal Chemistry. 
     Binding Assays in Intact Cells. 
     It is possible to measure binding of peptides or peptidomimetic macrocycles to their natural acceptors in intact cells by immunoprecipitation experiments. For example, intact cells are incubated with fluoresceinated (FITC-labeled) compounds for 4 hrs in the absence of serum, followed by serum replacement and further incubation that ranges from 4-18 hrs. Cells are then pelleted and incubated in lysis buffer (50 mM Tris [pH 7.6], 150 mM NaCl, 1% CHAPS and protease inhibitor cocktail) for 10 minutes at 4° C. Extracts are centrifuged at 14,000 rpm for 15 minutes and supernatants collected and incubated with 10 μl goat anti-FITC antibody for 2 hrs, rotating at 4° C. followed by further 2 hrs incubation at 4° C. with protein A/G Sepharose (50 μl of 50% bead slurry). After quick centrifugation, the pellets are washed in lysis buffer containing increasing salt concentration (e.g., 150, 300, 500 mM). The beads are then re-equilibrated at 150 mM NaCl before addition of SDS-containing sample buffer and boiling. After centrifugation, the supernatants are optionally electrophoresed using 4%-12% gradient Bis-Tris gels followed by transfer into Immobilon-P membranes. After blocking, blots are optionally incubated with an antibody that detects FITC and also with one or more antibodies that detect proteins that bind to the peptidomimetic macrocycle. 
     Cellular Penetrability Assays. 
     To measure the cell penetrability of peptidomimetic macrocycles and corresponding uncrosslinked macrocycle, intact cells are incubated with fluoresceinated peptidomimetic macrocycles or corresponding uncrosslinked macrocycle (10 μM) for 4 hrs in serum free media at 37° C., washed twice with media and incubated with trypsin (0.25%) for 10 min at 37° C. The cells are washed again and resuspended in PBS. Cellular fluorescence is analyzed, for example, by using either a FACSCalibur flow cytometer or Cellomics&#39; KineticScan® HCS Reader. 
     In Vivo Stability Assays. 
     To investigate the in vivo stability of the peptidomimetic macrocycles, the compounds are, for example, administered to mice or rats by IV, IP, PO or inhalation routes at concentrations ranging from 0.1 to 50 mg/kg and blood specimens withdrawn at 0′, 5′, 15′, 30′, 1 hr, 4 hrs, 8 hrs and 24 hours post-injection. Levels of intact compound in 25 μL of fresh serum are then measured by LC-MS/MS as above. 
     Clinical Trials. 
     To determine the suitability of the peptidomimetic macrocycles of the invention for treatment of humans, clinical trials are performed. For example, patients diagnosed with a muscle wasting disease or lipodystrophy and in need of treatment are selected and separated in treatment and one or more control groups, wherein the treatment group is administered a peptidomimetic macrocycle of the invention, while the control groups receive a placebo or a known BH3 mimetic. The treatment safety and efficacy of the peptidomimetic macrocycles of the invention can thus be evaluated by performing comparisons of the patient groups with respect to factors such as survival and quality-of-life. In this example, the patient group treated with a peptidomimetic macrocycle show improved long-term survival compared to a patient control group treated with a placebo. 
     Pharmaceutical Compositions and Routes of Administration 
     In some embodiments, the present invention provides a pharmaceutical composition comprising a peptidomimetic macrocycle of the invention and a pharmaceutically acceptable carrier. 
     The peptidomimetic macrocycles of the invention also include pharmaceutically acceptable derivatives or prodrugs thereof. A “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, ester, salt of an ester, pro-drug or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored pharmaceutically acceptable derivatives are those that increase the bioavailability of the compounds of the invention when administered to a mammal (e.g., by increasing absorption into the blood of an orally administered compound) or which increases delivery of the active compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Some pharmaceutically acceptable derivatives include a chemical group which increases aqueous solubility or active transport across the gastrointestinal mucosa. 
     In some embodiments, the peptidomimetic macrocycles of the invention are modified by covalently or non-covalently joining appropriate functional groups to enhance selective biological properties. Such modifications include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and alter rate of excretion. 
     Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl) 4   +  salts. 
     For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers include either solid or liquid carriers. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which also acts as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington&#39;s Pharmaceutical Sciences, Maack Publishing Co, Easton Pa. 
     In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. 
     Suitable solid excipients are carbohydrate or protein fillers include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. 
     Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution. 
     The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. 
     When the compositions of this invention comprise a combination of a peptidomimetic macrocycle and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. In some embodiments, the additional agents are administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents are part of a single dosage form, mixed together with the compounds of this invention in a single composition. 
     In some embodiments, the compositions are present as unit dosage forms that can deliver, for example, from about 0.0001 mg to about 1,000 mg of the peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these. Thus, the unit dosage forms can deliver, for example, in some embodiments, from about 1 mg to about 900 mg, from about 1 mg to about 800 mg, from about 1 mg to about 700 mg, from about 1 mg to about 600 mg, from about 1 mg to about 500 mg, from about 1 mg to about 400 mg, from about 1 mg to about 300 mg, from about 1 mg to about 200 mg, from about 1 mg to about 100 mg, from about 1 mg to about 10 mg, from about 1 mg to about 5 mg, from about 0.1 mg to about 10 mg, from about 0.1 mg to about 5 mg, from about 10 mg to about 1,000 mg, from about 50 mg to about 1,000 mg, from about 100 mg to about 1,000 mg, from about 200 mg to about 1,000 mg, from about 300 mg to about 1,000 mg, from about 400 mg to about 1,000 mg, from about 500 mg to about 1,000 mg, from about 600 mg to about 1,000 mg, from about 700 mg to about 1,000 mg, from about 800 mg to about 1,000 mg, from about 900 mg to about 1,000 mg, from about 10 mg to about 900 mg, from about 100 mg to about 800 mg, from about 200 mg to about 700 mg, or from about 300 mg to about 600 mg of the peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these. 
     In some embodiments, the compositions are present as unit dosage forms that can deliver, for example, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, or about 1000 mg of peptidomimetic macrocycles, salts thereof, prodrugs thereof, derivatives thereof, or any combination of these. 
     Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ophthalmic, pulmonary, transmucosal, transdermal, vaginal, otic, nasal, and topical administration. In addition, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injections. 
     In certain embodiments, a composition as described herein is administered in a local rather than systemic manner, for example, via injection of the compound directly into an organ. In specific embodiments, long acting formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. In such embodiments, the liposomes are targeted to and taken up selectively by the organ. In yet other embodiments, the compound as described herein is provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. In yet other embodiments, the compound described herein is administered topically. 
     In another embodiment, compositions described herein are formulated for oral administration. Compositions described herein are formulated by combining a peptidomimetic macrocycle with, e.g., pharmaceutically acceptable carriers or excipients. In various embodiments, the compounds described herein are formulated in oral dosage forms that include, by way of example only, tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like. 
     In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipient with one or more of the peptidomimetic macrocycles described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In specific embodiments, disintegrating agents are optionally added. Disintegrating agents include, by way of example only, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. 
     In one embodiment, dosage forms, such as dragee cores and tablets, are provided with one or more suitable coating. In specific embodiments, concentrated sugar solutions are used for coating the dosage form. The sugar solutions, optionally contain additional components, such as by way of example only, gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments are also optionally added to the coatings for identification purposes. Additionally, the dyestuffs or pigments are optionally utilized to characterize different combinations of active compound doses. 
     In certain embodiments, therapeutically effective amounts of at least one of the peptidomimetic macrocycles described herein are formulated into other oral dosage forms. Oral dosage forms include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In specific embodiments, push-fit capsules contain the active ingredients in admixture with one or more filler. Fillers include, by way of example only, lactose, binders such as starches, or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In other embodiments, soft capsules, contain one or more active compound that is dissolved or suspended in a suitable liquid. Suitable liquids include, by way of example only, one or more fatty oil, liquid paraffin, or liquid polyethylene glycol. In addition, stabilizers are optionally added. 
     In other embodiments, therapeutically effective amounts of at least one of the peptidomimetic macrocycles described herein are formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, by way of example only, tablets, lozenges, or gels. In still other embodiments, the peptidomimetic macrocycles described herein are formulated for parenteral injection, including formulations suitable for bolus injection or continuous infusion. In specific embodiments, formulations for injection are presented in unit dosage form (e.g., in ampoules) or in multi-dose containers. Preservatives are, optionally, added to the injection formulations. In still other embodiments, pharmaceutical compositions are formulated in a form suitable for parenteral injection as a sterile suspensions, solutions or emulsions in oily or aqueous vehicles. Parenteral injection formulations optionally contain formulatory agents such as suspending, stabilizing or dispersing agents. In specific embodiments, pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. In additional embodiments, suspensions of the active compounds are prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, by way of example only, fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. In certain specific embodiments, aqueous injection suspensions contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension contains suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, in other embodiments, the active ingredient is in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. 
     Pharmaceutical compositions herein can be administered, for example, once or twice or three or four or five or six times per day, or once or twice or three or four or five or six times per week, and can be administered, for example, for a day, a week, a month, 3 months, six months, a year, five years, or for example ten years. In some embodiments, a pharmaceutical formulation of the invention is administered no more frequently than once daily, no more frequently than every other day, no more frequently than twice weekly, no more frequently than three times weekly, no more frequently than four times weekly, no more frequently than five times weekly, or no more frequently than every other week. In some embodiments, a pharmaceutical formulation of the invention is administered no more than once weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than twice weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than three times weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than four times weekly. In some embodiments, a pharmaceutical formulation of the invention is administered no more than five times weekly. 
     Methods of Use 
     As used herein, the term “treatment” is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease. In some embodiments, a peptidomimetic macrocycle disclosed herein is used for treating a disease or condition in a subject in need thereof. In some embodiments, a peptidomimetic macrocycle disclosed herein is used for manufacture of a medicament for treating a disease or condition in a subject in need thereof. 
     In one aspect, the present invention provides novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to a natural ligand of the proteins or peptides upon which the peptidomimetic macrocycles are modeled. For example, labeled peptidomimetic macrocycles based on BIM can be used in a binding assay along with small molecules that competitively bind to BFL-1 or a BCL-2 family protein. Competitive binding studies allow for rapid in vitro evaluation and determination of drug candidates specific to the BIM/BFL-1 or a BCL-2 family protein interaction. Such binding studies may be performed with any of the peptidomimetic macrocycles disclosed herein and their binding partners. 
     The invention further provides for the generation of antibodies against the peptidomimetic macrocycles. In some embodiments, these antibodies specifically bind both the peptidomimetic macrocycle and the precursor peptides, such as BIM, to which the peptidomimetic macrocycles are related. Such antibodies, for example, disrupt the native protein-protein interactions, for example, between BIM and BFL-1 or a BCL-2 family protein. 
     In another aspect, the present invention provides methods to inhibit BFL-1 or a BCL-2 family protein, thereby stimulating death of a cell or tissue. In some embodiments, a subject suffering from a condition of suppressed cell death, such as B-cell lymphoma, is treated using pharmaceutical compositions of the invention. 
     In yet another aspect, the present invention provides methods for treating a disease driven by over-expression of BFL-1 or a BCL-2 family protein. In some embodiments, the disease driven by over-expression is a cancer. The cancer can be a liquid cancer or a solid cancer. Non-limiting examples of a liquid cancer include leukemia, lymphoma, myeloma, and myeloid dysplasia. Non-limiting examples of a solid cancer include lung cancer, breast cancer, colon cancer, brain cancer, liver cancer, soft-tissue sarcoma, pancreatic cancer, and melanoma. In some embodiments, the cancer is resistant, non-responsive, or determined unlikely to respond to a BCL-2 inhibitor. 
     In some embodiments, the compounds of the present invention are administered in combination with a second therapeutic agent. In some embodiments, the compounds of the present invention are administered with compounds that inhibit the activity of BCL-2 anti-apoptotic proteins. In some embodiments, the BCL-2 inhibitor is a BH3 mimetic. In some embodiments, the BCL-2 inhibitor is navitoclax (ABT-263), obatoclax (GX15-070), or venetoclax. These methods comprise administering an effective amount of a compound of the invention to a warm blooded animal, including a human. In some embodiments, a pharmaceutical composition provided herein used in the treatment of a BFL-1 over-expressing cancer is administered no more frequently than once daily, no more frequently than every other day, no more frequently than twice weekly, no more frequently than weekly, or no more frequently than every other week. 
     In some embodiments, provided herein are methods for treating neurodegenerative disorders. Many neurodegenerative diseases are a result of neurodegenerative processes including progressive loss of structure or function of neurons. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non limiting neurodegenerative disorders that may be treated by the methods of the present invention include Parkinson&#39;s disease, Alzheimer&#39;s, Amyotrophic lateral sclerosis (ALS) and Huntington&#39;s disease. 
     In some embodiments, provided herein are methods for treating cardiac disorders. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non limiting examples of cardiac disorders that may be treated by the methods of the present invention include coronary heart disease (also known as isohaemic heart disease or coronary artery disease), cardiomyopathy (diseases of cardiac muscle), hypertensive heart disease (diseases of the heart secondary to high blood pressure), heart failure, cor pulmonale (failure of the right side of the heart), cardiac dysrhythmias (abnormalities of heart rhythm), inflammatory heart disease, endocarditis (inflammation of the inner layer of the heart, the endocardium), inflammatory cardiomegaly, myocarditis (inflammation of the myocardium, the muscular part of the heart), valvular heart disease, cerebrovascular disease (disease of blood vessels that supplies to the brain such as stroke), peripheral arterial disease (disease of blood vessels that supplies to the arms and legs), congenital heart disease, and rheumatic heart disease. In some embodiments, the methods of the present invention may be used for the treatment of acute myocardial infarction or chromic ischemic heart disease. 
     Also provided herein are methods for promoting cardiac regeneration in a subject in need thereof. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. 
     In some embodiments, provided herein are methods for treating diabetes or diabetes mellitus. Diabetes is a group of metabolic diseases in which a person has high blood sugar, either because the pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. The diabetes may be Type 1 diabetes mellitus, type 2 diabetes, gestational diabetes, congenital diabetes, cystic fibrosis-related diabetes or several forms of monogenic diabetes. Treatment of diabetes may be by islet/beta cell transplantation. 
     In another aspect the invention provides methods of treating a subject by administering to the subject a beta cell, wherein the beta cell has been treated with an effective amount of a peptidomimetic macrocycle of the invention or a pharmaceutical composition thereof. Similarly, In another aspect the invention provides methods of treating a subject by administering to the subject a islet cell, wherein the islet cell has been treated with an effective amount of a peptidomimetic macrocycle of the invention or a pharmaceutical composition thereof. 
     In some embodiments, provided herein are methods for treating cancer. These methods comprise administering an effective amount of at least one peptidomimetic macrocycles of the invention or a pharmaceutical composition thereof to a warm blooded animal, including a human. Non-limiting examples of cancers that may be treated by the methods of the present invention include breast cancer such as a ductal carcinoma in duct tissue in a mammary gland, medullary carcinomas, colloid carcinomas, tubular carcinomas, and inflammatory breast cancer; ovarian cancer, including epithelial ovarian tumors such as adenocarcinoma in the ovary and an adenocarcinoma that has migrated from the ovary into the abdominal cavity; uterine cancer; cervical cancer such as adenocarcinoma in the cervix epithelial including squamous cell carcinoma and adenocarcinomas; prostate cancer, such as a prostate cancer selected from the following: an adenocarcinoma or an adenocarcinoma that has migrated to the bone; pancreatic cancer such as epithelioid carcinoma in the pancreatic duct tissue and an adenocarcinoma in a pancreatic duct; bladder cancer such as a transitional cell carcinoma in urinary bladder, urothelial carcinomas (transitional cell carcinomas), tumors in the urothelial cells that line the bladder, squamous cell carcinomas, adenocarcinomas, and small cell cancers; leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome (MDS); bone cancer; lung cancer such as non-small cell lung cancer (NSCLC), which is divided into squamous cell carcinomas, adenocarcinomas, and large cell undifferentiated carcinomas, and small cell lung cancer; skin cancer such as basal cell carcinoma, melanoma, squamous cell carcinoma and actinic keratosis, which is a skin condition that sometimes develops into squamous cell carcinoma; eye retinoblastoma; cutaneous or intraocular (eye) melanoma; primary liver cancer (cancer that begins in the liver); kidney cancer; thyroid cancer such as papillary, follicular, medullary and anaplastic; AIDS-related lymphoma such as diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma and small non-cleaved cell lymphoma; Kaposi&#39;s Sarcoma; viral-induced cancers including hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatocellular carcinoma; human lymphotropic virus-type 1 (HTLV-1) and adult T-cell leukemia/lymphoma; and human papilloma virus (HPV) and cervical cancer; central nervous system cancers (CNS) such as primary brain tumor, which includes gliomas (astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme), Oligodendroglioma, Ependymoma, Meningioma, Lymphoma, Schwannoma, and Medulloblastoma; peripheral nervous system (PNS) cancers such as acoustic neuromas and malignant peripheral nerve sheath tumor (MPNST) including neurofibromas and schwannomas, malignant fibrous cytoma, malignant fibrous histiocytoma, malignant meningioma, malignant mesothelioma, and malignant mixed Müllerian tumor; oral cavity and oropharyngeal cancer such as, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer; stomach cancer such as lymphomas, gastric stromal tumors, and carcinoid tumors; testicular cancer such as germ cell tumors (GCTs), which include seminomas and nonseminomas, and gonadal stromal tumors, which include Leydig cell tumors and Sertoli cell tumors; thymus cancer such as to thymomas, thymic carcinomas, Hodgkin disease, non-Hodgkin lymphomas carcinoids or carcinoid tumors; rectal cancer; and colon cancer. 
     In some embodiments, a peptidomimetic macrocycle disclosed herein is administered in combination with an additional therapy to treat a cancer. Non-limiting examples of the additional therapy include surgery, radiation therapy, chemotherapy, or immunotherapy. In some embodiments, the combination of the peptidomimetic macrocycle and surgery is on an adjuvant basis or a neo-adjuvant basis. 
     Non-limiting examples of chemotherapy include alkylating agents, angiogenesis inhibitors, antimetabolites, Bcr-Abl kinase inhibitors, cyclin-dependent kinase inhibitors, cyclooxygenase-2 inhibitors, epidermal growth factor receptor (EGFR) inhibitors, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, histone deacetylase (HDAC) inhibitors, heat shock protein (HSP)-90 inhibitors, inhibitors of inhibitors of apoptosis proteins (IAPs), antibody drug conjugates, activators of death receptor pathway, kinesin inhibitors, JAK-2 inhibitors, mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), platelet-derived growth factor receptor (PDGFR) inhibitors, platinum chemotherapeutics, polo-like kinase (Plk) inhibitors, phosphoinositide-3 kinase (PI3K) inhibitors, thrombospondin analogues, vascular endothelial growth factor receptor (VEGFR) inhibitors, intercalating antibiotics, topoisomerase inhibitors, antibodies, hormonal therapies, deltoids and retinoids, poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitors, plant alkaloids, proteasome inhibitors, biologic response modifiers, pyrimidine analogues, purine analogues, antimitotics, taxanes, and ubiquitin ligase inhibitors. 
     Non-limiting examples of alkylating agents include: altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine, chlorambucil, laromustine, cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine, mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, bendamustine, treosulfan, and rofosfamide. 
     Non-limiting examples of angiogenesis inhibitors include: endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogues, and vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors. 
     Non-limiting examples of antimetabolites include: pemetrexed disodium, 5-azacitidine, capecitabine, carmofur, cladribine, clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR, enocitabine, ethnylcytidine, fludarabine, 5-fluorouracil, leucovorin, gemcitabine, hydroxyurea, melphalan, mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosfate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, and UFT. 
     Non-limiting examples of Bcr-Abl kinase inhibitors include: dasatinib, nilotinib, and imatinib. 
     Non-limiting examples of CDK inhibitors include: AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib, and ZK-304709. 
     Non-limiting examples of COX-2 inhibitors include: ABT-963, etoricoxib, valdecoxib, BMS347070, celecoxib, lumiracoxib, CT-3, deracoxib, JTE-522, 4-methy dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), etoricoxib, NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474. T-614, and rofecoxib. 
     Non-limiting examples of EGFR inhibitors include: ABX-EGF, anti-EGFR immunoliposomes, EGF-vaccine, EMD-7200, cetuximab, IgA antibodies, gefitinib, erlotinib, TP-38, EGFR fusion protein, and lapatinib. 
     Non-limiting examples of ErbB2 receptor inhibitors include: CP-724-714, canertinib, trastuzumab, lapatinib, petuzumab, TAK-165, ionafarnib, GW-282974, EKB-569, PI-166, dHER2 HER2. vaccine, APC-8024 HER-2 vaccine, anti-HER2/neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecific antibodies, mAB AR-209, and mAB 2B-1. 
     Non-limiting examples of histone deacetylase inhibitors include: depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, and valproic acid. 
     Non-limiting examples of HSP-90 inhibitors include: 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, human recombinant antibody to HSP-90, NCS-683664, PU24FC1, PU-3, radicicol, SNX-2112, or STA-9090 VER49009, 
     Non-limiting examples of inhibitors of inhibitors of apoptosis proteins include: HGS1029, GDC-0145, GDC-0152, LCL-161, and LBW-242. 
     Non-limiting examples of antibody-drug conjugates include: anti-CD22-MC-MMAF, anti-CD22-MC-MMAE, anti-CD22-MCC-DM1, CR-0,1-vcMMAE, PSMA-ADC, MEDI-547, SGN-19Am SGN-35, and SGN-75. 
     Non-limiting examples of activators of death receptor pathway include: TRAIL, antibodies or other agents that target TRAIL or death receptors (e.g., DR4 and DR5) such as apomab, conatumumab, ETR2-ST01, GDC0145, lexatumumab, HGS-1029, LBY-135, PRO-1762, and trastuzumab. 
     Non-limiting; examples of kinesin inhibitors include: Eg5 inhibitors such as AZD4877, ARRY-520; and CENPE inhibitors such as GSK923295A. 
     Non-limiting examples of JAK-2 inhibitors include: lesaurtinib, XL019 or INCB018424. 
     Non-limiting examples of MEK inhibitors include: trametinib, ARRY-142886, ARRY-438162 PD-325901, CI-1040, and PD-98059. 
     Non-limiting examples of mTOR inhibitors include: AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive. TORC1/TORC2 inhibitors, comprising P1-103, PP242, PP30, and Torin 1. 
     Non-limiting examples of non-steroidal anti-inflammatory drugs include: salsalate, diflunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, ibuprofen cream, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, ketorolac, and oxaprozin. 
     Non-limiting examples of PDGFR inhibitors include: C-451, CP-673, and CP-868596. 
     Non-limiting examples of platinum chemotherapeutics include: cisplatin, eptaplatin, lobaplatin, nedaplatin, carboplatin, satraplatin, and picoplatin. 
     Non-limiting examples of polo-like kinase inhibitors include: BI-2536. 
     Non-limiting examples of phosphoinositide-3 kinase (MK) inhibitors include: wortmannin, LY294002, XL-147, CAL-120, ONC-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, and XL765. 
     Non-limiting examples of thrombospondin analogues include: ABT-510, ABT-567, ABT-898, and TSP-1. 
     Non-limiting examples of VEGFR inhibitors include: bevacizumab, ABT-869, AEE-788, ANGIOZYME™ (a ribozyme that inhibits angiogenesis, axitinib, AZD-2171, CP-547,632, IM-862, pegaptamib, sorafenib, pazopanib, vatalanib, sunitinib, VEGF trap, and vandetanib. 
     Non-limiting examples of antibiotics include: intercalating antibiotics aclarubicin, actinomycin amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, liposomal doxorubicin, doxorubicin, elsamitrucin, epirbucin, glarbuicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, vairubicin, and zinostatin. 
     Non-limiting examples of topoisomerase inhibitors include: aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, irinotecan, camptothecin, dexrazoxine, diflomotecan, edotecarin, epirubicin, etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, and topotecan. 
     Non-limiting examples of antibodies include: bevacizumab, CD40 antibodies, chTNT-1/B, denosumab, cetuximab, zanolimumab, IGF1R antibodies, lintuzumab, edrecolomab, WX G250, rituximab, ticilimumab, trastuzumab, CD20 antibodies types I and II, pernbrolizumab, nivolumab, rituximab, and panitumumab. 
     Non-limiting examples of hormonal therapies include: anastrozole, exemestane, arzoxifene, bicalutamide, cetrorelix, degarelix, deslorelin, trilostane, dexamethasone, flutamide, raloxifene, fadrozole, toremifene, fulvestrant, letrozole, formestane, glucocorticoids, doxercalciferol, sevelamer carbonate, lasofoxifene, leuprolide acetate, megesterol, mifepristone, nilutamide, tamoxifen citrate, abarelix, prednisone, finasteride, rilostane, buserelin, luteinizing hormone releasing hormone (TA-IRA), histrelin implant, trilostane, modrastane, fosrelin, and goserelin. 
     Non-limiting examples of deltoids and retinoids include: seocalcitol, lexacalcitrol, fenretinide, aliretinoin, liposomal tretinoin, bexarotene, and LGD-1550. 
     Non-limiting examples of PARP inhibitors include: ABT-888, olaparib, KU-59436, AZD-2281 AG-014699, BSI-201, BGP-15, INO-1001, and ONO-2231. 
     Non-limiting examples of plant alkaloids include: vincristine, vinblastine, vindesine, and vinorelbine. 
     Non-limiting examples of proteasome inhibitors include: bortezomib, carfilzomib, MG132, and NPI-0052. 
     Non-limiting examples of biological response modifiers include: krestin, sizofuran, picibanil, PF-3512676, and ubenimex. 
     Non-limiting examples of pyrimidine analogues include: cytarabine, cytosine arabinoside, doxifluridine, fludarabine, 5-fluorouracil, floxuridine, gemcitabine, ratitrexed, and triacetvluridine troxacitabine. 
     Non-limiting examples of purine analogues include: thioguanine, and mercaptopurine. 
     Non-limiting examples of antimitotic agents include: batabulin, epothilone D, N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone, paclitaxel, docetaxel, PNU100940, patupilone, XRP-9881 larotaxel, vinflunine, and epothilone. 
     Non-limiting examples of ubiquitin ligase inhibitors include paclitaxel and docetaxel. 
     Non-limiting examples of ubiquitin ligase inhibitors include: MDM2 inhibitors, such as nutlins, and NEDD8 inhibitors such as MLN4924. 
     Non-limiting examples of immunotherapies include: interferons or immune-enhancing agents. Interferons comprise interferon alpha, interferon alpha-2a, interferon alpha-2h, interferon beta, interferon gamma-1a, interferon gamma-1b, interferon gamma-n1. Other immune-enhancing agents comprise oxidized glutathione, tasonermin, tositumomab, alemtuzumab, CTLA4, decarbazine, denileukin, epratuzumab, lenograstim, lentinan, leukocyte alpha interferon, imiquimod, ipilumimab, melanoma vaccine, mitumomab, molgramostim, nivolumab, pembrolizumab, gemtuzumab ozogamicin, filgrastim, OncoVAC-CL, oregovomab, pemtumomab, sipuleucel-T, sargaramostim, sizofilan, teceleukin, Bacillus Calmette-Guerin, ubenimex, virulizin, Z-100, Tetrachlorodecaoxide (TCDD), aldesleukin, thymalfasin, daclizumab, and 90Y-Ibritumomab tiuxetan. 
     While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. 
     EXAMPLES 
     Example 1: Peptidomimetic Macrocycles of the Invention 
     Peptidomimetic macrocycles were synthesized, purified and analyzed as previously described and as described below (Schafmeister et al., J. Am. Chem. Soc. 122:5891-5892 (2000); Schafmeister &amp; Verdin, J. Am. Chem. Soc. 122:5891 (2005); Walensky et al., Science 305:1466-1470 (2004); and U.S. Pat. No. 7,192,713). Peptidomimetic macrocycles were designed by replacing two or more naturally occurring amino acids with the corresponding synthetic amino acids. Substitutions were made at i and i+4, and i and i+7 positions. Peptide synthesis was performed either manually or on an automated peptide synthesizer (Applied Biosystems, model 433A), using solid phase conditions, rink amide AM resin (Novabiochem), and Fmoc main-chain protecting group chemistry. For the coupling of natural Fmoc-protected amino acids (Novabiochem), 10 equivalents of amino acid and a 1:1:2 molar ratio of coupling reagents HBTU/HOBt (Novabiochem)/DIEA were employed. Non-natural amino acids (4 equiv) were coupled with a 1:1:2 molar ratio of HATU (Applied Biosystems)/HOBt/DIEA. The N-termini of the synthetic peptides were acetylated, while the C-termini were amidated. 
     Purification of cross-linked compounds was achieved by high performance liquid chromatography (HPLC) (Varian ProStar) on a reverse phase C18 column (Varian) to yield the pure compounds. Chemical composition of the pure products was confirmed by LC/MS mass spectrometry (Micromass LCT interfaced with Agilent 1100 HPLC system) and amino acid analysis (Applied Biosystems, model 420A). 
     Example 2: Metabolism by Purified Protease 
     Linear peptides and cross-linked peptidomimetic macrocycles are tested for stability to proteolysis by Trypsin (MP Biomedicals, Solon OH) by solubilizing each peptide at 10 μM concentration in 200 μL 100 mM NH4OAc (pH 7.5). The reaction is initiated by adding 3.5 μl of Trypsin (12.5 μg protease per 500 μL reaction) and shaking continually in sealed vials while incubating in a Room Temperature (22±2° C.). The enzyme/substrate ratio is 1:102 (w/w). After incubation times of 0, 5, 30, 60 and 135 min the reaction is stopped by addition of equal volume of 0.2% trifluoroacetic acid. Then, the solution is immediately analyzed by LC-MS in positive detection mode. The reaction half-life for each peptide is calculated in GraphPad Prism by a non-linear fit of uncalibrated MS response versus enzyme incubation time. 
     
       
         
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
             
               
                   
               
               
                 SEQ 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 Calc. 
                   
                   
                   
                   
                   
               
               
                 ID 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                 (M + 2)/ 
                 Found 
                 EC 50   
                 Ki 
                 Ki 
                 Ki 
               
               
                 NO: 
                   
                   
                 1 
                 2 
                 3 
                 4 
                 5 
                 6 
                 7 
                 8 
                 9 
                 10 
                 11 
                 12 
                 13 
                 14 
                 15 
                 16 
                 17 
                 18 
                 19 
                 20 
                 21 
                   
                 2 
                 mass 
                 (μM)* 
                 MCL-1 
                 BCL-X L   
                 BCL-2 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 1628 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                 R 
                 R 
                 —NH 2   
                 1344.74 
                 1345.7 
                   
                 10.6 
                 3.9 
                 12.9 
               
               
                   
               
               
                 1629 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 E 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                 R 
                 R 
                 —NH 2   
                 1373.75 
                 1373.56 
                   
                   
                 9.2 
                 23.5 
               
               
                   
               
               
                 1630 
                 Ac- 
                   
                   
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1103.1 
                 1103.12 
                   
                   
                 212.6 
                 423.8 
               
               
                   
               
               
                 1631 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 A 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 988.55 
                 988.45 
                   
                   
                 373.6 
                 877.5 
               
               
                   
               
               
                 1632 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 A 
                 A 
                   
                   
                 —NH 2   
                 964.04 
                 963.94 
                   
                   
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1633 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1159.64 
                 1159.87 
                 6.6 
                 8.4 
                 22.4 
                 84.8 
               
               
                   
               
               
                 1634 
                 Ac- 
                   
                   
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1103.1 
                 1102.94 
                   
                   
                   
                 410.2 
               
               
                   
               
               
                 1635 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1010.06 
                 1009.9 
                   
                   
                 308.6 
                 519.2 
               
               
                   
               
               
                 1636 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 981.55 
                 981.86 
                   
                   
                 255.9 
                 318.7 
               
               
                   
               
               
                 1637 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 A 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 967.53 
                 967.45 
                   
                   
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1638 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 A 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1017.07 
                 1016.93 
                   
                   
                 243.1 
                 272.5 
               
               
                   
               
               
                 1639 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 972.04 
                 971.89 
                   
                   
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1640 
                 Ac- 
                   
                   
                   
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 A 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 964.04 
                 963.94 
                   
                   
                 471.5 
                 803.9 
               
               
                   
               
               
                 1641 
                 Ac- 
                   
                 I 
                 $ 
                 I 
                 A 
                 Q 
                 $ 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1185.17 
                 1185.61 
                 &gt;40 
                 19.5 
                 11.6 
                 8.7 
               
               
                   
               
               
                 1642 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 % r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 % 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1160.14 
                 1161.28 
               
               
                   
               
               
                 1643 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 A 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1167.14 
                 1168.2 
                   
                 7.0 
                 15.4 
                 21.9 
               
               
                   
               
               
                 1644 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1150.13 
                 1151.09 
               
               
                   
               
               
                 1645 
                 FITC- 
                 Ba 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1368.67 
                 1369.79 
                   
                 ND 
                 ND 
                 ND 
               
               
                   
               
               
                 1646 
                 5- 
                 Ba 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1353.18 
                 1354.13 
                   
                 ND 
                 ND 
                 ND 
               
               
                   
                 FAM- 
               
               
                   
               
               
                 1647 
                 5- 
                 Ba 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1382.18 
                 1382.99 
                   
                 ND 
                 ND 
                 ND 
               
               
                   
                 FAM- 
               
               
                   
               
               
                 1648 
                 Ac- 
                   
                 I 
                 A 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1102.12 
                 1103.17 
                   
                 19.7 
                 22.3 
                 37.7 
               
               
                   
               
               
                 1649 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1188.64 
                 1189.57 
                 &gt;40 
                 1.8 
                 1.4 
                 3.2 
               
               
                   
               
               
                 1650 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1188.15 
                 1189.1 
                   
                 5.2 
                 12.0 
                 67.0 
               
               
                   
               
               
                 1651 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1160.13 
                 1161.17 
                   
                 1.0 
                 1.0 
                 6.0 
               
               
                   
               
               
                 1652 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1159.64 
                 1160.34 
                   
                 6.0 
                 4.0 
                 22.0 
               
               
                   
               
               
                 1653 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1131.13 
                 1132.12 
                   
                 6.7 
                 25.6 
                 65.4 
               
               
                   
               
               
                 1654 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 A 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.14 
                 1139.15 
                   
                 7.4 
                 55.7 
                 114.6 
               
               
                   
               
               
                 1655 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1160.13 
                 1160.98 
                 9.1 
                 7.5 
                 109.0 
                 211.6 
               
               
                   
               
               
                 1656 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1188.64 
                 1189.66 
                   
                 1.7 
                 28.8 
                 88.2 
               
               
                   
               
               
                 1657 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 H 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1150.12 
                 1151.09 
                   
                 &gt;1000 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1658 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 H 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1178.63 
                 1179.67 
                   
                 &gt;1000 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1659 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Q 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1145.62 
                 1146.55 
                   
                 76.2 
                 325.4 
                 364.7 
               
               
                   
               
               
                 1660 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Q 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1174.13 
                 1175.14 
                   
                 14.8 
                 6.3 
                 27.5 
               
               
                   
               
               
                 1661 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1121.62 
                 1122.5 
                   
                 7.5 
                 401.7 
                 139.7 
               
               
                   
               
               
                 1662 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 I 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1142.65 
                 1143.59 
                   
                 3.4 
                 14.1 
                 113.0 
               
               
                   
               
               
                 1663 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 I 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1171.16 
                 1171.9 
               
               
                   
               
               
                 1664 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 A 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1100.6 
                 1101.5 
                   
                 177.0 
                 154.0 
                 502.0 
               
               
                   
               
               
                 1665 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 A 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.83 
                   
                 96.3 
                 7.7 
                 84.0 
               
               
                   
               
               
                 1666 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 A 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1195.16 
                 1196.23 
                   
                 116.2 
                 7.7 
                 25.6 
               
               
                   
               
               
                 1667 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 A 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.62 
                 1139.61 
                   
                 182.7 
                 18.1 
                 59.6 
               
               
                   
               
               
                 1668 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 A 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1167.13 
                 1168.11 
                   
                 122.1 
                 1.9 
                 4.8 
               
               
                   
               
               
                 1669 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 F 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1176.63 
                 1177.63 
                   
                 27.8 
                 15.8 
                 68.5 
               
               
                   
               
               
                 1670 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 F 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1205.14 
                 1205.94 
                   
                 74.1 
                 25.6 
                 66.1 
               
               
                   
               
               
                 1671 
                 Ac- 
                   
                 I 
                 W 
                 F 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1176.63 
                 1177.63 
                   
                 22.0 
                 28.0 
                 179.4 
               
               
                   
               
               
                 1672 
                 Ac- 
                   
                 I 
                 W 
                 F 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1205.14 
                 1206.13 
                   
                 29.3 
                 25.9 
                 204.6 
               
               
                   
               
               
                 1673 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 A 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1117.11 
                 1118.15 
                   
                 73.8 
                 386.4 
                 &gt;1000 
               
               
                   
               
               
                 1674 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 N 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1159.15 
                 1159.63 
                   
                 194.7 
                 416.0 
                 404.9 
               
               
                   
               
               
                 1675 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 A 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.62 
                 1139.2 
                   
                 &gt;1000 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1676 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 A 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.3 
                   
                 22.8 
                 53.5 
                 84.9 
               
               
                   
               
               
                 1677 
                 Ac- 
                   
                 I 
                 W 
                 Cha 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1179.65 
                 1180.15 
                 3.9 
                 43.8 
                 14.4 
                 104.9 
               
               
                   
               
               
                 1678 
                 Ac- 
                   
                 I 
                 W 
                 hhL 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1173.65 
                 1174.39 
                 5.7 
                 21.2 
                 11.9 
                 160.7 
               
               
                   
               
               
                 1679 
                 Ac- 
                   
                 I 
                 W 
                 Adm 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1198.66 
                 1199.28 
                   
                 21.6 
                 7.3 
                 59.0 
               
               
                   
               
               
                 1680 
                 Ac- 
                   
                 I 
                 W 
                 hCha 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1186.66 
                 1186.98 
                   
                 22.2 
                 13.1 
                 182.3 
               
               
                   
               
               
                 1681 
                 Ac- 
                   
                 I 
                 W 
                 hF 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1183.64 
                 1184.48 
                 7.2 
                 53.1 
                 69.7 
                 221.2 
               
               
                   
               
               
                 1682 
                 Ac- 
                   
                 I 
                 W 
                 Igl 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1190.65 
                 1190.41 
                 5.9 
                 12.8 
                 145.5 
                 246.4 
               
               
                   
               
               
                 1683 
                 Ac- 
                   
                 I 
                 W 
                 F4CF3 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1210.62 
                 1211.31 
                   
                 76.7 
                 9.1 
                 237.0 
               
               
                   
               
               
                 1684 
                 Ac- 
                   
                 I 
                 W 
                 F4tBu 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1204.66 
                 1205.39 
                   
                 150.8 
                 16.9 
                 &gt;1000 
               
               
                   
               
               
                 1685 
                 Ac- 
                   
                 I 
                 W 
                 2Nal 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1201.64 
                 1202.2 
                 4.8 
                 163.2 
                 151.1 
                 264.6 
               
               
                   
               
               
                 1686 
                 Ac- 
                   
                 I 
                 W 
                 Bip 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1214.65 
                 1215.43 
                 6.4 
                 11.0 
                 3.0 
                 &gt;1000 
               
               
                   
               
               
                 1687 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 Cha 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1179.65 
                 1180.22 
                   
                 4.2 
                 81.1 
                 &gt;1000 
               
               
                   
               
               
                 1688 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 hhL 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1173.65 
                 1174.4 
                   
                 3.1 
                 135.9 
                 231.4 
               
               
                   
               
               
                 1689 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 Adm 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1198.66 
                 1199.05 
                 0.5 
                 40.2 
                 109.5 
                 &gt;1000 
               
               
                   
               
               
                 1690 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 hCha 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1186.66 
                 1187.25 
                   
                 3.8 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1691 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 hAdm 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1205.67 
                 1206.4 
                   
                 16.6 
                 &gt;1000 
                 240.3 
               
               
                   
               
               
                 1692 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 hF 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1183.64 
                 1184.29 
                   
                 7.5 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1693 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 Igl 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1190.65 
                 1190.4 
                   
                 47.7 
                 146.7 
                 &gt;1000 
               
               
                   
               
               
                 1694 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 F4CF3 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1210.62 
                 1210.94 
                   
                 188.1 
                 10.8 
                 &gt;1000 
               
               
                   
               
               
                 1695 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 F4tBu 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1204.66 
                 1205.29 
                   
                 169.0 
                 12.7 
                 288.0 
               
               
                   
               
               
                 1696 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 2Nal 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1201.64 
                 1202.15 
                   
                 119.7 
                 17.3 
                 234.4 
               
               
                   
               
               
                 1697 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 Bip 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1214.65 
                 1214.91 
                   
                 83.7 
                 8.0 
                 280.1 
               
               
                   
               
               
                 1698 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 Cba 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1165.64 
                 1166.07 
                   
                 26.6 
                 27.5 
                 89.0 
               
               
                   
               
               
                 1699 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.37 
                   
                 13.0 
                 6.0 
                 12.7 
               
               
                   
               
               
                 1700 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 Cha 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1179.65 
                 1180.22 
                   
                 15.9 
                 7.1 
                 109.1 
               
               
                   
               
               
                 1701 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 Tba 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.18 
                   
                 13.7 
                 35.4 
                 227.1 
               
               
                   
               
               
                 1702 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hhL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1173.65 
                 1173.93 
                   
                 34.6 
                 4.0 
                 23.1 
               
               
                   
               
               
                 1703 
                 Ac- 
                   
                 I 
                 AmW 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.18 
                   
                 9.9 
                 17.4 
                 70.6 
               
               
                   
               
               
                 1704 
                 Ac- 
                   
                 I 
                 Aib 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1109.13 
                 1109.46 
                   
                 42.5 
                 83.5 
                 97.9 
               
               
                   
               
               
                 1705 
                 Ac- 
                   
                 AmL 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.27 
                   
                 5.2 
                 8.4 
                 48.3 
               
               
                   
               
               
                 1706 
                 Ac- 
                   
                 I 
                 W 
                 AmL 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1137.37 
                   
                 19.8 
                 7.2 
                 24.8 
               
               
                   
               
               
                 1707 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 Aib 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 AmD 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1173.65 
                 1173.93 
                   
                 &gt;1000 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1708 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Aib 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.14 
                 1138.32 
                   
                 5.5 
                 59.0 
                 120.1 
               
               
                   
               
               
                 1709 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 AmD 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.37 
                 &gt;40 
                 &gt;1000 
                 15.5 
                 &gt;1000 
               
               
                   
               
               
                 1710 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1160.64 
                 1161.45 
                 2.1 
                 4.8 
                 9.5 
                 91.8 
               
               
                   
               
               
                 1711 
                 Ac- 
                   
                 I 
                 W 
                 Tba 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.37 
                   
                 10.9 
                 17.2 
                 36.6 
               
               
                   
               
               
                 1712 
                 Ac- 
                   
                 I 
                 W 
                 hL 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.37 
                   
                 3.7 
                 17.0 
                 36.5 
               
               
                   
               
               
                 1713 
                 Ac- 
                   
                 I 
                 W 
                 Chg 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1172.65 
                 1173.47 
                   
                 4.6 
                 20.9 
                 38.9 
               
               
                   
               
               
                 1714 
                 Ac- 
                   
                 I 
                 W 
                 Ac6c 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1165.64 
                 1166.44 
                   
                 10.4 
                 7.7 
                 25.7 
               
               
                   
               
               
                 1715 
                 Ac- 
                   
                 I 
                 W 
                 Ac5c 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1158.63 
                 1159.32 
                   
                 8.9 
                 8.4 
                 68.2 
               
               
                   
               
               
                 1716 
                 Ac- 
                   
                 E 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1139.11 
                 1139.52 
                   
                 2.2 
                 72.0 
                 117.8 
               
               
                   
               
               
                 1717 
                 Ac- 
                   
                 R 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1152.64 
                 1153.49 
                   
                 4.5 
                 32.8 
                 47.8 
               
               
                   
               
               
                 1718 
                 Ac- 
                   
                 K 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.63 
                 1138.97 
                   
                 3.9 
                 27.2 
                 49.7 
               
               
                   
               
               
                 1719 
                 Ac- 
                   
                 H 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1143.12 
                 1143.87 
                   
                 3.6 
                 25.2 
                 52.0 
               
               
                   
               
               
                 1720 
                 Ac- 
                   
                 S 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1118.1 
                 1118.8 
                   
                 3.9 
                 33.4 
                 53.2 
               
               
                   
               
               
                 1721 
                 Ac- 
                   
                 Q 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.62 
                 1139.24 
                   
                 4.8 
                 35.9 
                 64.9 
               
               
                   
               
               
                 1722 
                 Ac- 
                   
                 A 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1110.1 
                 1110.75 
                   
                 3.8 
                 32.6 
                 63.9 
               
               
                   
               
               
                 1723 
                 Ac- 
                   
                 Aib 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1117.11 
                 1117.78 
                   
                 4.0 
                 20.3 
                 56.0 
               
               
                   
               
               
                 1724 
                 Ac- 
                   
                 F 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1148.12 
                 1148.96 
                   
                 6.2 
                 33.9 
                 76.7 
               
               
                   
               
               
                 1725 
                 Ac- 
                   
                 I 
                 D 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1095.6 
                 1096.32 
                   
                 3.0 
                 36.3 
                 41.1 
               
               
                   
               
               
                 1726 
                 Ac- 
                   
                 I 
                 R 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1116.14 
                 1116.95 
                   
                 9.8 
                 20.5 
                 39.1 
               
               
                   
               
               
                 1727 
                 Ac- 
                   
                 I 
                 H 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1106.62 
                 1107.24 
                   
                 6.6 
                 19.5 
                 43.0 
               
               
                   
               
               
                 1728 
                 Ac- 
                   
                 I 
                 S 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1081.6 
                 1181.98 
                   
                 15.3 
                 56.2 
                 89.5 
               
               
                   
               
               
                 1729 
                 Ac- 
                   
                 I 
                 N 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1095.11 
                 1095.58 
                   
                 11.2 
                 37.3 
                 62.5 
               
               
                   
               
               
                 1730 
                 Ac- 
                   
                 I 
                 L 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1094.63 
                 1095.3 
                   
                 10.2 
                 71.8 
                 125.6 
               
               
                   
               
               
                 1731 
                 Ac- 
                   
                 I 
                 F 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1111.62 
                 1112.33 
                   
                 10.2 
                 45.3 
                 95.9 
               
               
                   
               
               
                 1732 
                 Ac- 
                   
                 I 
                 2Nal 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1136.63 
                 1137.3 
                   
                 13.7 
                 55.3 
                 144.3 
               
               
                   
               
               
                 1733 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 S 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1139.13 
                 1139.89 
                   
                 3.6 
                 67.8 
                 117.2 
               
               
                   
               
               
                 1734 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 L 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1152.15 
                 1152.94 
                   
                 19.7 
                 96.2 
                 170.5 
               
               
                   
               
               
                 1735 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 F 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1169.14 
                 1169.86 
                   
                 17.2 
                 109.9 
                 125.0 
               
               
                   
               
               
                 1736 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 L 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1152.15 
                 1152.84 
                   
                 11.6 
                 37.9 
                 75.8 
               
               
                   
               
               
                 1737 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 K 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1117.13 
                 1117.97 
                   
                 23.2 
                 11.7 
                 25.6 
               
               
                   
               
               
                 1738 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 Abu 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1145.14 
                 1145.9 
                   
                 106.2 
                 112.2 
                 130.6 
               
               
                   
               
               
                 1739 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 V 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1152.15 
                 1152.94 
                   
                 104.3 
                 139.5 
                 119.8 
               
               
                   
               
               
                 1740 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 E 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.14 
                 1138.87 
                   
                 63.6 
                 135.4 
                 141.9 
               
               
                   
               
               
                 1741 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 G 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1086.1 
                 1086.89 
                   
                 29.7 
                 171.4 
                 145.1 
               
               
                   
               
               
                 1742 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 W 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1179.14 
                 1180.04 
                   
                 2.3 
                 14.5 
                 17.7 
               
               
                   
               
               
                 1743 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 hF 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.46 
                   
                 2.7 
                 16.6 
                 38.9 
               
               
                   
               
               
                 1744 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F4CF3 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1193.63 
                 1194.38 
                   
                 8.2 
                 107.4 
                 103.8 
               
               
                   
               
               
                 1745 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F4tBu 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1187.67 
                 1188.36 
                   
                 21.2 
                 154.1 
                 158.3 
               
               
                   
               
               
                 1746 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 2Nal 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1184.65 
                 1185.5 
                   
                 4.4 
                 19.1 
                 35.1 
               
               
                   
               
               
                 1747 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 Bip 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1197.65 
                 1198.54 
                   
                 6.5 
                 100.2 
                 113.5 
               
               
                   
               
               
                 1748 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 D 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1131.62 
                 1132.4 
                   
                 1.5 
                 25.9 
                 35.3 
               
               
                   
               
               
                 1749 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 E 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.63 
                 1139.02 
                   
                 1.8 
                 17.9 
                 30.7 
               
               
                   
               
               
                 1750 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 Q 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1138.14 
                 1138.84 
                   
                 4.9 
                 36.5 
                 71.6 
               
               
                   
               
               
                 1751 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 S 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1117.62 
                 1118.5 
                   
                 8.0 
                 44.1 
                 67.5 
               
               
                   
               
               
                 1752 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 H 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1142.64 
                 1143.25 
                   
                 8.0 
                 36.3 
                 57.4 
               
               
                   
               
               
                 1753 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 L 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1106.14 
                 1107.05 
                   
                 17.6 
                 69.9 
                 124.9 
               
               
                   
               
               
                 1754 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 A 
                 A 
                   
                   
                 —NH 2   
                 1113.63 
                 1114.27 
                   
                 20.3 
                 51.8 
                 102.0 
               
               
                   
               
               
                 1755 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 L 
                 A 
                   
                   
                 —NH 2   
                 1134.65 
                 1135.33 
                   
                 23.4 
                 9.0 
                 18.9 
               
               
                   
               
               
                 1756 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Cha 
                 A 
                   
                   
                 —NH 2   
                 1154.66 
                 1155.31 
                   
                 24.1 
                 8.6 
                 28.9 
               
               
                   
               
               
                 1757 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 hF 
                 A 
                   
                   
                 —NH 2   
                 1158.65 
                 1159.5 
                   
                 8.0 
                 12.1 
                 30.7 
               
               
                   
               
               
                 1758 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 W 
                 A 
                   
                   
                 —NH 2   
                 1171.15 
                 1171.78 
                   
                 3.9 
                 15.4 
                 23.5 
               
               
                   
               
               
                 1759 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 2Nal 
                 A 
                   
                   
                 —NH 2   
                 1176.65 
                 1177 
                   
                 8.0 
                 26.1 
                 65.2 
               
               
                   
               
               
                 1760 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 D 
                   
                   
                 —NH 2   
                 1153.12 
                 1153.77 
                   
                 2.2 
                 116.4 
                 137.9 
               
               
                   
               
               
                 1761 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 E 
                   
                   
                 —NH 2   
                 1160.13 
                 1160.8 
                   
                 1.4 
                 45.4 
                 56.4 
               
               
                   
               
               
                 1762 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 Q 
                   
                   
                 —NH 2   
                 1159.64 
                 1160.26 
                   
                 4.6 
                 41.1 
                 64.7 
               
               
                   
               
               
                 1763 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 S 
                   
                   
                 —NH 2   
                 1139.13 
                 1139.47 
                   
                 4.7 
                 36.0 
                 62.4 
               
               
                   
               
               
                 1764 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 H 
                   
                   
                 —NH 2   
                 1164.14 
                 1165.05 
                   
                 10.6 
                 73.8 
                 98.8 
               
               
                   
               
               
                 1765 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 R 
                   
                   
                 —NH 2   
                 1173.66 
                 1174.4 
                   
                 18.5 
                 185.9 
                 141.8 
               
               
                   
               
               
                 1766 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 K 
                   
                   
                 —NH 2   
                 1159.66 
                 1160.26 
                   
                 6.6 
                 66.3 
                 43.4 
               
               
                   
               
               
                 1767 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 AmL 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.18 
                 0.98 
                 86.6 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1768 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 AmD 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.46 
                 15.2 
                 &gt;1000 
                 205.5 
                 &gt;1000 
               
               
                   
               
               
                 1769 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 F4F 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1160.64 
                 1161.26 
                 1.4 
                 14.9 
                 26.0 
                 199.8 
               
               
                   
               
               
                 1770 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 Aib 
                   
                   
                 —NH 2   
                 1166.65 
                 1167.46 
                 4.6 
                 29.0 
                 &gt;1000 
                 218.1 
               
               
                   
               
               
                 1771 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 A 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1139.11 
                 1139.71 
                 15.3 
                 &gt;1000 
                 85.0 
                 &gt;1000 
               
               
                   
               
               
                 1772 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 N 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1159.64 
                 1160.4 
                 5.0 
                 &gt;1000 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1773 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1122.12 
                 1122.87 
                 19.3 
                 39.5 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1774 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 V 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1136.13 
                 1136.47 
                 5.8 
                 0.8 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1775 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 A 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1113.63 
                 1113.9 
                 4.0 
                 5.3 
                 12.6 
                 111.6 
               
               
                   
               
               
                 1776 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 F4F 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1167.64 
                 1168.57 
                 1.0 
                 58.0 
                 43.0 
               
               
                   
               
               
                 1777 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1167.64 
                 1168.2 
                 0.7 
                 27.0 
                 13.0 
               
               
                   
               
               
                 1778 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 F4F 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1168.64 
                 1169.59 
                 0.7 
                 127.0 
                 121.0 
               
               
                   
               
               
                 1779 
                 Ac- 
                   
                 A 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1118.11 
                 1118.89 
                 0.6 
                 52.0 
                 37.0 
               
               
                   
               
               
                 1780 
                 Ac- 
                   
                 A 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 A 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1072.1 
                 1072.92 
                 0.9 
                 23.0 
                 9.0 
               
               
                   
               
               
                 1781 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 A 
                 R 
                 $r8 
                 hL 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 F4F 
                 F4F 
                 A 
                   
                   
                 —NH 2   
                 1147.62 
                 1148.59 
                 0.5 
                 &gt;1000 
                 &gt;1000 
               
               
                   
               
               
                 1782 
                 Ac- 
                   
                 I 
                 $r8 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 St 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $s8 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1199.18 
                 1199.74 
                 &gt;40 
                 1.1 
                 1.1 
                 22.0 
               
               
                   
               
               
                 1783 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 $ 
                 A 
                 L 
                 R 
                 St 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $s8 
                 Y 
                 Y 
                 A 
                   
                   
                 —NH 2   
                 1207.17 
                 1207.7 
                 &gt;40 
                 1.6 
                 1.6 
                 19.2 
               
               
                   
               
               
                 1784 
                 Ac- 
                   
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 St 
                 Y 
                 Y 
                 A 
                 $r5 
                 A 
                 —NH 2   
                 1306.72 
                 1307.42 
                 &gt;40 
                 11.6 
                 24.2 
                 57.7 
               
               
                   
               
               
                 *Raji Cell Viability, 48 h, 5% serum 
               
            
           
         
       
     
     Example 3: Dose-Dependent Cell Killing by Peptidomimetic Macrocycles 
     Aileron peptide A is formulated as a pharmaceutical formulation. Aileron peptide A is an alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 25 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide A has a single cross link spanning amino acids in the i to the i+4 position of the amino acid sequence and has 8 amino acids between the i+4 position and the carboxyl terminus. Aileron peptide A binds to MCL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2500-2550 m/e. 
     Aileron peptide B is formulated as a pharmaceutical formulation. Aileron peptide B is an alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 20 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide B has a single cross link spanning amino acids in the i to the i+7 position of the amino acid sequence and has 8 amino acids between the i+7 position and the carboxyl terminus. Aileron peptide 1 binds to MCL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2250-2300 m/e. 
     Aileron peptide C is formulated as a pharmaceutical formulation. Aileron peptide C is an alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 25 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide C has a single cross link spanning amino acids in the i to the i+7 position of the amino acid sequence and has 3 amino acids between the i+7 position and the carboxyl terminus. Aileron peptide C binds to MCL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2500-2600 m/e. 
     BIM peptidomimetic macrocycles were tested for cell killing at various concentrations. Human Raji cells were treated with increasing doses of peptidomimetic macrocycles corresponding to Aileron peptide A ( FIGS. 1 and 2 ), Aileron peptide B ( FIGS. 1-3 ), and Aileron peptide C ( FIGS. 3 and 4 ). An % Viable cells was calculated for each dose of the peptidomimetic macrocycle from a non-linear fit of response vs dose (GraphPad Prism). The effect of the peptidomimetic macrocycles corresponding to Aileron peptide A are presented in  FIGS. 1 and 2 . The effect of the peptidomimetic macrocycles corresponding to Aileron peptide B are presented in  FIGS. 1-3 . The effect of the peptidomimetic macrocycles corresponding to Aileron peptide C are presented in  FIGS. 3 and 4 . 
     Example 4: MCL-1 Displacement Study 
     BIM peptidomimetic macrocycles were tested for displacement of MCL-1 from a BAK fluorescence resonance energy transfer (FRET) peptide. Human Raji cells were treated with DMSO, ABT-263, and peptidomimetic macrocycles corresponding to Aileron peptide A and Aileron peptide B.  FIG. 5  shows the effect of the compounds on normalized BAK peptide FRET signal. 
     Example 5: Pharmacokinetic (PK) and Bio-Distribution Study in Mice 
     A peptidomimetic macrocycle corresponding to Aileron peptide A was administered to mice at a 5 mg/kg dose. Mice were sacrificed at specific time points both before and after dosing, up to 24 hours post-administration. Blood, liver, and spleen were collected from the mice at the specific time points. Plasma was prepared from the blood using K2EDTA tubes by centrifuging for 20 minutes at 4° C. at 2000G maximum 30 minutes after collection. From each plasma sample, an aliquot was transferred to a fresh tube for PK studies. From each liver and spleen sample, tissue was homogenized and extracts were prepared for bio-distribution studies.  FIG. 6  shows the PK and bio-distribution results for this study by concentration in nanograms of peptidomimetic macrocycle per gram mouse body weight (ng/g) over time. 
     Example 6: Human Plasma Stability Study 
     Peptidomimetic macrocycles corresponding to Aileron peptide A or Aileron peptide B were administered to humans. Blood was collected at specific time points both before and after dosing, up to 24 hours post-administration. Plasma was prepared from the blood using K2EDTA tubes by centrifuging for 20 minutes at 4° C. at 2000G maximum 30 minutes after collection. From each plasma sample, an aliquot was transferred to a fresh tube for plasma stability studies.  FIG. 7  shows the plasma stability results for this study as a percentage of peptidomimetic macrocycle remaining in plasma over time, with the dashed line corresponding to the initial amount of peptidomimetic macrocycle dosed. 
     Example 7: Cell Viability and Caspase-3/7 Assay 
     Cancer cells were cultured using a standard culture medium containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (A375P: DMEM; SK-MEL-2, SK-MEL-28: EMEM). Cells were plated in 96-well plates (5×103 cells per well) and, after overnight incubation, treated with the indicated concentrations of Stapled Peptides in the corresponding medium supplemented with 5% FBS for the indicated durations. Cell viability and caspase-3/7 activation was measured using CellTiter-Glo and Caspase-Glo 3/7 chemiluminescence reagents (Promega), respectively. Luminescence was detected by a microplate reader (Spectramax M5, Molecular Devices). 
     Aileron peptide 1 is formulated as a pharmaceutical formulation. Aileron peptide 1 is a warhead-containing alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 25 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide 1 has a single cross link spanning amino acids in the i to the i+4 position of the amino acid sequence and has 8 amino acids between the i+4 position and the carboxyl terminus. Aileron peptide 1 binds to BFL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2500-2600 m/e. 
     Aileron peptide 2 is formulated as a pharmaceutical formulation. Aileron peptide 2 is an alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 20 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide 2 has a single cross link spanning amino acids in the i to the i+7 position of the amino acid sequence and has 3 amino acids between the i+7 position and the carboxyl terminus. Aileron peptide 2 binds to BFL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2500-2600 m/e. 
     Aileron peptide 3 is formulated as a pharmaceutical formulation. Aileron peptide 3 is a warhead-containing alpha helical hydrocarbon cross-linked polypeptide macrocycle, with an amino acid sequence less than 20 amino acids long that is derived from BCL-2-like protein 11 (BIM). Aileron peptide 3 has a single cross link spanning amino acids in the i to the i+7 position of the amino acid sequence and has 3 amino acids between the i+7 position and the carboxyl terminus. Aileron peptide 3 binds to BFL-1 or a BCL-2 family protein to trigger apoptosis, and has a molecular weight in the range of 2400-2500 m/e. 
       FIG. 8  shows the results of treating A375P-cells with BIM SAHB A1  and Aileron peptide 1 (40 μM). The results show that neither BIM SAHB A1  nor Aileron peptide 1 affected proliferation and apoptosis induction in A375-P melanoma cells. 
       FIG. 9  shows the results of treating SK-MEL-2 cells with BIM SAHB A1  and Aileron peptide 1 (40 μM). The results show that neither BIM SAHB A1  nor Aileron peptide 1 affected proliferation and apoptosis induction in SK-MEL-2 melanoma cells. 
       FIG. 10  shows the results of treating SK-MEL-28 cells with BIM SAHB A1  and Aileron peptide 1 (40 μM). The results show that neither BIM SAHB A1  nor Aileron peptide 1 affected proliferation and apoptosis induction in SK-MEL-28 melanoma cells. 
       FIG. 11  shows the results of treating A375-P cells with Aileron peptide 2 or Aileron peptide 3 (40 μM). The results show that Aileron peptide 2 and Aileron peptide 3 inhibited proliferation and induced apoptosis in A375-P cells. 
       FIG. 12  shows the results of treating SK-MEL-2 cells with Aileron peptide 2 or Aileron peptide 3 (40 μM). The results show that Aileron peptide 2 and Aileron peptide 3 inhibited proliferation and induced apoptosis in SK-MEL-2 cells. 
       FIG. 13  shows the results of treating SK-MEL-28 cells with Aileron peptide 2 or Aileron peptide 3 (40 μM). The results show that Aileron peptide 2 and Aileron peptide 3 inhibited proliferation and induced apoptosis in SK-MEL-28 cells. 
     Example 8: Mechanism of Action of Stapled BIM Peptides 
     The stapled BIM peptides of the disclosure can inhibit anti-apoptotic proteins, including BCL-2, MCL-1, and BCL-X L . The stapled BIM peptides of the disclosure can also directly active BAX/BAK, which are two nuclear-encoded proteins present in higher eukaryotes that are able to pierce the mitochondrial outer membrane to mediate cell death by apoptosis. Organelles recruited by nucleated cells to supply energy that can be recruited by BAX and BAK to kill cells. The two proteins lie in wait in healthy cells, where they adopt a globular α-helical structure as monomers. 
     Following a variety of stress signals, BAX and BAK convert into pore-forming proteins by changing conformations and assembling into oligomeric complexes in the mitochondrial outer membrane. Proteins from the mitochondrial intermembrane space and empty into the cytosol to activate proteases that dismantle the cell.  FIG. 14  illustrates how a stapled peptide derived from the protein BIM broadly targets BCL-2 family proteins, neutralizes BIM&#39;s prosurvival relatives (e.g., BCL-2, MCL-1, and BCLX L ), and directly activates BAX.  FIG. 15  illustrates how a BH3-only protein (BIM) can directly activate mitochondrial BAK and cytosolic BAX, and inhibit the capacity of anti-apoptotic proteins to sequester activated forms of BAK and BAX, leading the inactive monomers of BAK and BAX to transform to toxic pore-forming proteins. 
     Example 9: Crystal Structure of Stapled BIM Peptide Bound to MCL-1 
       FIG. 16  compares high resolution X-ray structures of: a stapled BIM peptide bound to MCL-1; Noxa BH3 bound to MCL-1 (Peptide: PDB: 2NLA); and BIM BH3 bound to MCL-1 (Peptide: PDB: 2NL9).  FIG. 17  shows a 2 angstrom X-ray structure of a stapled BIM-BH3 peptide bound to MCL-1. The X-ray crystal structure showed that the crosslinker of the peptide was a cis-olefin. 
     Example 10: Evaluation of the Biological Activity of Stapled BIM Peptides 
     The sequence information for the cross-linked peptides used in the studies are shown in TABLE 5. Aib represents 2-aminoisobutyric acid. $ represents an alpha-Me S5-pentenyl-alanine olefin amino acid connected to another amino acid side chain by an all-carbon crosslinker comprising one double bond, and $r8 represents an alpha-Me R8-octenyl-alanine olefin amino acid connected to another amino acid side chain by an all-carbon crosslinker comprising one double bond. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 5 
               
             
            
               
                   
                   
               
               
                   
                 SEQUENCE 
                 SEQ ID 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 # 
                   
                 146 
                 147 
                 148 
                 149 
                 150 
                 151 
                 152 
                 153 
                 154 
                 155 
                 156 
                 157 
                 158 
                 159 
                 160 
                 161 
                 162 
                 163 
                 164 
                   
                   
                   
                 NO: 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1333 
               
               
                   
               
               
                 2 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1334 
               
               
                   
               
               
                 3 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1335 
               
               
                   
               
               
                 4 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 A 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1336 
               
               
                   
               
               
                 5 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1341 
               
               
                   
               
               
                 6 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 Cit 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1342 
               
               
                   
               
               
                 7 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1347 
               
               
                   
               
               
                 8 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 Q 
                 A 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1348 
               
               
                   
               
               
                 9 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 A 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1353 
               
               
                   
               
               
                 10 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 A 
                 G 
                 D 
                 Q 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1355 
               
               
                   
               
               
                 11 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 A 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1361 
               
               
                   
               
               
                 12 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 N 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1362 
               
               
                   
               
               
                 13 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 A 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                   
                   
                 NH2 
                 1363 
               
               
                   
               
               
                 14 
                 Ac 
                 R 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $ 
                 I 
                 G 
                 D 
                 $ 
                 L 
                 N 
                 Aib 
                 F 
                 Y 
                 A 
                 H 
                 H 
                 NH2 
                 763 
               
               
                   
               
               
                 15 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 I 
                 G 
                 D 
                 E 
                 F 
                 N 
                 $ 
                 Y 
                 Y 
                 A 
                 R 
                 R 
                 NH2 
                 545 
               
               
                   
               
               
                 16 
                 Ac 
                 I 
                 W 
                 I 
                 A 
                 Q 
                 A 
                 L 
                 R 
                 $r8 
                 hL 
                 g 
                 D 
                 A 
                 F 
                 N 
                 $ 
                 Y 
                 F4F 
                 A 
                   
                   
                 NH2 
                 1621 
               
               
                   
               
            
           
         
       
     
     The binding spectrum of stapled BIM BH3 peptides were tuned for BCL-2 family selectivity. TABLE 6 shows the Ki values (nM) of MCL-1, BCL-x L , and BCL-2 for ABT-199, and peptide #1-peptide #13. ABT-199 is venetoclax, and † represents values reported in the literature. 
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 6 
               
               
                   
               
               
                 Cross-linked 
                 Mcl-1 
                 Bcl-x L   
                 Bcl-2 
                   
               
               
                 Peptide # 
                 K i  (nM) 
                 K i  (nM) 
                 K i  (nM) 
                 Profile 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 ABT-199 †   
                 &gt;444 
                 48 
                 &lt;0.01 
                 Bcl-2 selective 
               
               
                 1 
                 1.8 
                 1.4 
                 3.2 
                 Pan-selective 
               
               
                 2 
                 5.2 
                 12 
                 67 
                 Pan-selective 
               
               
                 3 
                 1 
                 1 
                 6 
                 Pan-selective 
               
               
                 4 
                 6 
                 4 
                 22 
                 Pan-selective 
               
               
                 5 
                 7.5 
                 109.9 
                 211.6 
                 Mcl-1 selective 
               
               
                 6 
                 1.7 
                 28.8 
                 88.2 
                 Mcl-1 selective 
               
               
                 7 
                 7.5 
                 401.7 
                 139.7 
                 Mcl-1 selective 
               
               
                 8 
                 1.4 
                 24.9 
                 43.9 
                 Mcl-1 selective 
               
               
                 9 
                 116.2 
                 7.7 
                 25.6 
                 Bcl-xL/Bcl-2 selective 
               
               
                 10 
                 122.1 
                 1.9 
                 4.8 
                 Bcl-xL/Bcl-2 selective 
               
               
                 11 
                 73.8 
                 386.4 
                 1094.8 
                 negative control 
               
               
                 12 
                 194.7 
                 416.0 
                 404.9 
                 negative control 
               
               
                 13 
                 500.7 
                 100000 
                 100000 
                 negative control 
               
               
                   
               
            
           
         
       
     
     The stapled BIM peptides were shown to disrupt the formation of MCL-1/BAK complexes in living cells.  FIG. 18  illustrates how stapled BIM peptides of the disclosure can disrupt the formation of MCL-1/BAK complexes in living cells. An assay was performed to determine the inhibitory constant (K i ) of BCL-x L , BCL-2, and MCL-1 in the presence of cross-linked peptide #14. The data show that in the presence of cross-linked peptide #14, the K i  of MCL-1 was drastically lower than the K i  of BCL-x L  or BCL-2. TABLE 7 shows the results of the assay. 
     
       
         
           
               
               
               
             
               
                   
                 TABLE 7 
               
               
                   
                   
               
               
                   
                 Assay 
                 Peptide #14 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 BCL-x L  K i  (nM) 
                 178 
               
               
                   
                 BCL-2 K i  (nM) 
                 151 
               
               
                   
                 MCL-1 K i  (nM) 
                 11 
               
               
                   
                   
               
            
           
         
       
     
       FIG. 19  compares normalized FRET signals of samples to determine the samples&#39; effects in disrupting MCL-1/BAK protein-protein interactions. Cross-linked peptide #14 was highly effective in disrupting the MCL-1/BAK protein-protein interaction at concentrations of 10 μM and 20 μM. Cross-linked peptide #14 was equally effective at disrupting the interaction of MCL-1/BAK at 10 μM and 20 μM. ABT-263 (navitoclax) did not disrupt the protein-protein interaction of MCL-1/BAK. ABT-263 did not disrupt the protein-protein interaction of MCL-1/BAK at concentrations of 5 μM or 10 μM. 
     Peptides #14, #15, and #16 were tested against BH3 mimetic ABT-737, ABT-263 (navitoclax), and ABT-199 (venetoclax). TABLE 8 shows that crosslinked-peptide #16 was the most effective BIM stapled peptide. † represents valued reported in the literature. 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                 TABLE 8 
               
               
                   
               
               
                   
                   
                 Mcl-1 
                 Bcl-x L   
                 Bcl-2 
               
               
                 Compound 
                 Profile 
                 K i  (nM) 
                 K i  (nM) 
                 K i  (nM) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 BIM-SAHB A1   
                 Pan-selective 
                 2.7 
                 6.2 
                 29.6 
               
               
                 Peptide #14 
                 Mcl-1 selective 
                 17 
                 114.5 
                 214.7 
               
               
                 Peptide #15 
                 Pan-selective 
                 10.6 
                 5.2 
                 12.8 
               
               
                 Peptide #16 
                 Pan-selective 
                 27 
                 13 
                 ND 
               
               
                 ABT-737 
                 Bcl-xL/Bcl-2 selective 
                 &gt;1000 
                 1.7 
                 3.1 
               
               
                 ABT-263 
                 Bcl-xL/Bcl-2 selective 
                 &gt;1000 
                 0.4 
                 0.9 
               
               
                 ABT-263 †   
                 Bcl-xL/Bcl-2 selective 
                 &gt;224 
                 0.055 
                 0.044 
               
               
                 ABT-199 †   
                 Bcl-2 selective 
                 &gt;444 
                 48 
                 &lt;0.01 
               
               
                   
               
            
           
         
       
     
     Lactate Dehydrogenase Cytotoxicity Colorimetric Assay 
     When cell membranes are compromised or damaged, lactate dehydrogenase (LDH), a soluble yet stable enzyme found inside every living cell, is released into the surrounding extracellular space. The presence of LDH in the culture medium can be used as a cell death marker. The relative amounts of live and dead cells within the medium can then be quantified by measuring the amount of released LDH using a colorimetric or fluorimetric LDH cytotoxicity assay. When using an LDH colorimetric assay, the amount of LDH released in the surrounding environment is measured with an enzymatic reaction that converts iodonitrotetrazolium (INT) into red-colored formazan. When LDH is present in the cell culture, the LDH reduces NAD +  to NADH and H +  through the oxidation of lactate to pyruvate. Afterward, the catalyst (diaphorase) then transfers H/H +  from NADH + H +  to the trazolium salt INT to form the red-colored formazan salt. The amount of color produced is measured at 490 nm by standard spectroscopy, and is proportional to the amount of damaged cells in the culture. 
     Cross-linked peptide #16 exhibited on-mechanism cytotoxic activity in BAX-BAK″ wt  MEF cells, but not BAX-BAK −/−  double-knock outs. No off-target cytotoxicity was observed for peptide #16 in the LDH assay (all with 5% serum).  FIG. 20  shows that cross-linked peptide #16 exhibited on-mechanism cytotoxic activity against BAX-BAK wt/wt  (●) MEF cells but did not exhibit on-mechanism cytotoxic activity in BAX-BAK −/−  double knock outs (DKO) (▴). 
     Apoptotic Response Against BFL-1-Drive Melanoma Cell Lines 
     Cross-linked peptide #16 was tested to determine the compound&#39;s ability to yield an enhanced apoptotic response against BFL-1-drive melanoma cell lines. Relative caspase-3/7 activation and % cell viability were measured using A375-P, SK-MEL-2, and SK-MEL-28 cell lines. BIM SAHB A1  (40 μM, 5% serum) was used as a control. Consistent with greater cell potency, treatment of the cell lines with Peptide #16 induced higher levels of caspase-3/7 activation compared to the control.  FIG. 21  shows that treatment of A375-P (1), SK-MEL-2 (2), and SK-MEL-28 (3) with peptide #16 induced higher levels of caspase-3/7 activation than the BIM SAHB A1  control.  FIG. 22  shows that treatment of A375-P (1), SK-MEL-2 (2), and SK-MEL-28 (3) with peptide #16 decreased the % viability of the cells, while treatment with BIM SAHB A1  had no effect on % viability. 
     Anti-Proliferative Activity in ABT-199 Resistant Burkitt Lymphoma Raji Cell Line 
     WST-1 is a cell proliferation reagent that is used in colorimetric assays designed to measure the relative proliferation rates of cells in culture. The assay is based on the conversion of the tetrazolium salt WST-1 into a colored dye by mitochondrial dehydrogenase enzymes. The soluble salt is released into the media. Within a given time period, the reaction produces a color change that is directly proportional to the amount of mitochondrial dehydrogenase in a culture. The WST-1 assay measures the net metabolic activity of cells. 
     Raji cell proliferation was measured by treating ABT-199 resistant Burkitt lymphoma Raji cells with BIM SAHB A1 , ABT-199, and Peptide #16.  FIG. 23  shows that peptide #16 was ten times more potent than BIM SAHB A1  in the MCL-1-1 driven Raji cell line. TABLE 9 shows the IC50 values calculated using the data presented in  FIG. 22 . 
     
       
         
           
               
               
               
               
             
               
                   
                 TABLE 9 
               
               
                   
                   
               
               
                   
                 BIM SAHB A1   
                 ABT-199 
                 Peptide #16 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 IC 50   
                 23.67 
                 3.104 
                 2.000 
               
               
                   
                   
               
            
           
         
       
     
     Anti-Proliferative Effects 
     Combination Treatment with Peptide #16 with ABT-199 
     Fixed doses of cross-linked peptide #16 were combined with varying levels of ABT-199 (venetoclax) to evaluate the anti-proliferative effects of combination treatment. Raji cell proliferation was determined by treating cells with ABT-199 (●); ABT-199+0.95 μM peptide #16 (▪); ABT-199+1.9 μM peptide #16 (▴); and ABT-199+3.8 μM peptide #16 (▾). The anti-proliferative effects of BCL-2-selective ABT-199 (EC 50  3.7-4.9 μM) were enhanced by BIM-stapled peptide #16, a potent MCL-1 inhibitor, in MCL-1 driven Raji cells.  FIG. 24  shows that Raji cell proliferation (fraction of control) decreased with increasing doses of peptide #16 in a dose-dependent manner. 
     Raji cell proliferation was also determined by treating cells with peptide #16 (●); peptide #16+1.9 μM ABT-199 (▪); peptide #16+3.8 μM ABT-199 (▴); and peptide #16+3.8 μM ABT-199 (▾). The anti-proliferative effects of BCL-2-selective peptide #16 (EC 50  1.2-1.6 μM) were enhanced by ABT-199 in MCL-1 driven Raji cells.  FIG. 25  shows that Raji cell proliferation (fraction of control) decreased with increasing doses of ABT-199 in a dose-dependent manner. 
     The ABT-199/Peptide #16 combination studies revealed additive to synergistic complementarity effects.  FIG. 26  shows that the combination index (CI) of the combination study had additive to synergistic complementary effects. 
     EMBODIMENTS 
     The following non-limiting embodiments provide illustrative examples of the invention, but do not limit the scope of the invention. 
     Embodiment 1 
     A peptidomimetic macrocycle of Formula (Ic): 
     
       
         
         
             
             
         
       
     
     wherein: 
     each A, C, D, E, and F is independently a natural or non-natural amino acid; 
     each B is independently a natural or non-natural amino acid, amino acid analogue, 
     
       
         
         
             
             
         
       
     
     [—NH-L 3 -CO—], [—NH-L 3 -SO 2 —], or [—NH-L 3 -]; 
     WH is an amino acid with an electron accepting group susceptible to attack by a nucleophile; 
     each L is independently a macrocycle-forming linker; 
     each L′ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 1  and the atom to which both R 1  and L′ are bound forms a ring; 
     each L″ is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, each being optionally substituted with R 5 , or a bond, or together with R 2  and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 1  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L′ and the atom to which both R 1  and L′ are bound forms a ring; 
     each R 2  is independently-H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, each being optionally substituted with halo-, or together with L″ and the atom to which both R 2  and L″ are bound forms a ring; 
     each R 3  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 ; 
     each L 3  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R 4 —K—R 4 -] n , each being optionally substituted with R 5 ; 
     each R 4  is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; 
     each K is independently O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ; 
     each n is independently 1, 2, 3, 4, or 5; 
     each R 5  is independently halogen, alkyl, —OR 6 , —N(R 6 ) 2 , —SR 6 , —SOR 6 , —SO 2 R 6 , —CO 2 R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 6  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; 
     each R 7  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with a D residue; 
     each R 8  is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, each being optionally substituted with R 5 , or part of a cyclic structure with an E residue; 
     each v and w is independently an integer from 1-1000; 
     t is 0; 
     u is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and 
     each x, y and z is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or 
     a pharmaceutically-acceptable salt thereof. 
     Embodiment 2 
     The peptidomimetic macrocycle of embodiment 1, wherein the peptidomimetic macrocycle comprises two crosslinks, wherein a first crosslink is of a first pair of amino acid residues, and a second crosslink is of a second pair of amino acid residues. 
     Embodiment 3 
     The peptidomimetic macrocycle of embodiment 1 or 2, wherein the first pair of amino acid residues and the second pair of amino acid residues do not share a common amino acid residue. 
     Embodiment 4 
     The peptidomimetic macrocycle of embodiments 1 or 2, wherein the first pair of amino acid residues and the second pair of amino acid residues share one common amino acid residue. 
     Embodiment 5 
     The peptidomimetic macrocycle of any one of embodiments 1-4, wherein w is at least 2 and at least two E amino acids are His residues. 
     Embodiment 6 
     The peptidomimetic macrocycle of any one of embodiments 1-5, wherein the peptidomimetic macrocycle comprises a helix. 
     Embodiment 7 
     The peptidomimetic macrocycle of any one of embodiments 1-6, wherein the peptidomimetic macrocycle comprises an α-helix. 
     Embodiment 8 
     The peptidomimetic macrocycle of any one of embodiments 1-7, wherein each of v and w is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. 
     Embodiment 9 
     The peptidomimetic macrocycle of any one of embodiments 1-8, wherein each of v and w is independently 3, 4, 5, 6, 7, 8, 9, or 10. 
     Embodiment 10 
     The peptidomimetic macrocycle of any one of embodiments 1-9, wherein v is 8. 
     Embodiment 11 
     The peptidomimetic macrocycle of any one of embodiments 1-10, wherein w is 6. 
     Embodiment 12 
     The peptidomimetic macrocycle of any one of embodiments 1-11, wherein L is 
     
       
         
         
             
             
         
       
     
     Embodiment 13 
     The peptidomimetic macrocycle of any one of embodiments 1-12, wherein R 1  and R 2  are H. 
     Embodiment 14 
     The peptidomimetic macrocycle of any one of embodiments 1-12, wherein R 1  and R 2  are independently alkyl. 
     Embodiment 15 
     The peptidomimetic macrocycle of any one of embodiments 1-12 and 14, wherein R 1  and R 2  are methyl. 
     Embodiment 16 
     The peptidomimetic macrocycle of any one of embodiments 1-15, wherein the peptidomimetic macrocycle exhibits a selectivity ratio of one target over another that is from about 2:1 to about 1000:1. 
     Embodiment 17 
     The peptidomimetic macrocycle of any one of embodiments 1-16, wherein the peptidomimetic macrocycle exhibits a selectivity ratio of one target over another that is from about 5:1 to about 1000:1. 
     Embodiment 18 
     The peptidomimetic macrocycle of any one of embodiments 1-17, wherein the peptidomimetic macrocycle exhibits a selectivity ratio of one target over another that is from about 10:1 to about 1000:1. 
     Embodiment 19 
     The peptidomimetic macrocycle of any one of embodiments 1-18, wherein the peptidomimetic macrocycle exhibits a selectivity ratio of one target over another that is from about 100:1 to about 1000:1. 
     Embodiment 20 
     The peptidomimetic macrocycle of any one of embodiments 1-19, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 1-1625. 
     Embodiment 21 
     The peptidomimetic macrocycle of any one of embodiments 1-20, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 2-400. 
     Embodiment 22 
     The peptidomimetic macrocycle of any one of embodiments 1-20, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 707-757. 
     Embodiment 23 
     The peptidomimetic macrocycle of any one of embodiments 1-20, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 912-922. 
     Embodiment 24 
     The peptidomimetic macrocycle of any one of embodiments 1-20, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 1600-1625. 
     Embodiment 25 
     The peptidomimetic macrocycle of any one of embodiments 1-23, wherein the peptidomimetic macrocycle comprises an amino acid sequence that has at least 60% identity to any one of SEQ ID NOs.: 12, 755, and 920. 
     Embodiment 26 
     The peptidomimetic macrocycles of any one of embodiments 1-25, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     wherein:
         X is alkylene, CH, CH 2 , NR α , O, or S, wherein R α  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl;   R a  is H, CN, or C(O)CH 3 ;   R b  is H, methyl, ethyl, allyl, propyl, isopropyl, butyl, or isobutyl;   each R c , R d , and R e  is independently —H, C 1 -C 4  saturated or unsaturated, straight or branched, hydrocarbon chain, or an electron-withdrawing group, wherein at least one of R c , R d , and R e  is an electron withdrawing group;   R f  is halogen, a C 2  alkynyl or alkenyl side chain optionally substituted with oxo, halogen, NO 2 , or CN; and   n′ iso, 1, 2, 3, 4, or 5.       

     Embodiment 27 
     The peptidomimetic macrocycles of any one of embodiments 1-25, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     wherein:
         X is alkylene, CH, CH 2 , NR α , O, or S, wherein R α  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl; and   each R c , R d , and R e  is independently —H, C 1 -C 4  saturated or unsaturated, straight or branched, hydrocarbon chain, or an electron-withdrawing group, wherein at least one of R c , R d , and R e  is an electron withdrawing group.       

     Embodiment 28 
     The peptidomimetic macrocycle of any one of embodiments 1-25, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     Embodiment 29 
     The peptidomimetic macrocycles of any one of embodiments 1-26, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     Embodiment 30 
     The peptidomimetic macrocycles of any one of embodiments 1-26, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     wherein:
         X is alkylene, CH, CH 2 , NR α , O, or S, wherein R α  is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl;   each R c , R d , and R e  is independently —H, C 1 -C 4  saturated or unsaturated, straight or branched, hydrocarbon chain, or an electron-withdrawing group, wherein at least one of R c , R d , and R e  is an electron withdrawing group; and   n′ is 0, 1, 2, 3, 4, or 5.       

     Embodiment 31 
     The peptidomimetic macrocycle of any one of embodiments 1-26, wherein WH is an amino acid with a side chain of the formula: 
     
       
         
         
             
             
         
       
     
     wherein each R c , R d , and R e  is independently —H, C 1 -C 4  saturated or unsaturated, straight or branched, hydrocarbon chain, or an electron-withdrawing group, wherein at least one of R c , R d , and R e  is an electron withdrawing group; and n′ is 0, 1, 2, 3, 4, or 5. 
     Embodiment 32 
     A pharmaceutical composition comprising a peptidomimetic macrocycle of any one of embodiments 1-31 and a pharmaceutically-acceptable carrier. 
     Embodiment 33 
     A method of treating a disorder, the method comprising administering to a subject in need thereof a therapeutically-effective amount of the peptidomimetic macrocycle of any one of embodiments 1-31. 
     Embodiment 34 
     The method of embodiment 33, wherein the disorder is a cancer. 
     Embodiment 35 
     The method of embodiments 33 or 34, wherein the cancer is a solid cancer. 
     Embodiment 36 
     The method of embodiments 33 or 34, wherein the cancer is a liquid cancer. 
     Embodiment 37 
     The method of any one of embodiments 33-36, wherein the cancer is resistant to a BCL-2 inhibitor therapy. 
     Embodiment 38 
     The method of any one of embodiments 33-37, wherein the BCL-2 inhibitor therapy is navitoclax or obatoclax. 
     Embodiment 39 
     The method of any one of embodiments 33-35, 37, or 38, wherein the cancer is a lymphoma. 
     Embodiment 40 
     The method of any one of embodiments 33-35 or 37-39, wherein the cancer is B-cell lymphoma. 
     Embodiment 41 
     The method of any one of embodiments 33-40, wherein the administration is intravenous. 
     Embodiment 42 
     The method of any one of embodiments 33-40, wherein the administration is subcutaneous. 
     Embodiment 43 
     The method of any one of embodiments 33-40, wherein the administration is oral. 
     Embodiment 44 
     The method of any one of embodiments 33-43, further comprising administering to the subject a therapeutically-effective amount of a BCL-2 inhibitor. 
     Embodiment 45 
     The method of any one of embodiments 33-44, wherein the BCL-2 inhibitor is obatoclax. 
     Embodiment 46 
     The method of any one of embodiments 33-44, wherein the BCL-2 inhibitor is venetoclax. 
     Embodiment 47 
     The method of any one of embodiments 33-44, wherein the BCL-2 inhibitor is navitoclax.